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Abstract
The aim of this project was to characterize the expression of members of the Kop
channel family in osteoblastic cells. Recent studies in the literature had indicated
the presence of members of the TREK sub-family in human and rodent
osteoblasts, but no examination of the other sub-families had been reported.
Primers were designed against all functional members of the Kyp family and RT-
PCR was used to screen cDNA from primary osteoblasts and a number of
osteosarcomacell lines. The results revealed the expression of TASK-1, -2, -3 &
-5, TWIK-1 & -2, TRAAK and TREK-1 in humanosteoblastic cells. Results that
wereparticularly consistent and strong acrossthe cells studied included those for
TASK-2, TWIK-1 & 2, TRAAK and TREK-1. Immunocytochemistry confirmed
the RT-PCR findings, with TREK-1 displaying one of the most convincing
examples of localising to the plasma membrane. Western blotting with the same
set of antibodies also confirmed protein expression of Kyp channels over a range
of osteoblastic cells. The evidence for mRNAand protein expression provided a
basis for the design of some functional assays. SaOS-2 reporter cells transfected
with the c-fos promoter were used to screen the effects of a variety of K” and
Ca** channel agents. PTH was used as a c-fos stimulant to compare with the
effects of the channel agents on basal expression levels. The putative TREK-1
activators riluzole and BL-1249 produced significant changes to the PTH-
induced rise in c-fos. Riluzole enhanced the PTH-induced stimulation (P<0.001)
but had no effect on its own. Conversely, BL-1249 reduced both basal and PTH-
induced c-fos expression (P<0.001 for PTH stimulated cells). The difference
between these results was explained through the known effects of riluzole on
other proteins; particularly the inhibition of phosphodiesterases. The generic
KCBs Ba” and TEAfailed to show anysignificant effects, whereas modulators
of Karp channels (glibenclamide and pinacidil) produced limited changesin c-fos
expression. Activation and inhibition of VDCCsdid not consistently affect the
expression of c-fos or the production of ALP. Investigation into the mechanism
behind PTH stimulation appeared to support the involvement of PKA in the
second messenger pathway. Electrophysiological observations revealed an
increase in whole-cell current following the addition of BL-1249 to SaOS-2 cells
(P<0.05 at +80mV). AA was used as a positive control and also increased whole
cell current in the same cell type. TE-85 cells displayed broad variation in their
response to BL-1249, and whole-cell currents were inhibited upon application of
AA. Recordings of membrane potential were taken from SaOS-2 cells and
revealed the resting membrane potential to be -22.9mV (n=6). A significant
hyperpolarization was seen after exposure to BL-1249, which brought the
membrane potential down to -31.6mV (P<0.001). The effects on membrane
potential and whole-cell current were reversed following wash-out of BL-1249.
This work has demonstrated the expression of various Kp channels in several
types of osteoblastic cell including primary human osteoblasts. If BL-1249 can
be shown to solely activate TREK-1, then the results contained here suggest that
the currents produced by this channel may play a role in normal osteoblast
functions.
1.0 Introduction
1.1 Bone
1.1.1 Skeletal tissue
The mammalian skeleton exists to provide mechanical and metabolic support.
The skeleton enables mechanical movement and gives protection to the major
organs. It also provides a calcium store which can be utilised when serum Ca’*
levels drop. Bone tissue is able to release OHin order to balance low blood pH,
and houses the process of haematopoiesis. Bone is a dynamic tissue that
constantly undergoes remodelling based upon the input of various endocrine,
autocrine and paracrine signals.
Twostructural formations of bone exist; cortical and trabecular. Cortical boneis
extremely compact and constitutes the majority of an individuals bone mass.It
covers the outer part of bony structures, providing strength and protection.
Trabecular bone is less dense, but contains most of the surface area within the
skeleton. As such,it is often targeted when metabolic needs override mechanical
function. It is found within the metaphyseal and epiphyseal regions of the long   bones. Articular : : :Epiphysis corlings Figure 1.1. Cross-sectional diagramshowing the gross anatomical
Diaphysis _ features of a long bone.Periosteum_—
Medullary .cavky Bone is covered by the
recs periosteum, a layer’ of
fibroblastic and osteogeniccells.
The fibrous outermost surface is
highly innervated and
vascularised. The innermost part is the cambium layer which contains
mesenchymalprogenitors (Allen eg al., 2004). Breaks and fractures can damage
the periosteum causing pain and bleeding. During embryonic development the
bone collar derives from the periosteal bud to initiate vascularisation and
osteogenesis.
Osteoblasts are the cells responsible for creating bone. They secrete an
extracellular matrix which becomes mineralized. Osteoclasts are large cells
derived from haematopoietic precursors that are able to resorb bone. They are
easily recognisable due to their large size and multinucleated appearance.
Osteoclasts possess a ruffled border in contact with the resorbing substrate. The
clear zone forms an effective seal to allow acidification and secretion of
lysosomal enzymes onto the resorbing surface. Bone formation and resorption
are coupled in the process of bone remodelling. Remodelling by osteoblasts and
osteoclasts is a tightly controlled process; an imbalance in bone remodelling can
lead to conditions such as osteoporosis and osteopetrosis. The remodelling
processstarts with resorption and is followed by bone formation. The resorption
period is brief, lasting around 3 weeks but formation takes several months to
complete. Osteoblast stimulatory factors such as insulin-like growth factor and
Transforming growth factor-B (TGF-f) are released through degradation of the
matrix thereby helping to ensure that formation follows resorption (Heberden er
al., 1998).
Mineralization of the skeleton occurs through the deposition of hydroxyapatite
crystals (Cas(PO,4)30H) onto a collagenous matrix, making bone a valuable
reservoir of calcium ions. Bone resorption can be increased to facilitate
homeostasis during bouts of low plasma Ca’*. The two key hormones that
control this process are parathyroid hormone (PTH) and 1,25(OH)2D3. The
thyroid hormone calcitonin is also involved in calcium regulation; it lowers
plasma Ca** by inhibiting osteoclast activity and decreasing resorption of
calcium and phosphate from the renal proximal tubule (Miller, 2008).
Despite the variety and prevalence of bone disorders, there are relatively few
pharmacological compoundsavailable for their treatment. Bisphosphonates are
the most commonly used drugs, and are used to inhibit bone resorption in
osteoporotic patients. The inhibition of resorption helps to restore bone mass
homeostasis (Rodan, 1997). Despite its resorptive effects, PTH can also stimulate
bone formation. Low-dose intermittent PTH administration in the form of
teriparitide is an effective anabolic tool in the treatment of osteoporosis.
Oestrogen replacement may be also used as a therapy for post-menopausal
osteoporosis as can selective oestrogen receptor modulators (SERMs) such as
tamoxifen and raloxifene. The SERMsare thought to have a positive effect on
bone formation due to an upregulation in TGF-B (Grainger and Metcalf, 1996).
Other therapies in clinical use include strontium ranelate, dietary calcium
supplementation and calcitonin administration (Miller, 2008). A recent and
welcome addition to the field has been a monoclonal antibody known as
denosumab, which targets the RANKL pathway (Lewiecki, 2008). This therapy
has the potential to be effective in a number of bone disorders including
osteoporosis and myeloma. Drugs in development for the treatment of
osteoporosis include cathepsin K inhibitors and osteoprotegerin.
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Figure 1.2. Osteoblasts, chondrocytes, myocytes and adipocytes are all derived from
mesenchymal stem cells (MSCs). Bone lining cells are quiescent osteoblasts that can be
reactivated by stimulatory factors such as PTH. Osteocytes are cells of the osteoblast
lineage which become embedded in the bone matrix. These cells play an importantrole
in mediating the response to mechanicalloading.
1.1.2 Osteoblasts
Osteoblasts are primarily secretory cells that synthesize and deliver the organic
components of bone matrix, which can be divided into collagenous and non-
collagenous proteins. Collagen I is the predominant substrate for the
mineralization process. Many of the various non-collagenous proteinsfacilitate
the deposition of calcium and phosphate onto the collagen fibrils. Stimulatory
factors such as bone morphogenic proteins (BMPs) encourage the osteoblasts
multipotent precursors to differentiate along the osteoblastic pathway. The early
cells produced by progression along this route are known as preosteoblasts.
Osteoblast developmentcan be dividedinto three sequential stages; proliferation,
extracellular matrix maturation and matrix mineralization (Franceschi, 1999).
Traditionally, osteoblast differentiation has been measured by the expression of
certain marker proteins. Collagen I is an early stage marker secreted by pre-
osteoblasts and osteoblasts. Collagen I bindsto the af; integrin expressed on the
osteoblast cell surface which encourages further differentiation (Xiao ef al.,
1998, Damsky, 1999). Mid-stage marker proteins are numerous and include
alkaline phosphatase (ALP), osteonectin and osteopontin (Dworetzky et al.,
1990, Sommeret al., 1996). An osteoblast is considered mature by the time it
begins to express osteocalcin. This event marks the transition from matrix
maturation to mineralization. Osteoblasts can express the proteins
osteoprotegerin (OPG) and receptor activator of NF-KB ligand (RANKL).
RANKLencourages osteoclastic precursors to differentiate and fuse, forming
cells capable of bone resorption. OPG acts as a decoy receptor for RANKL,and
subsequently can inhibit osteoclast activity through reduced signalling at the
receptoractivator ofNF-KB (RANK) (Boyce and Xing, 2008).
1.1.3 Genetics and the development of bone
There are two ways in which bone can be created: endochondral and
intramembranous ossification. Endochondral bone formation occurs when a
cartilage modelrecruits osteoblasts to convert it into bone. When the developing
bone becomes vascularized, the chondrocytes undergo apoptosis and the bone
structure becomes mineralized by osteoblasts. Intramembranousossification does
not require a cartilage intermediary and bone is formed in the first instance by
osteoblasts. Most bones are formed through the process of endochondral
ossification, but the clavicles and some cranial bones are created by
intramembranousossification.
Patterning of the skeleton must occur before the differentiation of tissue specific
cell-types. Many genes are required to successfully complete this process and
Sox-9 is one of the earliest to be expressed. It is required for the formation of
mesenchymal condensations, the first stage in both methods of ossification
(Lefebvre ef al., 2001). Cbfal or Runx2 is one of the most studied transcription
factors in skeletal genetics. Cbfal coordinates the early and late stages of
osteoblast and chondrocyte differentiation respectively (Karsenty, 2001 and
Wagner and Karsenty, 2001, Ducy ef al., 2000b). In Cbfal-deficient mice,
chondrocytes fail to hypertrophy and osteoblast differentiation does not occur
(Otto et al., 1997). Heterozygous knockout mice appear to mimic the human
disorder cleidocranial dysplasia (CCD). This condition results in hypoplastic
clavicles and delayed fusion of some cranial sutures due to a defect in
intramembranous ossification. Osterix acts downstream of Cbfal during
osteoblast differentiation. Osterix -/- mice display a similar phenotype to the
Cbfal-null mice, although chondrocyte hypertrophy is enabled and consequently
vascular invasion occurs. Osteoblast differentiation is completely abolished in
both these mutants (Nakashimaef al., 2002). Although the use of mouse models
can present difficulties due to species variation, the genes controlling skeletal
development are extremely conserved (Karsenty, 2003). This fortuitous detail
has resulted in a huge advancein our understanding of bone biology over the two
decades.
1.1.4 Mechanical stimulation
Mechanical force has a well-documented anabolic effect on bone. In support of
this observation, bone unloading which may occur during periods of immobility
has a catabolic effect on bone mass. Mechanical strain is transferred into shear
stress in the extracellular fluid surrounding bone matrix. Osteocytes embedded in
the matrix are perfectly placed to respond to these variations in shear stress.
Mechanical stimulation results in nitric oxide (NO) and prostaglandin E2 (PGE2)
release from these cells (Nomura and Takano-Yamamoto, 2000). NO release
inhibits the activity of osteoclasts (Mancini ef al., 1998) but encourages the
differentiation of osteoblasts (Vezeridis et al., 2006).
1.1.5 Wnt Signalling
Wnts are a family of around 20 proteins secreted at various stages of
development that have a potent anabolic effect on bone tissue. Their expression
promotes osteoblast differentiation, proliferation and mineralization and also
inhibits osteoblast and osteocyte apoptosis. The anabolic effects of Wnts on bone
are due to their ability to stabilize the intracellular protein f-catenin.
Phosphorylation of B-catenin by glycogen synthase kinase 3 (GSK3), results in
its proteosomal degradation. Unphosphorylated B-catenin translocates to the
nucleus and activates gene transcription (Novak and Dedhar, 1999). This is
commonly referred to as the canonical pathway. LRP5 forms a complex with the
Frizzled G-protein coupled receptor (GPCR) which when activated by Wnt
binding inhibits GSK3 activity. Mutations in the LRPS5 gene can result in loss or
gain of function and therefore produce either high or low bone mass phenotypes
(Balemansand Van Hul, 2007). Canonical Wntsignalling is tightly controlled by
several inhibitory factors, including Dickkopf-1 (Dkk1), sclerostin (SOST), WIF-
1 and sFRP (Krishnanef al., 2006). Wnt proteins are upregulated during the early
stages of fracture repair (Zhong et al., 2006). The canonical Wntsignalling
pathway represents an exciting potential target for pharmacological interventions
in bone disease.
1.2 Hormonal modulation ofbone
1.2.1 Parathyroid hormone
PTHis secreted by the parathyroid glands in response to low serum Ca’. PTHis
84 aminoacids in length, although amino acids 1-34 are sufficient to evoke most
of its biological activity. The effects of parathyroid hormone on bone can often
be difficult to review due to its wide ranging influence over the remodelling
process. Fundamentally, PTH can stimulate bone formation and resorption but
both of these effects are somewhat dose-dependent; making comparisons
between studies awkward. Given the hormones’ role in calcium homeostasis it
would seem that high levels of PTH or continuous administration will result in
net resorption so as to release Ca’*. Lower concentrations of PTH orintermittent
administration appear to support bone formation. At high doses PTH inhibits the
proliferation of osteoblastic cells, but at low doses can stimulate their
proliferation (Partridge et al., 1985, MacDonald etal., 1986).
The effects of continuous PTH onthe skeleton were first observed in patients
with hyperparathyroidism. These patients often suffer from osteitis fibrosa,
symptoms of which include osteomalacia, peritrabecular fibrosis and increased
osteoclastic resorption (Lotinun ef al., 2002). The anabolic effect of intermittent
PTH in vivo is largely due to the activation of quiescent bone lining cells rather
than an increase in osteoblastic progenitors (Dobnig and Turner, 1995).
Stimulation of osteoblasts by PTH increases expression of RANKL and
decreases expression of OPG; encouraging osteoclastogenesis and consequently
an increase in bone resorption. (Huang ef al., 2004). PTH can potentiate the Ca**
response induced by nucleotide binding to P2 receptors (Buckley ef al., 2001).
Parathyroid hormonerelated peptide (PTHrP) has a similar biological role to
PTH. It has been shown to be important in early bone development and is
involved in hypercalcemia of malignancy. PTH can induce rapid up-regulation of
PTHrP mRNA in osteoblasts (Walsh et al., 1997). PTH and PTHrP share a
GPCR known as PTHR1. PTHR1 has beenreported to couple both Ga, and Gag.
This results in a dual signal transduction pathway leading to cAMP formation
and/or release of Ca”* from intracellular stores (Abou-Samraef al., 1992). The
cAMPsignalling pathway is induced following Ga, stimulation of adenylyl
cyclase (AC) and results in the phosphorylation of proteins and transcription
factors by PKA. Gag activates phospholipase C (PLC) which hydrolyses PIP2 to
produce IP; and DAG. IP3 mediates store-operated Ca’* release from the
endoplasmicreticulum while DAG activates PKC.
The investigation into downstream signalling occurring from PTHRI1 in
osteoblasts is contentious. In the rat osteoblast cell line UMR-106, c-fos
induction was reported to be mediated mainly by PKC (Kano ef al., 1994a) but
the same group suggest PKA is responsible for the positive effects of PTH on
ALPexpression (Kanoet al., 1994b). Ca’* and cAMPresponses to PTH have
been reported in UMR-106 cells (Reid et al., 1987, Yamaguchi et al., 1987).
Bizzarri and Civitelli (1994) observed that PTH induced rises in [Ca”"], were cell
cycle dependent in UMR-106 cells. Boland et al, (1986) failed to find any
changes in [Ca’*]; after PTH administration to various osteoblastic cells. PTH
results in cAMP generation in the SaOS-2 cell line (Rodan ef al., 1987). PKA
was shown to be almost solely responsible for c-fos induction in SaOS-2 cells
(Evans et al., 1996). Few genes have been shown to be regulated via PKC
activation in osteoblasts (Qin ef al., 2004) and AC activity is necessary for
anabolic effects in vivo (Golzman, 1999). Both PKA and PKC stimulation by
PTHcanlead to an increase in MAPKactivity (Cole, 1999).
Adding complexity to the role of PTH in bone and other tissues is the
desensitization and down-regulation of PTHR1. As is common with receptors
coupled to AC, PTHR1 undergoes homologousdesensitization when challenged
and subsequently rechallenged with PTH. This process is complex and appearsto
involve multiple pathways (Fukayamaet al., 1992). Activated PTHR1is rapidly
phosphorylated by G protein-coupled receptor kinases (GRKs), resulting in B-
arrestin recruitment. This mediates the inactivation of the receptor through
internalization. Both G protein and f-arrestin interaction with PTHR1 can
stimulate extracellular signal-related kinase (ERK)-1 and -2 activity (Gesty-
Palmeret al., 2006).
PTH plays an important role in the response to mechanical loading. In
thyroparathyroidectomized rats no osteogenic response is seen in loaded
vertebrae. This effect was reversed by administration of PTH prior to mechanical
stimulation (Chow ef al., 1998). The presence of PTH during bone loading
appears to increase levels of c-fos mRNA in osteocytes. PTH was shown to
inhibit eNOSactivity produced by mechanical strain (Bakkeref al., 2003). These
observations demonstrate the dual effects of PTH on increasing bone formation
and resorption even in a mechanically stimulated bone environment.
1.2.2 Vitamin D;
Vitamin D3 is formed by the exposure of 7-dehydro-cholesterol to UV light. It
must undergo hydroxylation to become metabolically active. Firstly, it is
hydroxylated in the liver to give 25(OH)D3. The renal enzyme 1a-hydroxylase
catalyses the final stage of the process to produce 1,25(OH)2D3, also knownas
calcitriol. 1,25(OH)2D3 is produced during bouts of hypocalcemia to increase
calcium absorption from the small intestine and re-absorption from the kidneys
(Lips, 2006). In preosteoblasts, 1,25(OH)2D3 arrests differentiation and
proliferation but in more mature osteoblasts it increases matrix protein
expression (Mulkinset al., 1983, Owenet al., 1991, St-Arnaud, 2008, Beresford
et al., 1986). 1,25(OH)2Dsis crucial for normal longitudinal bone growthasit is
required by proliferating and hypertrophic chondrocytes at the epiphyseal growth
plates. 1,25(OH)2D3 exerts its genomic effects via the nVDR while ion channels
and other membrane proteins mediate the rapid non-genomic effects.
1,25(OH)2D3 administration produces wide-ranging effects on osteoblast ion
channels. A study by Zanello and Norman (2003) showsthe activation of three
different types of ion channelin responseto physiological levels of 1,25(OH)2D3.
The effect of 1,25(0H)2D3 on calcium channels in osteoblasts has been
investigated by several groups. 1,25(OH)D3 increases the mean opening time of
L-type Ca** channels and shifts the threshold of activation towards the resting
potential (Caffrey and Farach-Carson 1989). The effect of 1,25(OH)2D3 can be
mimickedby the addition of a cAMPanalog,indicating that it may play a role in
channel phosphorylation (Zanello and Norman, 2003). 1,25(OH)2D3 treatment of
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primary osteoblasts results in an increase in Ca** entry and release from
intracellular stores (Lieberherr, 1987, Civitelli et al., 1990). Transcriptional
changes eg. downregulation of Cav1.2 (aic) require the nuclear vitamin D
receptor (nVDR)(Meszaroset al., 1996). Liu et al., (1999) demonstrated that the
ac subunit was responsible for 1,25(OH)2D3 and depolarization induced calcium
influx in ROS 17/2.8 osteoblastic cells via ribozyme ablation. The
downregulation of ajc in response to 1,25(OH)2D3 treatment may be a
preventative measure against Ca*" toxicity and subsequent cell damage (Berghet
al., 2006).
1.2.3 Sex steroids and leptin
Circulation of sex steroids, particularly oestrogen, helps to maintain bone mass.
Both osteoblasts and osteoclasts express receptors for oestrogen. Both types of
oestrogen receptor (ERa and ERf) are found in bone, indicating the importance
of the hormone in bone homeostasis. Signalling through these receptors in
osteoblasts causes secretion of OPG. The effect of oestrogen on osteoclasts is
more complex, involving cytokine expression and the immune system (Zallone,
2006). Following the menopause oestrogen levels decline and this can trigger the
onset of osteoporosis.
Leptin is a hormone produced by adipocytes. Leptin-deficient mice were
observed to be obese, suffer from hypogonadism, hypercortisolism and increased
bone mass. This hormonalinteraction with bone is not direct — it requires leptin
signalling in the hypothalamus (Ducy ef al., 2000a). Leptin acts on the
sympathetic nervous system to induce noradrenaline signalling. Subsequent
activation of B-adrenoceptors in boneresults in an inhibition of bone formation
(Harada and Rodan, 2003).
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1.2.4 Non-hormonalinfluences on bone homeostasis
Glucocorticoid (GC) administration is known to result in rapid bone loss and
osteoporosis (Alesci ef al., 2005). GCs appear to stabilise the cytosolic
1,25(OH)2D3 receptor in bone, and so have a synergistic effect on resorption
(Manolagasef al., 1979). Another GC effect on bone is to repress Wnt signalling
by increasing the expression of Dkk1 and sFRP1 (Ohnakaef al., 2005). Low pH
potentiates the activity of RANKL, 1,25(OH).D3, PTH and ATP/ADP on
osteoclasts (Arnett, 2008). Osteoclast stimulation may require initial acid
activation, followed by the addition of pro-resorptive agents. Acidosis reduces
matrix mineralization by osteoblasts. Both these actions serve to increase
available hydroxyl ions to provide a buffer for excess [H_’].
1.3 Potassium Channels
1.3.1 Three families of K* channel
More than 70 genes encoding potassium channels have been cloned from
humans. All K* channels contain a conserved motif in the pore-forming region,
called the P domain. This is a repeated sequence of GXG which ultimately
confers K" selectivity on these channels. They can be placed into one of three
classes dependent upon their basic structure; those that have two, four or six
transmembrane domains (TMD). Two and six TMD classes form tetramers of
pore-forming subunits, while the four TMDclassare likely to form dimers (Patel
and Honoré, 2002). This is because four pore forming domains per functional
unit are necessary to confer K” selectivity (Doyle et al., 1998).
Table 1.3. The three families of potassium channelandtheir basic characteristics
 
 
Transmembrane Channel type Pore Nomenclature
domains domains
6 Voltage-gated 1 Ky
4 Two-pore domain 2 Kop
2 Inward rectifier 1 Kir    
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Potassium channels are required for cell proliferation and progression ofthe cell
cycle, particularly into the G,; phase (Pardo, 2004, Wonderlin and Strobl, 1996).
They are also important in the maintenance of membrane potential. Opening of
potassium channelsleads to an increase in K” efflux from the cells whichresults
in membrane hyperpolarisation. K” channel closure can lead to depolarization,
showingthat regulation of these channels is importantin controlling excitability.
1.3.2 K, channels
Voltage-gated K* channels are activated by depolarization, and help to restore
resting membranepotential (Shieh ef al., 2000). This family includes KCNQ,
Shaker-related, ether-a-go-go-related (hERG) and Ca’"-activated K* channels.
The positively charged residues contained within the S4 TMDareconsidered to
be important in voltage-sensing (Shieh ef al., 2000). Conformational changes
inducedby alterations in membranepotential result in pore openingorclosing.
1.3.3 K;, channels
Ki, channels help to stabilise resting membrane potential and control K*
transport. (Reimann and Ashcroft, 1999). 15 genes encoding the o subunit of
the Kj, channel have been observed in human DNA (Kuboef al., 2005). This
family of channels can conduct K* in an inward direction at negative membrane
potentials, due to a partial blockade in the internal part of the pore by Mg”* and
polyamines (Shieh ef al., 2000). Karp channels are K;, channels that open when
[ATP]; decreases and [ADP]; increases i.e. during metabolic stress (Amoroso ef
al., 1990). All Ki, channels are modulated by PIP» and several are modulated by
G-proteins.
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1.3.4 K,p Channels
Two-pore domain potassium channels are responsible for the background “leak”
of K* ions first described by Hodgkin and Huxley (1952). They are able to
modulate the membrane potential of cells by passing K" currents and therefore
they help to regulate excitability. Initially thought to be present within the CNS,
overthe last few years many K»p channels have also been observed in other areas
of the body (Medhurst et al. 2001). Kzp channels are relatively insensitive to a
number of broad spectrum KCBsanddisplay little time- or voltage-dependence
(Lesage, 2003).
 
AN [K'], = 4mm
[K’] = 155mM (
COOH ——
Figure 1.3. Diagram showing
the membrane topology of a
K>p channel subunit, and the
potassium ion gradient across
a typical cell membrane. P1
represents the first pore-
domain and P2 the second.
M1-4 represent the TMDs.
Kp channels contain two pore (P) domains and have 4 transmembrane domains
(TMDs). This family of 15 channels can be subdivided into 6 subgroups.
1.
2
3.
4
on
Acid-sensitive outward rectifiers. TASK-1, -3 and 5
Weak inwardrectifiers. TWIK-1, -2 and KCNK7 (non-functional)
Halothane-inhibited Kyp channels. THIK-1 and -2 (non-functional)
Alkaline-activated background K* channels. TASK-2, TALK-1 and -
2
Calcium activated. TRESK
Lipid and thermosensitive, mechano-gated K’ channels. TREK-1, -2
and TRAAK
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Many K»p channels have a phenylalanine (F) residue instead of a tyrosine (Y) in
the GXG motif of the selectivity filter in the second pore domain. In homomeric
channels this would result in a loss of K” selectivity. Interaction between the X in
the GXG motif and a conserved aspartate (D) in the 2" P domain immediately
following the GXG motif, allows for variation in ion-selectivity and gating
properties of Kyp channels (O’Connell et al., 2002). TWIK-1 and -2 contain a
GLG motif in the second pore domain (Chavez ef al., 1999). Kop channels are
conserved between M1 and M4, but the N- and C-termini show much more
diversity (Shieh ef al., 2000).
The modulation of Kyp channels by GPCRs is reviewed by Mathie (2007).
Activation of Ga, inhibits activity of TASK channels. The mechanism behind
this effect has not been defined and is proposed to be direct, or via the
breakdown of PIP2. TRESK channels are enhanced by the action of Ga, on
calcineurin. TREK channels exhibit the most complex relationship with GPCRs.
Consistent with its actions on the TASK family Gag and also Gas inhibit TREK
activity but Ga; activation results in channel stimulation.
Recent advances in the understanding of Kp channel activity have been gained
from the use of knockout mice, reviewed by Sabbadini and Yost (2009). So far,
the most exciting results have been obtained by using TASK and TREK
knockout animals. TREK-1 knockout mice require longer exposure to higher
concentrations of volatile anaesthetics than their wild-type counterparts, to
produce the same plane of anaesthesia (Heurteaux ef al., 2006). Neuroprotection
is reduced in TREK-1 but not TRAAK knockout mice, in response to drug-
induced seizures and ischemia (Heurteaux ef al., 2006). The removal of TASK
channel genes produces physiological effects on the adrenal gland and in
respiratory control (Heitzmann efal., 2008, Mulkey et al., 2007).
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1.4 K>p channelfamilies
1.4.1 TASK
TASK channels are thought to be important in neuroprotection and
chemoreception. TASK channels are expressed in brainstem respiratory neurons
andrat arterial chemoreceptors (Bayliss ef al., 2001, Buckler et al., 2000). TASK
channels are thought to have a role in oxygen sensing in the carotid body
(Buckler, 2007). TASK-1, -2, and -3 over-expression inhibited apoptosis in
neuronal cells cultured in reduced serum and hypoxic conditions. TASK-3 over-
expression conferred protective effects on oxygen and glucose deprived cultured
rat hippocampal slices. This effect was potentiated by incubating slices with
isoflurane. TASK-3 may be moreeffective at protecting cells from insults due to
its relative insensitivity to low pH when compared with TASK-1 and -2 (Liu et
al., 2005). The pH sensing mechanism in TASK-1 and -3 involvesa histidine (H)
residue distal to the first pore domain. If this amino acid is mutated to aspartate
(D) or neutrally charged asparagine (N) there is a reduction in pH sensitivity, but
not total abolition of the response (O’Connell ef al., 2002). Dibasic sites on
TASK-1 and -3 interact with coatamer proteins, specifically B-COP to retain
channels in the endoplasmic reticulum. Escape from the ER is regulated by a
phosphorylation site on the C-terminus of TASK-1 and -3. A phosphorylated
channel binds 14-3-3B, which suppresses B-COP binding — allowing forward
trafficking of channels to the plasma membrane. The protein pll has been
observed in some tissues to be involved in release of TASK-1 and -3 to the
plasma membrane(Plantef al., 2005).
1.4.2 TWIK
TWIK-1 wasthe first of the Kop channels to be cloned. It is a weak inward-
rectifier activated by PKC andinhibited by intracellular acidification (Lesage et
al., 1996a). TWIK-1 channels form dimers via a disulphide bridge in order to
produce functional currents (Lesage ef al., 1996b). TWIK-1 activity is silenced
by covalent modification with SUMO. If K274 (lysine) is mutated, TWIK-1
becomes active, as SUMO is unable to covalently modify the channel (Plant ef
al., 2005). There is 53.8% sequence homology between TWIK-1 and -2 (Chavez
16
et al., 1999). Little information is available on TWIK-2, and to date the only
papers characterising the electrophysiology of this channel are contradictory.
Chavez ef al. (1999) propose that TWIK-2 currents from transfected Xenopus
oocytes are non-inactivating and display weak inward rectification. Channel
activity was inhibited by intracellular acidification. Patel et al. (2000) report that
TWIK-2 is an outwardly-rectifying, inactivating K2p channel. This study also
demonstrates that rat TWIK-2 currents are around 15 times larger than human
TWIK-2 currents. Little is known about the biological role of TWIK-2 channels
despite their seemingly broad expression in peripheral tissues (Medhurst ef al.,
2001). KCNK7is a memberof the TWIK family, but no functional currents have
been recorded from this channel. It is thought to be a silent subunit which may
regulate the properties of other channels.
1.4.3 THIK
THIK-1 channels are widely expressed in rat tissue and are inhibited by
halothane (Rajan ef al., 2001). THIK-2 displays no functional activity and its
expression does not appear to influence THIK-1 currents, indicating that
membersofthis family do not form heterodimers (Rajan et al., 2001). THIK-1 is
strongly inhibited by the halothane and weakly inhibited by extracellular
acidification.
1.4.4 TALK
TALK-1 and TASK-2 are sensitive to pH in the range of 6 — 10 whereas TALK-
2 is sensitive to more alkaline pH in the range of 7 — 10 (Kang and Kim, 2004).
Lu et al., (2007) propose that TALK-1 and -2 are modulated by the NO pathway,
and therefore are involved in the response to metabolic ischaemia. TALK-1 and-
2 are expressed in the exocrine pancreas and are activated by NO (Dupratef al.,
2004). TASK-2 is also a member of this sub-family and is activated by several
general anaesthetics and is sensitive to both intracellular and extracellular pH,
with channel inhibition seen upon intracellular acidification (Gray et al., 2000).
Changes in cell volume can also regulate the activity of this channel. TASK-2
channels are downregulated by chronic hypoxia. The downstream signalling for
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this modulation occurs through Elk-1 binding to the promoter region (Brazieret
al, 2005).
1.4.5 TRESK
TRESKchannels are highly localised to the dorsal root ganglia of human spinal
cord, and display low homology with other members of the Kp channel family
(Sano ef al., 2003). TRESK currents are outwardly-rectifying and are activated
by anaesthetics, but the properties of this channel are subject to large inter-
species variation (Keshavaprasad ef al., 2005). TRESK channels are highly
sensitive to volatile anaesthetics and activate rapidly upon exposure to these
agents (Kindler and Yost, 2005).
1.4.6 TREK
The TREK family consists of TREK-1 (KCNK2), TREK-2 (KCNK10) and
TRAAK (KCNK4). They have the highest sequence identity among K»p channels
at 63 — 78%. Human TREK channels are highly expressed in both the central and
peripheral nervous systems (Medhurst et al., 2001). Of all the K»p channels,
TREK-1 has been particularly well studied with respect to regulatory aspects of
its C-terminal domain. TREK channels are activated by membrane stretch and
therefore changes in cell volume. Intracellular acidosis constitutively activates
TREK channels, and heat stimulates the opening of TREK-1. Anionic
polyunsaturated fatty acids, such as arachidonic acid are stimulators of TREK
activity. Inhalational general anaesthetics such as halothane and isoflurane are
also knownto activate this family of channels. The carboxy terminus and the
MI1P1 loopare vital for the activation of TREK channels. TREK channel activity
is negatively regulated by protein kinases. PKA-mediated phosphorylation of the
carboxy terminal Ser333 results in the closure of TREK-1. PKC also has an
inhibitory effect on TREK-1, although its target amino acid has yet to be
determined. The actin cytoskeleton tonically represses the mechanosensitivity of
TREK-1 (Lauritzen et al., 2005). TREK channels are functionally similar to the
Aplysia S-type K* channel. The S channel controls presynaptic facilitation of
neurotransmitter release which is needed for behavioural sensitization. TREK
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channels are expressed at high levels in the cerebral cortex and the hippocampus,
which suggests they are important in higher brain processes in humans(Patel and
Honoré 2002).
Membrane stretch reversibly opens the TREK channels. Increasing steps of
negative pressure give increasingly larger currents in TREK-1 transfected COS
cells. TRAAK displays faster desensitization than TREK-1. TREK-2 shows a
high basal current but virtually no desensitization (Patel and Honoré 2002).
TREK-1 is also opened by intracellular acidosis. This property is dependent on
the negative charge of a glutamate (E) residue at position 306 in the proximal C-
terminal domain (Honoré ef al., 2002). Desensitization aids signal plasticity, and
helps protect cells from harmful overstimulation. A channel may desensitize via
inactivation or adaptation. Inactivation is the process whereby the channel is
prevented from activating whereas adaptation refers to an uncoupling of the
stimulus from the channel (Patel et a/., 2001). AA is able to inhibit TREK-1
desensitization. When the brain becomes ischemic, neurons swell, and AA is
released. Intracellular acidosis occurs — activating the TREK channels and
reducing their desensitization. Resultant hyperpolarisation prevents a rise in
[Ca?"], and therefore reduces excitotoxicity (Honoréef al., 2006).
TRAAK currents are instantaneous and non-inactivating. Channel activity is
potentiated by arachidonic acid and docosahexaenoate. This is a direct action and
does not involve protein kinase C. When whole cells are subjected to negative
pressures, TRAAKchannels are opened in a dose-dependent fashion (Lesage ef
al., 2000). In an inside-out patch configuration, TRAAK is opened by negative
pressure, but positive pressure is able to produce activation of TRAAKin the
outside-out patch configuration. This suggests TRAAKis activated by convex
curvature of the plasma membrane (Maingret et al., 1999). Cell depolarisation
lowers the threshold for mechanical activation and also increases the maximal
channelactivity.
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TREK-2 wasthe first Kop channelto be identified in bone, specifically in the rat
UMR-201-10B osteoblastic cell line (Chen et al., 2005). This channel was shown
to have a role in the induction of PTHrP in response to mechanical strain
independent of calcium signalling. Other mechanosensitive channels are
required, as siRNA knockdown of TREK-2 results in a 30% decrease in PTHrP
expression. TREK-2 has also been identified in another peripheral secretory cell
type: the pancreatic B cell line, MIN6 (Kangef al., 2004).
1.5 Ion channels in bone
1.5.1 Expression of various ion channels in osteoblasts
Early osteoblastic cells have been shown to express both L- and T-type Ca**
channels (Bergh et al., 2003, Zahanich et al., 2005). These are voltage-dependent
Ca’* channels (VDCCs) which allow Ca”* influx at depolarized potentials. Their
involvement in the response to 1,25(OH)D3 has been particularly well-
documented (Caffrey and Farach-Carson 1989, Lieberherr, 1987, Civitelli ef al.,
1990, Meszaroset al., 1996 and Zanello and Norman, 2003). Many ion channels
have mechanosensitive properties, which has drawn interest into the possibility
that they may play a role in bone homeostasis. A study by Rawlinson et al.
(1996) noted that gadolinium chloride, a traditionally used blocker of stretch-
sensitive cation channels abolished loading induced PGI (prostacyclin) and NO
release and also reduced PGE) levels in rat ulnae. Nifedipine-sensitive channels
were also shown to be important in the osteoblast response to strain (Rawlinson
et al., 1996). P2 receptors mediate nucleotide-induced signalling in many cell
types. The family is divided into two subclasses; P2X are ligand-gated ion
channels and P2Y are GPCRs. P2 receptors are abundant in bonecells and are
important in localising systemic hormone responses (Gallagher, 2004). N-
methyl-D-aspartate (NMDA) receptors are another ligand-gated ion channel
present in osteoblasts (Gu ef al., 2002). Upon glutamate binding, these channels
allow the influx Ca** and other cations. Recently, osteoblastic cells have been
shown to express several members of the transient receptor potential (TRP)
family of cation channels (Abed ef al., 2009). TRPs are a large family of
channels which havethe ability to form homo- or hetero-tetramers. Various TRP
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channels have already been assigned roles in capacitative calcium entry (CCE),
proliferation and mechanotransduction in murine and human osteosarcomacells
(Baldi ef al., 2003, Labelle et al., 2007).
1.5.2 Potassium channels in bone
Twotypes of potassium currents were observed by Yellowleyet al, (1998) in the
MG-63 cell-line. One displayed characteristics of a K;, channel, i.e. an inward
current sensitive to barium, membrane voltage and external [K"] and the other
appeared to be produced by a Kc, channel. Ca”*-activated K* channels have also
been observed in chick osteoblasts (Raveslootet al., 1990). Moreau etal. (1997)
found that blockade of Ca’’-activated and ATP-dependent K* channels
potentiated 1,25(OH).D3-induced osteocalcin secretion in MG-63 cells. Large-
conductance K” (BK) channels have also been reported to have effects on
mineralization and proliferation in human osteoblasts (Henney ef al., 2009).
Recordings from voltage-gated K” channels have been made from articular
chondrocytes and several K” channels have been observed in murine osteocytes
(Wilson et al., 2004, Gu et al., 2001). Osteoclasts have also been shown to
express various types of K* channels (Komarovaet al., 2001, Ypey et al., 1992,
Weidemaef al., 1997).
1.5.3 Kyp channels in bone
Investigations into the expression of Kp channels in skeletal tissue have been
recent and brief. To date, only two publications have described the presence of
these channels in bone. TREK-1 expression was reported in primary human
osteoblasts and MG-63 cells (Hughesef al., 2006). TREK-2 channels were found
to be a key element in the production of PTHrP following mechanical loading of
rat osteoblastic UMR-201-10b cells (Chen et al., 2005). Chesnoy-Marchais and
Fritsch (1994), used arachidonic acid to modulate ion channel currents in
neonatal rat calvarial osteoblasts. One of the potassium currents they describe
seemsto fit the profile of a TREK channel, although the authors do not suggest a
K»p channel as a possible candidate, this may be due to the very limited
knowledge regarding the Kp channels at the time the paper was published.
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TREK-1 expression has been observed in human tenocytes cultured from human
patellar tendon samples. Recordings from the tenocytes showed an increase in
the TREK-1 current when the cells were exposed to lipophosphtidylcholine
(LPC), a distinguishing characteristic of TREK channels (Magra et al., 2007).
TREK-1 currents have also been reported in humanperiodontal ligament (PDL)
fibroblasts (Saeki ef al., 2007).
1.6 Aims ofthe project
Kop channels are a large and diverse family of ion channel that were initially
found in the nervous system but are increasingly being observedin the periphery.
As previously mentioned, K»p channels are present in bonebuttheir exact profile
is unknown. The hypothesis behind this project is that K2p channels are expressed
in bone and their presence is a requirement for normal osteoblastic function.
Osteoblasts are subject to various tightly controlled processes in an environment
which is physiologically unique. Osteoblasts are conceivably exposed to
mechanicalstrain, elevated extracellular Ca’*, low pH and hypoxia andyet are
still expected to fulfil their bone-forming duties. This project will determine
whether channels other than TREK are present in osteoblasts by creating an
expression profile of the functional members of the K2p family in this cell type.
Further experiments will attempt to characterize the channels shown to be
present and propose an explanation oftheir existence in osteoblasts.
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2.0 Methods
2.1 Tissue culture
2.1.1 Osteosarcoma and primary osteoblastcell culture
All bone-derived cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma) supplemented with penicillin and streptomycin (Sigma), L-
glutamine (Gibco) and 10% FCS (Biosera). SK-N-AS neuroblastoma cells were
kindly provided by Dr Kate Haddley from the School of Biomedical Sciences,
University of Liverpool. They were cultured in DMEM with high glucose
(Sigma) and supplemented with 1% non-essential amino acids in minimal
essential medium (MEM)(Gibco). 9cm Petri dishes were used for general stock
culture and cells were incubated at 37°C with 5% CQy. Cells were routinely
passaged upon reaching confluence using 0.25% trypsin/EDTA
(ethylenediaminetetraacetic acid) (Sigma) in a class II microbiological safety
cabinet. A primary osteoblast sample named MA16 wasobtained from Dr. B.
Mwaura Kimani. Ethical committee approval was obtained for the use of bone
tissue from patients undergoing primary knee replacement surgery in
Wrightington Hospital from the Wrightington, Wigan and Leigh Local Research
Ethics Committee (REC reference number 05/Q1410/13 Date: 21 March 2005).
Only patients with osteoarthritis were included and informed consent was
obtained prior to collection of the tissue. Patients with other arthropathies and
those on steroids and diabetics were excluded. Bone shavings from thetibial and
femoral cuts of a patient with osteoarthritis undergoing total knee replacement
were collected and an explant culture was performed to grow the osteoblasts in
vitro. The cells were frozen downin liquid nitrogen at passage | until they were
required for use in experiments. MA16 cells were used to passage number eight
before being discarded. Passage numbers of the human osteosarcoma cell lines
MG-63, TE-85 and SaOS-2 were unrecorded.
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2.2 Reverse transcriptase polymerase chain reaction (RT-PCR)
2.2.1 mRNA (Messengerribonucleic acid) extraction
Medium was removed from a confluentpetri dish ofcells. Cells were rinsed with
1X phosphate buffered saline (PBS) and 0.5ml of TRI Reagent® (Sigma) was
added over the surface of the dish. A cell scraper was usedto collect the lysate,
which was removed to an eppendorf tube and incubated at RT for 5 minutes.
100ul of chloroform was added to the lysate and the tube gently shaken. This was
then left at RT for a further 15 minutes, before being spun at 12,000g for 15
minutes at 4°C (Megafuge 1.0R, Heraeus Instruments). This process causes the
lysate to separate into three phases containing RNA (ribonucleic acid), DNA
(deoxyribonucleic acid) and protein. The colourless phase at the top of the tube
contains the RNA andsothis was carefully removedto a fresh eppendorf. 0.25ml
of isopropanol was added to the aqueous RNA. This mixture was briefly
vortexed and incubated at RT for 10 minutes, then spun at 12,000g for 10
minutes at 4°C. This step precipitates the RNA into a pellet. Supernatant was
discarded and Iml 100% ethanol was added to the eppendorf. The pellet was
gently loosened by inversion, and the tube spun at 10,000g for 5 minutes at 4°C.
Supernatant was removedandthepellet was air dried for 5 -10 minutes, without
being allowed to dry out completely. 30p1 of molecular biology grade H2O
(Sigma) was added tothe pellet which consequently dissolved.
2.2.2 DNAse (deoxyribonuclease) treatment
2ul DNAse I and 3p! of 10 x PCR buffer (both Qiagen) were added to the
aqueous RNA. The tube wasthen incubatedin a water bath for 1 hour at 37°C.
The DNAse I was inactivated by heating the mixture to 70°C for 15 minutes,
directly after incubation. 31 of 3M sodium acetate, and 90ul of 100% ethanol
were added to re-precipitate the RNA. The tube was centrifuged at 12,000g for 5
minutes at 4°C. Supernatant was removed and the pellet air dried and
resuspendedin 30p1 H2O (Sigma).
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2.2.3 Reverse transcription of mRNA
The concentration of mRNA present in each sample was analysed using a
GeneQuant II machine (Pharmacia Biotech). The 260/280 ratio was calculated
for each sample, and any mRNA with a value lowerthan 1.8 was discarded. Sug
of total RNA wastaken for each cDNApreparation. The appropriate volume of
aqueous RNA wasadded to 1pl of oligo-dT primers (Qiagen) and the total
volume made up to 12ul with H,O. This was incubated in a Peltier Thermal
Cycler, or PTC-200 (MJ Reaseach) for 10 minutes at 70°C. At this point two
reactions were performed per RNA sample, to allow for a non-reverse
transcribed (-RT) control. After incubation 4yl of 5 x first strand buffer, 2ul
0.1M DTT (both Invitrogen) and 1p] dNTPs (deoxynucleotide triphosphates)
were addedto the initial mix. Tubes were incubated for 2 minutes at 70°C before
1ul SuperScript® II (Invitrogen) reverse-transcriptase was added to the +RT tube
and 1yl HO was added to the -RT control. After a brief flick to mix the sample,
tubes were again placed in the PTC-200 andheatedat 42°C for 50 minutes, then
70°C for 15 minutes. After the reaction was complete a test PCR was performed
using Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primers and the
cDNAwasstoredat -20°C.
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2.2.4 PCR sample preparation andreaction conditions
PCRreaction mix
1pl 10 x PCR buffer (Qiagen)
8.111 H2O (Sigma)
0.2ul dNTPs (Amersham)
0.141 SOuM forward primer (0.5.M final)
0.11 50M reverse primer (0.5uM final)
0.11 HotStarTaq (Qiagen)
0.4ul cDNA
Stock solutions were made up containing the 10 x buffer, water,NTPs, primers
and Taq polymerase. 9.61 of this solution was added to a PCR tube (Sigma)
followed by 0.4ul of cDNA. This allowed increased pipetting volume and
therefore ensured a greater degree of accuracy. All reactions were performedin a
PTC-200. Volumes were kept at 10ul total. When a fresh batch of cDNA was
made, the first primers to be run through a PCR were always GAPDHtotest the
presence and quality of the cDNA on gel.
Table 2.1. A description of the conditions used for RT-PCRreactions.
 
  
Step Temperature Time Reaction phase
CC)
1 95 15 minutes Required for activation of the DNA
polymerase.
2 94 30 seconds Denaturation phase.
3 60 30 seconds Annealing phase.
4 72 40 seconds Extension phase. Then back to step 2
(x 35)
3 72 5 minutes Final extension.   
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2.2.5 Gel electrophoresis
PCR reactions were run out on 1.1% agarose gels consisting of 0.66g agarose
(GIBCO BRL) added to 60mls of 1 x TBE (Tris/Borate/EDTA) buffer This
solution was microwaved for approximately 50 seconds, until it began to boil.
Once removed from the microwave and allowed to cool for around 5 minutes,
Sul of SYBR® Safe DNA gel stain (Invitrogen) was added and the gel was cast
in a tray (Appligene). 2ul of type I gel-loading buffer (0.25% bromphenolblue,
0.25% xylene cyanol FF, 40% w/v sucrose made up in distilled water) was added
to each 10u] completed PCR reaction to aid the addition of samples to the gel.
The mixture was vortexed and briefly spun, then loaded into the gel. 2 lanes on
each gel were loaded with 5ul of 50bp DirectLoad™ step ladder (Sigma) to
enable the products to be accurately sized (See figure 2.1 below). The gel was
run at 110V for approximately 50 minutes. The gel was allowed to cool in the
tank for 10 minutes and was viewed using Safe Imager™ transilluminator
(Invitrogen).
Figure 2.1. An image of DirectLoad™step ladder taken from a
1.1% agarose gel. This product contains 17 bands ranging
from 50 bp to 3000 bp.
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2.2.6 Sequencing
A PCRreaction was performed with a larger than normalfinal volume of 50ul.
The PCR product was extracted using QIAquick PCR purification kit (Qiagen)
according to manufactured instructions. 1p of the eluted 50ul final volume was
taken to run on an agarose gel, to confirm the presence of the amplified cDNA.
The concentration of the purified product was determined using the GeneQuant
Il, prior to sending the sample off to be sequenced. The samples were
accompanied by 10ul of 10uM forward and reverse primers. The purified PCR
product was sequenced with the chain-termination method, using the ABI 373
automated DNA sequencer (Applied Biosystems). The samples were processed
by Mr Tadge Szestak in the School of Tropical Medicine, Liverpool University.
Sequencing results were opened in Chromas 2.33 (Technelysium Pty Ltd). The
sequence was then run through a_ nucleotide BLAST search
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) where a percentage value was obtained
for the sequence similarity with the published mRNA.
2.2.7 Primer design and sequences
Primers were designed and then ordered through Oligo Perfect! Designer on the
Invitrogen website. Primers all spanned intron/exon boundaries to distinguish
any genomic amplification. Upon arrival, they were reconstituted using
molecular biology grade H2O (Sigma) to make a stock concentration of 50uM.
Tm for all primers was set at 60°C during the design process and all reactions
were runat this temperature.
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2.3 Immunocytochemistry
2.3.1 Fixation, quenching and permeabilisation
Cells were counted using a haemocytometer (Incyto) and seeded at a
concentration of approximately 1 x 10°cells/ml. Cell suspension was placed onto
38mm glass coverslips (thickness 1) and cultured in 24-well plates overnight in
medium containing 10% FCS. This allowed the cells time to adhere to the
coverslips. The next morning medium was removed from the plate and the cells
were fixed using freshly made 2% paraformaldehyde in PBS, pH 7.4. Following
removal of the fixative after 10 minutes at room temperature, any unbound
paraformaldehyde was quenched with the addition of 100mM glycine, pH 7.4.
The glycine solution was left on for 10 minutes before being replaced by a
permeabilisation solution of 0.1% Triton-X 100 in PBS, pH 7.4 for a further 10
minutes. This allowed the antibodies to gain accessto intracellular epitopes.
2.3.2 Addition of primary and secondary antibodies
Cells were then washed three times in PBS and left at room temperature for a
period of 10 minutes per wash. ~200u1 of antibody buffer (2% v/v goat serum,
0.05% v/v Triton-X 100 and 1% w/v bovine serum albumin (BSA) made upin 1
x SSC, final pH was 7.2) was then added to each well and kept at room
temperature for 30 minutes. After the non-specific binding sites had been
blocked, the anti-rabbit primary antibody (Alomone Labs) could be added.
Antibodies were reconstituted according to manufacturers instructions and
resulted in final concentrations of 0.8mg/ml for TASK-1, TRAAK, TREK-1.
TASK-2 gave a final concentration of 0.3mg/ml and TWIK-2 was used at
0.6mg/ml. All antibodies underwent a 1:200 dilution in antibody buffer prior to
their addition to the cells. The coverslips were incubated with the antibody
solution at 4°C overnight.
After the primary antibody was removed the cells were washed for 10 minutes,
three times using antibody wash solution (0.05% v/v Triton-X 100, made up in
1x SSC and pH adjusted to 7.2). Alexa Fluor-488 goat anti-rabbit IgG secondary
antibody (Invitrogen) was then addedto the coverslips at a 1:500 dilution. The
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plate was covered in foil, to prevent bleaching of the fluorophore. Cells were
exposed to the secondary antibody for 1 hour at room temperature. After this the
3 x 10 minute washes were repeated with antibody wash solution. Prior to
mounting, the coverslips were immersed twice in MilliQ water, covered in foil
and air dried for 2-3 hours.
2.3.3 Mounting
Coverslips were mounted onto a labelled slide using VECTASHEILD® Hard-set
mounting medium with 4',6-diamidino-2-phenylindole (DAPI) (Vector Labs).
20ul mounting medium was applied to each coverslip to give a final
concentration of 1.5ug/ml DAPI. DAPI excites at 360nm and emits at about
460nm when bound to DNA.It is a useful tool in localising the staining of the
primary/secondary antibody complex.
2.3.4 Control experiments
Antibody specificity was tested by using primary antibodies that had been pre-
incubated for 1 hour at 37°C with the corresponding control peptide, at a protein
ratio of 1:1. The control antigen/antibody complex was addedto cells at the same
dilution as primary antibody. Negative controls were produced by omitting the
primary antibody, and incubating with secondary antibody as normal.
2.3.5 Confocal microscopy
Cells were imaged using the 40x oil immersion objective on a Leica confocal
microscope. LCS software was used to operate the microscope and save images
to disk. Alexa Fluor-488 absorbs light at 495nm and emits at 519nm which gives
a green colourto the staining.
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2.4 Western Blotting
2.4.1 Protein Extraction
Lysis buffer
1M Trizma HCI was made up andthe pH adjusted to 8.8.
2ml of 1M Trizma HCl (20mM)
1.46g NaCl (250mM)
0.09g EDTA (3mM)
0.11g EGTA (3mM)
500ul Triton X 100 (0.5%)
The solution was made up to 100ml with distilled and de-ionised water. The pH
was adjusted to 7.6 and the buffer was stored at 4°C. 10u1 of protease inhibitors
were added to every Iml of lysis buffer immediately prior to the protein
extraction.
Confluent petri dishes of cells were placed on ice and their culture medium
removed. 500ul of lysis buffer with protease inhibitors was added to each dish
and left over the ice for 5 minutes. A cell scraper was used to dislodge the cells
from the dish which were then collected into a labelled 1.5ml eppendorf tube.
The lysate was spun in a Megafuge 1.0R (Heraeus) pre-cooled to 4°C at
13,000rpm for 10 minutes. The supernatant wascarefully removedto a fresh tube
and an equal volume of Laemmli 2x sample buffer added (~500p1). The solution
was gently mixed and placed in a heat block at 98 °C for 10 minutes. The protein
extract wasthenstoredat -20 °C.
2.4.2 SDS-PAGE (Sodium dodecyl sulphate-polyacrylamide gel)
A 10% resolving gel was made up using 3.3ml of 30% acrylamide, 2.5ml of
resolving buffer, 100ul of 10% SDS, 3.97ml H2O, 100p1 of 10% ammonium
persulfate (APS) and 5u1 TEMED (tetramethylethylenediamine). The solution
was vortexed and immediately loaded between 2 glass plates assembled in the
casting tray. Enough room wasleft for the stacking gel to sit on top. Isopranolol
was added to makea clean line between the two gels, and prevent the resolving
gel from drying out. The 4% stacking gel consisted of, 1.3ml of 30% acrylamide,
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2.5ml stacking buffer, 100u1 of 10% SDS, 6ml H20, 100p1 of 10% APS and 10ul
TEMED.Isopranolol was poured off the resolving gel once set, which was then
rinsed once with water. The stacking gel was then loaded in the remaining space
between the two glass plates and the comb placed at the top. Once the stacking
gel wasset, the plates were transferred to a clamp which wasplaced into a gel
tank. The 1x SDS running buffer (60g trizma base, 288g glycine and 20g SDS,
madeup into 2L water) was poured into the tank, making sure the inner cell was
completely full and the electrode was fully immersed. The combs were removed
and the Rainbow™ molecular weight markers (GE Healthcare) and protein
extracts were loaded. A charge of 120V wasapplied for 1 hour.
2.4.3 Protein transfer
The nitrocellulose membranesand filter paper were cut to the size of the gel and
the membranes soaked in H2O then transfer buffer. The plates were removed
from the tank and gently prised apart. The 4% stacking gel was removed using a
scalpel and the 10% resolving gel was carefully removed from the plate. A
nitrocellulose membrane wasplaced on top of the gel and smoothed out to ensure
good contact. The gel and membrane were then sandwiched between two damp
filter papers and gauze on either side and placed into a clamp. Once the clamp
had been gently shut, it was put into the gel tank in the appropriate orientation for
transfer. The transfer buffer was poured into the tank and ice packed around the
outside, before 110V were applied for lhr. Transfer buffer was made using, 4.5g
trizma base (25mM), 21.6g glycine (192mM) and 300ml of 100% Methanol
(20%). It was made up to 1.5L and covered to prevent evaporation of the
methanol.
34
2.4.4 Addition of primary and secondary antibodies
Tris-Buffered Saline Tween-20 (TBST) was created using 2.42g Trizma base
(20mM), 8.0g NaCl (127mM) and Iml Tween-20 (0.1%) and made up to 1L
using H2O. The pH wasthen adjusted to 7.6. Once removed from the clamp, the
membrane wasplaced in TBST and trimmedto size using the coloured ladders
on either side of the protein extract as a guide. The membrane was then
incubated in 1% or 5% skimmed milk (Marvel) TBST for a minimum of 1-2
hoursprior to the addition of rabbit primary antibodies (Alomone Labs). Primary
antibodies were used as a 1:200 dilution in milk TBST, and incubated with the
membraneat 4 °C overnight. Three 10 minute washes were performed in TBST
following the removal of the antibody. The goat anti-rabbit horseradish
peroxidase-linked secondary antibody (Sigma) was used at a 1:5000 dilution in
1% milk TBST, and incubated at RT with the membrane for 90 minutes. Three
10 minute washes were repeated, and ECL reagent made up using equal parts of
detection reagents 1 and 2. The ECL waskeptin the dark until it was applied to
the membrane for one minute. The ECL was then removed and the membrane
wrapped in cling film. Small amounts of tape were used secure the covered
membranein a Hypercassette’™ (Amersham Biosciences).
2.4.5 Development
Once in a dark room, a safe light was used to apply Hyperfilm' ECL
(Amersham Biosciences) to the front of the blot. The film was exposed in the
Hypercassette™ for 5 minutes and then a fresh film applied, this time for 10
minutes. The film was developed and then rinsed in water before being fixed and
given a final rinse. Once dry the film could then be overlaid onto the membrane
which wasstill secured in the Hypercassette™. The location of the molecular
weight markers wasthen addedto the film to aid the sizing of the bands.
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2.5 C-fos reporter assay
2.5.1 Cell culture
Stably transfected SaOS-2 cells were cultured as normal in DMEM
supplemented with penicillin, streptomycin, L-glutamine and 10% FCS. G-418
disulphate salt solution (Sigma) was added to this medium at a final
concentration of 5Oyg/ml. This provides cells transfected with the c-fos reporter
gene a survival advantage over wild-type cells. The plasmid used here is
described in the paper by Bowler ef al., (1999), where various cells are
transfected with different versions of the c-fos promoter. Briefly, the fragment
containing the c-fos promoter (spanning positions -721 to -1, accession number
M16287) linked to the luciferase gene was subcloned from pUC19foslucl
(obtained from Dr L. Runkel) into pSV2neo, to create pfoslucneol. The SaOS-2
reporter cells used in this Thesis were created by performing a transfection with
pfoslucneol using Lipofectin (Invitrogen). Cells were frozen in liquid nitrogen
by MsJane Dillon, and stored until they were required for use in experiments.
2.5.2 Assay technique
Cells were seeded into luminometric (white) 96-well plates and allowedto settle
for 24hrs. Cells were then serum starved overnight in DMEM with penicillin,
streptomycin and L-glutamine. The following morning, solutions were made up
according to manufacturer’s instructions (Sigma) and diluted in serum-free
supplemented DMEM. After 4 hours exposure to the agents, medium was
removed and the cells were washed with PBS. 5x cell culture lysis reagent
(Promega) wasdiluted in MilliQ H2O. 20ul of 1x lysis reagent was then added to
each well and left at RT for 15 minutes before the plate was stored at -80°C
overnight. Plates were fully defrosted at RT before being placed in the
luminometer (LUCY 1, Labtech Int). Reagents were added to the plate by
injection, one well at a time. RLU recordings were transferred to a PC using the
Stingray program,and saved in Microsoft excel format.
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2.6 Intracellular calcium imaging
2.6.1 Preparation and loading ofcells
Cells were counted using a haemocytometer and seeded at a concentration of
approximately 1 x 10°cells/ml. The cell suspension was placed onto 22mm glass
coverslips (thickness 1) and cultured in 12-well plates overnight in medium
containing 10% FCS, to allow the cells time to adhere to the coverslips. The
following morning medium was removed from the wells and cells were washed
with HEPES incubation buffer. The wash solution was removed and replaced
with 1ml HEPES loading buffer containing 2u1 of 1mM Fura2-AM (Molecular
Probes), ll sulphinpyrazone and 1pl pluronic F-127. Cells were then placed
back into the incubator and left to load at 37°C for 20 minutes. HEPES (4-(2-
Hydroxyethyl)piperazine-1-ethanesulfonic acid) buffer stock solution comprised
of; HEPES (10mM), NaCl (121mM), KCl (4.7mM), KH2PO,4 (1.2mM), 1M
CaCl, (2mM), NaHCO; (5mM), MgSO, (1.2mM). Reagents were dissolved in
sterile MilliQ water. HEPES incubation buffer was made using 100ml of HEPES
buffer stock solution, stored at 4°C. The following reagents were added; 0.18g
Glucose (10mM) and 0.2g BSA (0.2%). HEPES loading buffer was made by
adding 0.18g BSA to 10ml of HEPESincubation buffer to bring the final BSA
content to 2%.
2.6.2 Recording from cells
After loading was complete, the coverslip was carefully extracted from the plate
using forceps and placed in the incubated chamber kept at 30°C above the oil
immersion lens. 1ml HEPES incubation buffer was added to the chamber. The
cells were brought into focus and a small group of around 5 cells were selected to
record from using the imaging software, although results from individual cells
could be displayed. Recording wasinitiated and 1 minute was allowed to record
background Ca** levels before any compounds were addedto the bath. Changes
in fluorescence were monitored with a PTI Deltascan imaging system coupled to
a Nikon Diaphot inverted microscope and Photon Science Ltd. (Robertsbridge,
UK) Extended ISIS camera. The data were analyzed using PTI ImageMaster
a7
software. Rises in [Ca"]; could be observed by calculating the ratio of emitted
light from Fura-2 (measured at 520 nm), after excitation at 340 and 380 nm.
2.7 Alkalinephosphatase assay
2.7.1 Preparation and treatmentofcells
SaOS-2 cells were seeded into 24-well plates and incubated at 37°C overnight.
The following day, the medium on the cells was changed to include various
treatments. The cells were incubated for a further 24 hours. The medium was
removed from the well into pre-labelled 1.5ml eppendorf tubes, and spun at
13000rpm for 10 minutes (Galaxy 16DH mini microfuge, VWR) to remove any
cell debris. The medium wascarefully decanted into a fresh eppendorf tube and
frozen at -20°C. The cell layer was briefly washed with PBS. 500pl of 1%
TritonX 100 in PBS was added to each well. Plates were then stored at -80°C
overnight. The cell layer underwent a freeze-thaw cycle before analysis.
2.7.2 Assay technique
The cell layer was defrosted at room temperature. The bottom of the wells was
scraped with a pipette tip and then a 20ul sample was taken and placed into a
clear 96-well plate. 2 PNPP tablets were added to 2ml diethanolamine substrate
buffer (5x) (both Pierce) and 8ml distilled H2O. 80yl of the resulting solution
wasaddedto the cell lysate by a multichannel pipette (Rainin). The reaction was
left to run at room temperature for 15 minutes. The reaction was stopped by the
addition of 100u] of 3M NaOH.The absorbanceof the sample was then read in a
spectrophotometer (Anthos Lucy 1, Labtech International) at a wavelength of
405nm.
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2.8 Electrophysiology
2.8.1 Preparation ofcells
Cells were trypsinised as in a routine passage. About Iml of the cell suspension
was addedto a bijou containing 4ml of fresh medium with 10% FCS. Cells were
best whenleft to recover for at least 2hrs after passage. Following the recovery
period, 2001 of the cell suspension was added into the recording chamber. After
the cells were added to the chamber they were left for 15mins to settle on the
bottom before the bathing solution was circulated. This short delay wasto try and
prevent cells being washed away uponactivation of the perfusion system.
2.8.2 Recording from cells
Single osteoblast cells in solution were placed in an experimental chamber
through which control and treatment solutions were perfused. Seals were formed
using a small amount of negative pressure in an extracellular solution containing
(mM): 6 KCl, 134 NaCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 10 glucose (pH adjusted
.to 7.4 with NaOH). The standard pipette (intracellular) solution contained (mM):
107 KCl, 33 KOH, 10 HEPES, 10 EGTA, 3 MgCl2, 3 Na2ATP, pH 7.2.
Membranecurrent and voltage were amplified using an EPC-8 amplifier (List
Instruments), digitised via a Digidata 1200 analogue to digital interface (Axon
Instruments), and recorded on computer using pCLAMP8 software (Axon
Instruments). Data were analysed using pCLAMP8and SigmaPlot. Experiments
were conducted at room temperature (18-22°C). A fresh glass microelectrode
was used for each cell patch. Arachidonic acid (AA) and BL-1249 were obtained
from Sigma Chemicals. AA was made up as 100mM stock solution in
ethanol. Due to the short half-life of this compound in solution, the stock was
prepared immediately before the addition into the recording chamber. BL-1249
was made up as a 10 mMstock solution in DMSO. Stock solutions were added
to the extracellular solution to give the desired concentration.
After the cells were patched, a voltage-step protocol was performed which
recorded current at voltages between -120mV and +100mV in 10mV increments.
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Twocontrol recording were taken from single cell whilst cells were perfused in
the extracellular solution described above. Then either 20uM AA or 10uM BL-
1249 were perfused through the recording chamberandafter three minutes, two
further recordings were taken from the cell. Immediately after the second
recording with the treatment, the recording chamber was washed out. After a
further three minutes two washout recordings were taken to determine if the
response wasreversible. Vehicles were not addedto the control recordings, due
to experiments involving the different compounds being performed on the same
day whilst using the same perfusion system i.e. there was one extracellular
solution (containing 6mM K”*) which was used to perform all the initial
recordings and the wash-out step. For recordings of membrane potential, current
was clamped and voltage was recorded continuously over a period of
approximately 10 minutes. Initially, the cell was perfused with the extracellular
solution, and after a suitable baseline was recorded 10u4M BL-1249 was
circulated through the recording chamber. After several minutes, BL-1249 was
washed out and the recovery of the membrane potential was observed.
2.9 Statistics
All statistics were produced using the InStat® 3.0 program (GraphPad Software,
Inc). On samples which were not matched, a one-way analysis of variance
(ANOVA)wasperformed onthe data. Onresults obtained from matched groups,
such as membrane potential recordings, a one-way ANOVA with repeated
measures was used to compare the means. Data which was not normally
distributed was analysed using a Kruskal-Wallis Test (non-parametric ANOVA)
to test for significance (see Chapter5).
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3.0 Detection of K,p Channel mRNAin Osteoblastic Cells
Using RT-PCR
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3.1 Introduction
The aim of the experiments performed in this chapter was to catalogue the
expression of members of the K2p channel family in osteoblastic cells using RT-
PCR. A range of osteoblastic cell lines were chosen to try and build a
comprehensive and reliable set of data. Included in the study were commonly
used osteosarcomacell lines (MG-63, TE-85 and SaOS-2), primary osteoblasts
obtained from a routine joint replacement operation (MA16) and a neuronalcell
line was utilised as a positive control (SK-N-AS). All of these cells were human
in origin, meaning that the same set of primers could be used forall reverse-
transcribed DNA.Previous studies have identified mRNA encoding members of
the TREK K»p channel family in rodent and humanosteoblastic cells (Chen ef
al., 2005, Hughes ef al., 2006). To date there have been no published
investigations into the expression of other Kyp channel families in bonecells. It
was felt necessary to initiate a thorough investigation into the expression profile
of Kp channels in osteoblasts.
PCR was chosen as a technique to screen for Kp channels asit is a relatively
quick and cost-efficient method and can be performed on multiple cell types.
PCR amplifies a DNA sequenceusing oligonucleotide primers which correspond
to the ends of the target sequence. A PCR cycle consists of three main stages.
The first is carried out at 94°C to denature the double stranded DNA present in
the reaction mix. The second step is the annealing of the primers to the target
DNA sequence which occurs at approximately 55-60°C. Both these phases last
for around 30 seconds. Finally, a slightly longer step allows extension or
polymerisation of the primer-template complex. This cycle is repeated between
30 and 40 times to amplify the template cDNA (complementary DNA) to
amounts detectable on an agarose gel with SYBR®safe. Primers were designed
to be 20bp in length and have a GC content of 45-55%.
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3.2 Methods
Primers were designed against functional human Kp channels using the Oligo
Perfect™ Designer on the Invitrogen website. The primers used in this study
were designed to span intron/exon boundaries within the target gene so that
amplification of genomic DNA would yield a separate band of a higher weight
and therefore be clearly distinguishable from cDNA on gel. After the design
process, all primers were screened using a nucleotide basic local alignment
search tool (BLAST) to confirm they targeted the mRNA for the appropriate Kyp
channel, and that there was no cross-reaction with any other Kop mRNA
sequence. RNA wasextracted from confluent cell cultures using TRI reagent®
(Sigma) and treated with DNAse I (Qiagen) before being reverse transcribed.
PCR reactions were run using HotStarTaq and its appropriate buffer (Qiagen).
Each experiment included the sample mRNAto betested, a negative reverse-
transcribed control and a blank reaction containing no mRNA. This was to
eliminate the possibility of genomic or environmental contamination giving a
false positive result. Only the sample mRNAresults are shown in Section 3.3, as
no bands were observedin any of the negative controls or blanks. Reactions were
run on 1.1% agarose gels in 1x TBE buffer. Included on the gel was a marker
(50bp DirectLoad™ step ladder, Sigma) to enable the products to be accurately
sized. Accurate sizing of the bands close to their expected weight was an early
indicator that the primers were detecting Kop mRNA. To confirm this was the
case, PCR products were sequenced at the School of Tropical Medicine,
Liverpool University. The resulting sequence was viewed in Chromas 2.33
(Technelysium Pty Ltd) and then entered into the nucleotide BLAST database
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) to compare with published mRNA
sequences. A percentage value of similarity between the observed and the
published sequences wasrecorded.
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3.3 Results
Each row represents a separate experiment performed on mRNA which was
extracted freshly each time another PCR screen began. The columnsare headed
by the cell type from which the mRNAwastaken from.
3.3.1 TASK-1
MG-63 TE-85 SaOS-2 MAI16 SK-N-AS
Figure 3.1. TASK-1 mRNA expression in MG-63, TE-85, MAI6, SaOS-2 and SK-N-AS
   
cells. The expected band size was 451bp.
Strongly positive bands can be clearly seen when TE-85 and SK-N-AS cDNA
were run with primers for TASK-1. What appear to be very faint bands can be
observed in the column for MA16 cells. In the third experiment using MG-63
cells a very faint band can just be seen. No positive signals were obtained for
TASK-1 in SaOS-2 cells. A sequencing reaction was performed on the PCR
product from the TE-85cell line. The product was shown to have 100% sequence
identity with TASK-1 mRNA when a BLASTwas used to compare the product
sequence with published sequences (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
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gi|11093519| gbj|AF065163.1)| Homo sapiens Kcnk3 channel mRNA, complete cds
Length=2590
GENE ID: 3777 KCNK3 | potassium channel, subfamily K, member 3 [Homo sapiens]
(Over 10 PubMed links) 
Score = 821 bits (414), Expect = 0.0
Identities = 414/414 (100%), Gaps = 0/414 (0%)
Strand=Plus/Minus
Query 1 AGGCCACGTACTGCGGCTGCGTCTGCAGGGCCTGGTCCTTCTGCAGCGCCACGTAGTCGC 60
PPPEEEL EEE EEE EEE EE EEE EEE PPE EEE EEE PE EEE EEE EE EEE EE EEE EEE EE Et
Sbjct 792 AGGCCACGTACTGCGGCTGCGTCTGCAGGGCCTGGTCCTTCTGCAGCGCCACGTAGTCGC 733
Query 61 CGAAGCCGATGGTGGTGAGGGTGATGAAGCAGTAGTAGTAGGCCTGGAAGAAGGTCCAGT 120
PELPEE EEE EEE EEE EEE EE EE EEE EEE EEE EEE EEE EE EEE EEE EEE EEE EEE Erte
Sbjct 732 CGAAGCCGATGGTGGTGAGGGTGATGAAGCAGTAGTAGTAGGCCTGGAAGAAGGTCCAGT 673
Query 121 GCTCGTAGTGGGAGAAGGCGGCGGCGCCGATGCACAGCGTGCTGATGCACGAGAAGAAGC 180
PEEEEEEEEE EE EEEE EEE EEE EEE EEE EEE EEE EEE EEE EE EEE EEE EE EEE EEE Et
Sbjct 672 GCTCGTAGTGGGAGAAGGCGGCGGCGCCGATGCACAGCGTGCTGATGCACGAGAAGAAGC 613
Query 181 CCATGAGCACCATGTTGGCCATGGACACGTCGGCGCGCCGCATGCCCAGCCCCTICTTGG 240
PPT EE PEEP EEE EEE EEE EEE EEE EEE EE EEE EE EEE EEE EEE EE EEE EEE EEE Ey
Sbjct 612 CGATGAGCACCATGTTGGCCATGGACACGTCGGCGCGCCGCATGCCCAGCCCCTTCTTGG 553
Query 241 CGCGGTGCAGCAGGTACCTCACCAAGGTGTTGATGCGCTCGCCCAGGCTCTGGAACATGA 300
PPEEE EEE EEE EEE EEE EEE EEE EEE EE EEE EEE EEE EE EE EE EE EEE EEE EEE Etre
Sbjct 552 CGCCGTGCAGCAGGTACCTCACCAAGGTGTTGATGCGCTCGCCCAGGCTCTGGAACATGA 493
Query 301 CGAGCCTGAGCGGGATGCCCAGCAGCGCGTAGAACATGCAGAACACCTTGCCGCCATCCG 360
PEELE E EEE ET EE EEE EEE EEE PEEL PEEP EEE EE PEEP EEE EE EEE EERE EE EEE
Sbjct 492 CGAGCCTGAGCGGGATGCCCAGCAGCGCGTAGAACATGCAGAACACCTTGCCGCCATCCG 433
Query 361 TCCTGGGTGCCGCGTGCCCGTAGCCGATGGTGGTGATGACGGTGATGGCGAAGT 414
PEEEEEE EET EEE EEE EP EEE EEE EEE EEE EEE EEE EEE EE EE EEE EEE Err
Sbjct 432 TGCTCGGTGCCGCGTGCCCGTAGCCGATGGTGGTGATGACGGTGATGGCGAAGT 379
Figure 3.2. TASK-1 PCR product sequence obtained using cDNA from TE-85 cells
aligned with a published TASK-1 sequence using nucleotide BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
3.3.2 TASK-2
MG-63 TE-85 SaOS-2 MA16 SK-N-AS  
Figure 3.3. TASK-2 mRNAexpression in MG-63, TE-85, MA16, SaOS-2 and SK-N-AS
cells. The expected band size was 503bp.
TASK-2 expression was strong in TE-85 and SK-N-AScells. Strong expression
was seen in MA16 and MG-63cells in one experiment, and was negative on
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other occasions. A weak band can be observed in the second row for SaOS-2
cells, but this result was not repeated. TASK-2 was observedinall cell lines
studied, although its expression was not seen consistently. A BLAST search on
the PCR product from TE-85 cells was performed and revealed 98% homology
between the product and published TASK-2 sequences.
gi|88999598|ref|NM 003740.3]| Homo sapiens potassium channel, subfamily K, member
5 (KCNKS),
mRNA
Length=3800
GENE ID: 8645 KCNK5 | potassium channel, subfamily K, member 5 [Homo sapiens]
(Over 10 PubMed links)
Score = 831 bits (419), Expect 0.0
Identities = 464/473 (98%), Gaps = 7/473 (1%)
Strand=Plus/Plus
Il
Query 1 AGACGTGTGAGTCTGCGTGAAGGCACAGATCACGTTGGCACAGTCATCTTGCATCGTGTG 60
PEEPT TEEPE EEE EE PEEEEE TEEEEEE EEE PEPE EE PEEP tl LETEttttt
Sbjct 815 AGACCTGTGAGTCTGCG-GAAGGCGCAGATCACGT--GCACAGTCATCTT-CATCGTGTG 870
Query 61 GCCCGTGCCTAGTCCACCTGGTGATCCCACCCTTCGTATTGTCATGGTGACTGAGGGGTG 120
PIEEEE EEEPET EE EEE EEE EEE EEE PEE EEE EEE FLEET E ETE EE ttt eel
Sbjct 871 GGGCCT-CCTAGTCCACCTGGTGATCCCACCCTTCGTATT--CATGGTGACTGAGGGGTG 927
Query 121 GAACTACATCGAGGGCCTCTACTACTCCTTCATCACCATCTCCACCATCGGCTTCGGTGA 180
PEEL EE PEELE EEE EEE EEE EEE EEE EE EEE EEE EEE EEE EEE EE EE EEE EE EEE
Sbjct 928 GAACTACATCGAGGGCCTCTACTACTCCTTCATCACCATCTCCACCATCGGCITCGGTGA 987
Query 181 CTTTCTGGCCGGTGTGAACCCCAGCGCCAACTACCACGCCCTGTACCGCTACTTCGTGGA 240
PEEP PEEP EEE EEE EEE EE EE EEE E EEE EE EE EE PEE EE EE EE EEE EE EE EEE Ett
Sbjct 988 CTTTGTGGCCGGTGTGAACCCCAGCGCCAACTACCACGCCCTGTACCGCTACTTCGTGGA 1047
Query 241 GCTCTGGATCTACTTGGGGCTGGCCTGGCTGTCCCTTTTTGTCAACTGGAAGGTGAGCAT 300
PPP PEE EEE EE EEE EE EEE EE EEE EEE EEE EE EEE EEE EE EEE PEE EE EEE EEE
Sbjct 1048 GCTCTGGATCTACTTGGGGCTGGCCTGGCTGTCCCTTTTTGICAACTGGAAGGTGAGCAT 1107
Query 301 GTTTCTGGAAGTCCACAAAGCCATTAAGAAGCGGCGGCGGCGACGGAAGGAGTCCTTTGA 360
PPP EEE EEE EEE EEE EEE EEE EE EE EEE EEE EEE EEE EEE EE EEE PEE EE EE Eee
Sbjct 1108 GITTGTGGAAGTCCACAAAGCCATTAAGAAGCGGCGGCGGCGACGGAAGGAGTCCTTTGA 1167
Query 361 GAGCTCCCCACACTCCCGGAAGGCCCTGCAGGTGAAGGGGAGCACAGCCTCCAATGACGT 420
PPPP ETE E PEELE EEE EEE EE EEE EEE EE EEE EE EEE EEE EEE EE EEE Et Hit
Sbjct 1168 GAGCTCCCCACACTCCCGGAAGGCCCTGCAGGTGAAGGGGAGCACAGCCTCCAAGGACGT 1227
Query 421 CAACATCTTCAGCTTTCTTTCCAAGAAGGAAGAGACCTACAACGACCTCATCA 473PEPE LEE EE EE EE EEE EE EEE PEE EE EEE EEE EEE EEE EEE EEE EEE EET
Sbjct 1228 CAACATCTTCAGCTTTCTTTCCAAGAAGGAAGAGACCTACAACGACCTCATCA 1280
Figure 3.4. TASK-2 PCR product sequence obtained using cDNA from TE-85 cells
aligned with a published TASK-2 sequence using nucleotide BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
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3.3.3 TASK-3
MG-63 TE-85 SaOS-2 MA16 SK-N-AS
 
   
Figure 3.5. TASK-3 mRNA expression in MG-63, TE-85, MA16, SaOS-2 and SK-N-AS
cells. The expected band size was 310bp.
SK-N-AScells gave a strongly positive signal for TASK-3 on two occasions.
The other positive signal came from MA16 cDNA. All bands obtained with
TASK-3 primers appear to be very thick and in the two bands in the first row
look like two bandsvery closely related in size.
3.3.4 TASK-5
MG-63 TE-85 SaOS-2 MAI6 SK-N-AS
  
Figure 3.6. TASK-5 mRNAexpression in MG-63, TE-85, MA16, SaOS-2 and SK-N-AS
cells. The expected bandsize was 560bp.
TASK-5 signal wasonly faintly detected in cDNA from MA16 cells. The bands
are faint but appeared on both occasionsthe experiment wasrun. Nosignal was
observed in any ofthe othercell types.
3.3.5 TWIK-1
MG-63 TE-85 SaOS-2 MAI6 SK-N-AS
Figure 3.7. TWIK-1 mRNA expression in MG-63, TE-85, MA 16, SaOS-2 and SK-N-AS
cells. The expected band size was 502bp.
  
gi|15451900|ref|NM 002245.2| Homo sapiens potassium channel, subfamily K, member
1 (KCNK1),
mRNA
Length=1901
 
GENE ID: 3775 KCNK1 | potassium channel, subfamily K, member 1 [Homo sapiens]
(Over 10 PubMed links)
Score = 926 bits (467), Expect = 0.0
Identities = 467/467 (100%), Gaps = 0/467 (0%)
Strand=Plus/Plus
Query 1 TCTACTCCGTCATTGGCATTCCCTTCACCCTCCTGTTCCTGACGGCTGTGGTCCAGCGCA 60
PEIPT EEE ELE EEE EEE EEE E EE EE EE EE EEE EE EE EE EEE EE EE EE EE EEE EEE tt
Sbjct 589 TCTACTCCGTCATTGGCATTCCCTTCACCCTCCTGTTCCTGACGGCTGTGGTCCAGCGCA 648
Query 61 TCACCGTGCACGTCACCCGCAGGCCGGTCCTCTACTTCCACATCCGCTGGGGCTTCTCCA 120
PPP ET PEPE EE EEE EE EE EEE EEE EEE EEE EE EEE PEE EEE EE EEE EEE EEE EEE
Sbjct 649 TCACCGTGCACGTCACCCGCAGGCCGGTCCTCTACTTCCACATCCGCTGGGGCTTCTCCA 708
Query 121 AGCAGGTGGTGGCCATCGTCCATGCCGTGCTCCTTGGGTTTGTCACTGTGTCCTGCTICT
180
PPPEEEE EEE EE EE EEE EE PEEP EE EEE EEE EEE EEE EE EE EEE PEE EEE EEE EEE
Sbjct 709 AGCAGGTGGTGGCCATCGTCCATGCCGTGCTCCTTGGGTTTGTCACTGTGTCCTGCTICT 768
Query 181 TCTTCATCCCGGCCGCTGTCTTCTCAGTCCTGGAGGATGACTGGAACTTCCTGGAAT
CCT 240
PELLET PEELE EEE EEE EE EEE EEE EEE EEE PEELE EEE EEE EEE EEE EEE
Sbjct 769 TCTTCATCCCGGCCGCTGTCTTCTCAGTCCTGGAGGATGACTGGAACTTCCTGGAATCCT 828
Query 241 PTPATTTTTGTTTTATTTCCCTGAGCACCATTGGCCTGGGGGATTATGTGCCTGGGGAAG 300
PPPPEE IEEE PEEP EEE EEE PEPE EEE EEE EEE EEE EEE EEE EEE EEE Et
Sbjct 829 PTTATTTTTGTTTTATTTCCCTGAGCACCATTGGCCTGGGGGATTATGTGCCTGGGGAAG 888
Query 301 GCTACAATCAAAAATTCAGAGAGCTCTATAAGATTGGGATCACGTGTTACCTGCTACTIG 360
PPELITP ELIE PEEEEE EEE EE EEE EE EEE EEE EEE EEE EEE EEE EEE EEE
Sbjct 889 GCTACAATCAAAAATTCAGAGAGCTCTATAAGATTGGGATCACGTGTTACCTGCTACTTG 948
Query 361 GCCTTATTGCCATGTTGGTAGTTCTGGAAACCTTCTGTGAACTCCATGAGCTGAAAAAAT 420
TTP UTEP PEELE EEE PEELE EEE EEE EEE EEE EEE PEELE EEE
Sbjct 949 GCCTTATTGCCATGTTGGTAGTTCTGGAAACCTTCTGTGAACTCCATGAGCTGAABABAT 1008
Query 421 TCAGAAAAATGTTCTATGTGAAGAAGGACAAGGACGAGGATCAGGTG
=
467
PEPE EEE E PEELE EE EEE EEE EEE EEE EEE EEE EEE EEE EEE
Sbjct 1009 TCAGAAAAATGTTCTATGTGAAGAAGGACAAGGACGAGGATCAGGTG 1055
Figure 3.8. TWIK-1 PCR product sequence obtained using cDNA from MG-63 cells
aligned with a published TWIK-1 sequence using nucleotide BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
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TWIK-1 primers gavepositive results in all of the cells lines studied with the
exception of SaOS-2. The signal was variable in MG-63 cells but was
nonetheless detected on two occasions. PCR product from MG-63 cDNA was
purified and sequenced. A BLAST search on the product revealed 100%
homology with the published sequence for TWIK-1 mRNA.
3.3.6 TWIK-2
MG-63 TE-85 SaOS-2 MAI6 SK-N-AS
Figure 3.9. TWIK-2 mRNAexpression in MG-63, TE-85, MA16, SaOS-2 and SK-N-AS
 
cells. The expected bandsize was 393bp.
Remarkably, TWIK-2 was present in all of the samples studied in each
experiment. Signals appeared stronger in TE-85 and MA16 cells when compared
with MG-63 and SaOS-2. A sequencing reaction was performed on purified PCR
product which originated from MG-63 cDNA.A BLASTsearch showed the PCR
product had 97% homology with a published sequence for TWIK-2.
gi|13325107| gb|BC004367.1| Homo sapiens potassium channel, subfamily K, member 6,
mRNA (cDNA
clone MGC:10363 IMAGE:3639657), complete cds
Length=2604
GENE ID: 9424 KCNK6 | potassium channel, subfamily K, member 6 [Homo sapiens]
(Over 10 PubMed links)
Score = 444 bits (224), Expect = 2e-121
Identities = 264/272 (97%), Gaps = 4/272 (1%)
Strand=Plus/Minus
Query 5 GAGAGTTGCTGGTGCGACTCCGGCTGGGGGCCCATGGATGTCCACCCGATCGTCCTCATC 64
PCEEEEEE LEE EE EEE |
Sbjct 942 GAGAGTTGCTGGTGCGACTCCGGCTGGGGGCCCA-GGATGTCCACCCGATCGTCCTCATC 884
Query 65 CGCATTGAAACTGGCAGGGCACGGAGGGGGCAGCAGGATGAGCTCCGTGAGGCCGTGGAG 124
PEPE EE PEPE EEE PEEP PEEP EEE EEE EEE PEE EEE EEE EE EEE EEE EE EEE EEE
Sbjct 883 CGCATTGAAACTGGCAGGGCACGGAGGGGGCAGCAGGATGAGCTCCGTGAGGCCGTGGAG 824
Query 125 GTCGGACATCGTGGCGGAAGGTCTGCAGCACCAGCACCATGGCCACCAGGCCCAGGAAGA 184
PELEEEEE PEPER EEE PEE EE EEE EEE EEE PEEP EEE EEE EEE EEE EEE Een
Sbjct 823 GTCGGACA-CGTGGCGGAAGGTCTGCAGCACCAGCACCATGGCCACCAGGCCCAGGAAGA 765
Query 185 GGTAGACTGTGACCGCCGCCTTGGTAGAGGGCCCGGTACGGCTGGCCAGGGGCCTCCCGC 244
POPIRVMEL GMM UAeMeNe ey tes LU Melee Det SUE TET NE TPT
eM
STN SERTSL ISDST ASSET Lets
Sbjct 764 GGTAGACTGTGACCAGCACCTT-GTAGAGGGCCCGGTAGGGCTGGCCAGGGGCCTCCC-C 707
Query 245 GGGCACGTAGTCGCCCAGGCCGATGGTGGACA 276PIEEEEEE EEE PEPE PEEP EEE EEE Eten
Sbjct 706 GGGCACGTAGTCGCCCAGGCCGATGGTGGACA 675
Figure 3.10. TWIK-2 PCR product sequence obtained using cDNA from MG-63cells
aligned with a published TWIK-2 sequence using nucleotide BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
3.3.7 THIK-2
MG-63 TE-85 SaOS-2 MAI6 SK-N-AS
 
Figure 3.11. THIK-2 mRNAexpression in MG-63, TE-85, MA16, SaOS-2 and SK-N-
AScells. The expected band size was 488bp.
THIK-2 mRNA wasnot detected in any of the osteoblastic samples despite
multiple experiments using cDNA extracted on different occasions. It was also
undetected in the neuronal cell line SK-N-AS.
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3.3.8 TALK-1
MG-63 TE-85 SaOS-2 MA16 SK-N-AS
Figure 3.12. TALK-1 mRNA expression in MG-63, TE-85, MA16, SaOS-2 and SK-N-
  
  
AScells. The expected band size was 235bp.
No positive results were observed when any ofthe cell lines were screened with
primers targeted at TALK-1 cDNA.
3.3.9 TALK-2
MG-63 TE-85 SaOS-2 MAI6 SK-N-AS
 
Figure 3.13. TALK-2 mRNA expression in MG-63, TE-85, MA16, SaOS-2 and SK-N-
AScells. The expected band size was 344bp.
TALK-2 mRNAwasnotdetected in any of the samplesdespite multiple attempts
at running the reaction.
3.3.10 THIK-1
MG-63 TE-85 SaOS-2 MAI16 SK-N-AS
Figure 3.14. THIK-1 mRNA expression in MG-63, TE-85, MA16, SaOS-2 and SK-N-
  
AScells. The expected band size was 451 bp.
No THIK-1 mRNAwasdetected in anyofthe cell lines.
3.3.11 TRESK
MG-63 TE-85 SaOS-2 MA16 SK-N-AS
Figure 3.15. TRESK mRNAexpression in MG-63, TE-85, MA16, SaOS-2 and SK-N-
AScells. The expected band size was 530bp.
TRESK-1 productwasnot detected in any ofthe experiments.
3.3.12 TRAAK
MG-63 TE-85 SaOS-2 MA16 SK-N-AS   
Figure 3.16. TRAAK mRNAexpression in MG-63, TE-85, MA16, SaOS-2 and SK-N-
AScells. The expected band size was 447bp.
gil 7576934 |gb|AF247042.1|AF247042 Homo sapiens tandem pore domain
 
channel TRAAK (KCNK4)
mRNA,
Score 283 bits (143), Expect
complete cds
Length=2772
6e-73Il
Identities = 318/371 (85%), Gaps = 4/371 (1%)
Strand=Plus/Minus
Query
Sbjct
Query
Sbjct
Query
Sbjct
Query
Sbjct
Query
Sbjct
Query
Sbjct
Query
Sbjct
33
797
93
7137
153
213
619
273
559
333
501
393
441
ACATAATCGCCAAAGCCTACAGTGGTGAGTGTCACTATAACAAAGTAGATGGCTTCCAGC
PELE TEEEEEEEEEE EE PEERED EE TEEPE EEE EEEEEE EEE EEE rh EEtetACATAGTCGCCAAAGCCCACGGTGGTAAGCGTCACTATGACAAAGTAGATGGCCTCCAGC
TTGCTCCAGACTCTCCATGTAGGAGAACACGAAGGTAGGAGTGAGGACAAAGAGCAGGCA
PEPEEEETE POPPER TEE EEEEEEEEEE EE EE EEEEEE PEPE EEE EEE EtTTGCTCCAGTC-CTCCATATAGCAGAACACGAACGTGGGCGTGAGGACAAAGAGCAGGCA
GCCAATCAACAGGAAGAGCACCGCAGACAGCATATCTCACCAGCCCTGGTGGCACATGCC
PEE TEL TEEEEE PEEP TEE TEEEEEE TPE EE PEE b TEEEEEEE EEtlGCCGATCAGCAGGAAAAGCATCGCCGACAGCAC-TCTTACTAGCTCCGGTGGCACGTGCC
ACTTCAAGAAAACTGCTTCGATGTGACCGATGCCCCGGCGCAGAGAGGAGCCCAGCCGGT
PEPEEEEE EE PO EEEEE PEPEEEEEE EE EEE TEEEEEE PEPE EE EE EE EEEACTTCAAGAAGATGGCTTCAATGTGACCGATGCCATGGCGCAGGGAGGAGCCCAGCCGGT
CCCCGACTCCAGCCAGCAGGCATCCCGAACAGTGGGATCCCCACCAGTGCATAGTAAGAT
PLETE TE PEELE PEE TEEPE TEEPE EE TEEEEEEEE EE PEPEr th PitreCCCCGACCCCTGCCAGTAGG-ATCCCAAACAGCGGAATCCCCACCAGCGCATAG-AAGAT
ACAAAAGAGACGCCCAGCATCTGTGTGTAAGGCTATATTGCCGTAGCCGATGGTAGTGAT
PE TITLE PEELE TEEPE EEE Pb EEE E PEEP EE PEER EEE EEE EdGCAGAAGAGGCGCCCGGCATCTGTGCGCAGGGCCACATTGCCATAGCCGATGGTGGTGAT
GATGGTCCCTG 403
TEtttittielGATGGTCCCTG 431
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Figure 3.17. TRAAK PCR product sequence obtained using cDNA from MG-63cells
aligned with a published TRAAK sequence using nucleotide
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
a2
BLAST
TRAAK mRNA was detected in all cell lines, for each experiment. The
osteoblastic cell lines MG-63 and SaOS-2 appear to express TRAAK more
strongly than the neuronalcell line. In the first band in the MG-63 column and
the second experiment for SaOS-2 it appears there are two bands very close in
size and almost overlapping. Purified product from a PCRreaction using MG-63
cDNA showed 85% homology with a published human TRAAK sequence.
Although this was a lower value than some of the other sequences achieved,it
wasstill the best match against all human mRNAin the PubMeddatabase.
3.3.13 TREK-1
MG-63 TE-85 SaOS-2 MA16 SK-N-AS  
 
Figure 3.18. TREK-1 mRNA expression in MG-63, TE-85, MAI16, SaOS-2 and SK-N-
AScells. The expected band size was 591 bp.
TREK-1 was detected in TE-85, SaOS-2, MA16 and SK-N-AS. As with the
TRAAKresults, TREK-1 expression appears stronger in the osteoblastic cells
than in the neuronalcell line. TREK-1 mRNA wasabsent from the MG-63 cells
studied. A sequencing reaction was performed against purified PCR product
originating from TE-85 cDNA. There was 99% homology between the product
and published sequences for TREK-1.
gi|126723760|ref|NM 014217.3| Homo sapiens potassium channel, subfamily K, member
2 (KCNK2),
transcript variant 2, mRNA
Length=3274
GENE ID: 3776 KCNK2 | potassium channel, subfamily K, member 2 [Homo sapiens]
(Over 10 PubMed links)
Score = 1072 bits (541), Expect 0.0
Identities = 551/553 (99%), Gaps = 1/553 (0%)
Strand=Plus/Plus
Query 5 ACTGGGATTTGGGAAGTTCCTTCTTCTTTGCTGGCACTGTTATTACAACCATAGGATTTG 64
POPPE PEPE EE EEE EEE EEE EEE EEE EE EEE EEE EE EEE EE EEE EEE EEE EE EEE Et
Sbjct 467 ACTGGGATTTGGGAAGTICCTTCTTCTTTGCTGGCACTGTTATTACAACCATAGGATITG 526
Query 65 GAAACATCTCACCACGCACAGAAGGCGGCAAAATATTCTGTATCATCTATGCCTTACTGG 124
PEEEE EEE EEE EE EEE EEE EEE EEE EE EEE EE EEE EEE EEE EE EEE EEE EE EEE EEE Ey
Sbjct 527 GAAACATCTCACCACGCACAGAAGGCGGCAAAATATTCTGTATCATCTATGCCTTACTGG 586
Query 125 GAATTCCCCTCTTTGGTTTTCTCTTGGCTGGAGTTGGAGATCAGCTAGGCACCATATTTG 184
PEELE EP EEE EE EP EEE EEE EP EP EEE EEE EEE EEE EE EEE EE EE EEE EE EE EEE
Sbjct 587 GAATTCCCCTCTTTGGTTTTCTCTTGGCTGGAGTTGGAGATCAGCTAGGCACCATATITG 646
Query 185 GAAAAGGAATTGCCAAAGTGGAAGATACGTTTATTAAGTGGAATGTTAGTCAGACCAAGA 244
PEELE EEE EEE EEE E EE EEE PEPE PEEP EE EE EEE EE EEE EEE EEE EEE EE EET
Sbjct 647 GAAAAGGAATTGCCAAAGTGGAAGATACGTTTATTAAGTGGAATGTTAGTCAGACCAAGA 706
Query 245 TTCGCATCATCTCAACAATCATATTTATACTATTTGGCTGTGTACTCTTTGTGGCTCTGC 304
PEPE LEE E PEEP EEE EEE EE EE EEE EEE EEE EE EEE EEE EEE EEE EE EEE EE EEE
Sbjct 707 TTCGCATCATCTCAACAATCATATTTATACTATTTGGCTGTGTACTCITTGIGGCTCTGC 766
Query 305 CTGCGATCATATTCAAACACATAGAAGGCTGGAGTGCCCTGGACGCCATTTATTTTGTGG 364
PPPEEE EP PEEP EEE EE EE EEE EEE EE EE EE EEE EE EE EEE EEE EEE EEE EEE EEE
Sbjct 767 CTGCGATCATATTCAAACACATAGAAGGCTGGAGTGCCCTGGACGCCATITATTTTGTGG 826
Query 365 TTATCACTCTAACAACTATTGGATTTGGTGACTACGTTGCAGGTGGATCCGATATTGAAT 424
PEEP PEEP PEELE EE EEE EEE PEEL EE EE EE EE EP EEE EE EE EE EEE EEE EEE EEE
Sbjct 827 TTATCACTCTAACAACTATTGGATTTGGTGACTACGTTGCAGGTGGATCCGATATTGAAT 886
Query 425 ATCTGCGACTTCTATAAGCCTGTCGTGTGGTTCTGGATCCTTGTAGGGCTTGCTTACTTITG 484
PEEP EE EEE EEE EEE EEE E EE EE EE EE EEE EEE EEE EEE EE EE EE EEE EEE EEE
Sbjct 887 ATCTGGACTTCTATAAGCCTGTCGTGTGGTTCTGGATCCTTGTAGGGCTTGCTTACTTTG 946
Query 485 CTGCTGTCCTGAGCATGATTGGAGATTGGCTCCGAGTGATATCTAAAAAGAACAAAAGAG
=
544
PET EPELEE EE EEE EEE EEE EEE EE EEE EEE EEE EE EEE EEE EET Ete PEEL tttl
Sbjct 947 CTGCTGTICCTGAGCATGATTGGAGATTGGCTCCGAGTGATATCTAAAAAG-ACAAAAGAA 1005
Query 545 GAGGTGGGAGAGT 557PLETE EEP titel
Sbjct 1006 GAGGTGGGAGAGT 1018
Figure 3.19. TREK-1 PCR product sequence obtained using cDNA from TE-85 cells
aligned with a published TREK-1 sequence using nucleotide BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
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3.3.14 TREK-2
MG-63 TE-85 SaOS-2 MAI16 SK-N-AS
 
Figure 3.20. TREK-2 mRNAexpression in MG-63, TE-85, MA16, SaOS-2 and SK-N-
AScells. The expected band size was 364bp.
TREK-2 mRNAwasdetected once in a sample from SK-N-AScells. It was not
detected in any of the osteoblastic cell lines or primary osteoblasts. TREK-2
primers were designed to target all three transcript variants described for
productsofthis gene.
Table 3.1. Summary of PCR results for all primer sets screened in MG-63, TE-85,
MA16, SaOS-2 and SK-N-AScells.
 
        
TE-85 MG-63 SaOS-2 MA16 SK-N-AS
TASK-1 ++ ~ - + ++
TASK-2 ++ + ~ ++ +
TASK-3 - - - + ++
TASK-5 - - - + :
TWIK-1 =P + - ++ ++
TWIK-2 + ++ + ++ ++
THIK-2 - - - - -
TALK-I - - - - -
TALK-2 - - - - -
THIK-1 - - - - -
TRESK - - - - -
TRAAK + ++ ++ + +
TREK-1 ++ - + ++ +
TREK-2 - : - - + |
- no expression detected ~ possible weak expression
+ weak expression ++ strong expression
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3.4 Discussion
The screening of primary osteoblasts and osteoblast cell lines for all functional
members of the Kp family of channels gave a number of repeatable positive and
negative outcomes. These results are summarized in Figure 3.1. Out of 14 primer
sets used, 9 of these gave positive results in at least one of the cell lines used. Of
the 9 positive results, 6 were sequenced and all of these samples were found to
match the published sequences to an acceptable degree. Members of the TASK,
TWIK and TREKsub-families dominated the expression profile of Kyp channels
in osteoblastic cells. TASK-2 was the sole representative of the alkaline-
activated, or TALK sub-family. THIK and TRESK channels were absent from
the various osteoblastic cells studied and the neuronally derived cell line SK-N-
AS.
Previous work has described the expression of members of the TREK family of
Kop channels in osteoblastic cells (Chen ef al., 2005, Hughes ef al., 2006).
Hugheset al., (2006) reported the expression of TREK-1 in three out of three
primary human osteoblast samples and in MG-63 cells. The expression of
TRAAKand TREK-? variant c was observed in some of the primary osteoblasts
and appeared to vary between passage numbers. MG-63 cells expressed TRAAK
but not TREK-2c. The aboveresults confirm the finding that primary osteoblasts
strongly express TREK-1 mRNA, but we did not observe TREK-1 mRNAin
MG-63 cells. Hughes and co-workers reported the expression of TRAAKin most
of the primary human osteoblasts and in MG-63 cells which these results also
agree with. Chen ef al. (2005) reported the expression of TREK-2 mRNAin the
rat osteoblastic cell line UMR201. TREK-2 expression was not seen in the
humanosteoblastic cells studied here, but it was detected in SK-N-AScells. The
TREK-2 primers in this Chapter were designed to target all three splice variants
of the TREK-2 gene. Hugheset al., (2006) detected TREK-2c mRNAin anearly
passage of one of the primary osteoblast samples but all other experiments
proved negative. Because Chenef al. (2005) did not report on the expression of
TRAAK or TREK-1, it is not possible to directly compare the expression of
TREK channels between humanandrat osteoblastic cells. It seems possible that
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there is some species variation in the expression of this sub-family of Kop
channels in osteoblasts.
To date, no other reports have been published on the expression of the remaining
sub-groups in the Kp channel family in bone. However, a small number of
studies have observed K»p channels in other skeletal tissues. Magra et al. (2007)
described the expression of TREK-1 in tenocytes from humanpatellar tendon
and a study by Saeki ef al. (2007) looked into the expression of several Kop
channels in PDL fibroblasts. The PDL acts as a cushion between bone and tooth
and is exposed to large forces during mastication. The fibroblasts revealed a
strikingly similar pattern to that seen in the data for osteoblastic cells above.
They described the mRNA present by order of its relative expression level as
follows: TWIK-2 > TREK-1 > TWIK-1 >> TASK-1> TRAAK > TASK-2. They
did not detect any TREK-2 mRNAin their sample which also complements the
findings reported here.
The studies mentioned above claim that the mechanosensitive, and to an extent,
AA-sensitivity of the TREK channels explains their presence in skeletal tissue
(Chenet al., 2005, Hugheset al., 2006, Magraet al., 2007 & Saeki etal., 2007).
Boneis an organ which is subjected to large mechanical stimuli on a regular
basis. This is a necessary duty and one whichis in fact required to maintain bone
health. The presence and subsequent activation of a TREK Kop channel in
response to mechanical force may have a numberof advantageous effects. The
first major benefit may be transduction of the stimulus into an intracellular signal
via a change in the membranepotential. The second benefit may come simply
from change in the membrane potential to a more negative value. This would
confer a protective effect in an environment where repeated stimulation may lead
to excitotoxicity. Finally, the release of AA from membranelipids in response to
stretch would also activate a TREK channel which could lead to either or both of
the above scenarios.
TASK channels are sensitive to external influences such as pH, glucose
concentration and hypoxia (Duprat ef al., 2007). They are inhibited by
extracellular protons prompting the possibility they may act as an acid sensor for
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osteoblasts. TASK-3 is less sensitive to low pH than TASK-1 & -2 channels
(Liu et al., 2005). This simple fact may help to explain the presence of TASK-3
in primary osteoblasts and its absence in osteosarcoma cell lines. TASK-1
displays a relatively even pattern of expression between the CNS and the
periphery whereas TASK-2 channels are mainly found in the periphery and
TASK-3is highly expressed in the CNS, (Goldstein et al., 2005, Medhurst efal.,
2001).
The presence of TWIK-1 & -2 channels is more difficult to explain, given the
poor functional data available for these channels in the literature. TWIK-1 & -2
expression has been documented in the nervous system and in peripheral tissues
such as pancreas, spleen and stomach (Goldstein et al., 2005, Medhurster ai.,
2001). Given that TWIK-1 & -2 have been showninthis chapter to be expressed
very consistently across a numberofdifferent osteoblastic cells and considering
the data published by Saeki er al., (2007), a functionalrole is likely to exist for
them in osteoblasts. The other member of the TWIK family not mentionedis this
chapter is KCNK7. This was notincludedin the initial primer design due toits
lack of functional activity. Perhaps in retrospect, it would have beeninteresting
to look at the expression ofthis silent subunit in comparisonto its close relations
TWIK-1 &-2.
The lack of THIK-1 & -2, TALK-1 & -2 and TRESK maybeexplained by the
limited expression and functional activity of these channels. THIK-1 is widely
expressed in rat but not human tissues and no functional activity has been
observed from THIK-2 (Rajan ef al., 2001). TALK-1 & -2 are sensitive to
alkaline pH andare activated by NO (Dupratet al., 2005, Kang & Kim, 2004).
The latter property of TALK channels may be useful in a mechanically
stimulated bone environment, although it is possible that they are presentin other
skeletal cell types. TRESKis highly localised to dorsal root ganglia, and does not
posses any specific properties which might aid osteoblast function.
59
As yet there are no investigations which have focussed on Kp expression in
osteoclasts or osteocytes. It would be interesting to see if the profile of channel
expression seen in osteoblasts is similar to, or complementary to that which may
be seen in osteoclasts and osteocytes. Given that an osteoclast performsits duties
in acidic and basic conditions, it may be expected that members of the TASK
family are present in this cell type. By the same logic, one might expect the
mechanosensitive osteocytes to express some membersofthe TREK family.
3.5 Conclusion
Screening of human osteoblasts and osteosarcomacell lines revealed mRNA
expression of TASK-1, -2, -3 & -5, TWIK-1 & -2, TREK-1 and TRAAK. mRNA
for TALK-1 & -2, TRESK, THIK-1 & -2 and TREK-2 was not observed in
osteoblastic cells. Further experiments are necessary to determine if protein
expression matches that of the transcript and to characterise the functional role of
these proteins in bone. The data in this Chapter reveals that Kp channel
expression in osteoblasts is not confined to members of the TREK family.
Although no published studies have stated that Kyp expression in osteoblasts is
limited to TREK channels, the lack of discussion and experimentation regarding
the other sub-families needs to be addressed.It is perhaps surprising that so many
membersof the Kp family are expressed in osteoblasts. The volume of channels
that gave positive results in the RT-PCRindicate that there may be more than
one functional role for these proteins in bone.
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4.0 Detection of K,p Channel Proteins in Osteoblastic
Cells Using Immunocytochemistry & Western Blotting
4.1 Introduction
The aim of these experiments wasto utilise commercially developed antibodies
targeting Kp channels, to screen for the presence of these proteins in human
osteoblastic cell lines and primary osteoblasts. The mRNAexpression profile for
this family of channels is detailed in the previous Chapter and summarised in
Table 3.1. Antibodies were chosen based on both the probability of finding the
protein when taking into account the PCR data, and their availability at the time
of performing the experiments. Two commonly used techniques were chosen to
investigate Kp protein expression; immunocytochemistry and western blotting.
Immunocytochemistry gives an indication of the location of the protein within
the cell, whereas western blotting can reveal the rough quantity of the protein
present and any discrepancies in band sizing. As is the case throughout this
Thesis. it is difficult to directly compare these results to published data.
Relatively few studies have looked at K* channel protein expression in this cell
type using immunocytochemistry and western blotting (Butler ef al., 2010,
Hughes etal., 2006, Moreauet al., 1997, Hernandezet al., 2007).
Immunoglobulin G (IgG) is the one of the simplest and most commontypes of
antibody. IgG antibodies contain 3 segments that form a “Y” shape; two
“Fragments having the Antigen Binding site” (fab) connected by a hinge to one
“Fragment that Crystallizes” (fc). The fe section allows other proteins involved
in the immune response to recognise the antibody and complete the removal of
the antigen. The hinge is a small peptide sequence which allows lateral and
rotational movements of the fab fragments. This increases the chance of an
antibody binding site gaining accesstoits antigen.
Figure 4.1. Schematic
cane representation of an IgG
— A A antibody. The blue lines
Fab domain —_ Y VA represent the heavy chain
hee fragments and the brown
Fe domain — lines the light chain
Hinge fragments.
62
Amino acids are charged molecules, so the overall charge of a protein is
dependant on the composition and number of amino acids it contains. The
detergent sodium dodecyl sulphate (SDS) binds to hydrophobic regions within
proteins. Roughly one molecule of SDS binds for every pair of amino acids. This
causes a protein to revert to its secondary structure and eliminates any protein-
protein interactions. SDS is added to protein samples in addition to the reducing
agent B-mercaptoethanol which breaks any disulphide bonds. Protein/SDS
complexes are negatively charged. This means that any protein, regardless of
whetherit is initially positively or negatively charged can be analysed using the
charge-to-massratio conferred by SDS binding. When the complex is run out on
an SDS polyacrylamide gel (SDS-PAGE), protein migrates towards the positive
electrode and the porous polyacrylamide slows down the migration of the larger
proteins, allowing size separation. The addition of ammonium persulphate (APS)
and TEMEDinto the acrylamide solution assists in the polymerization of the
acrylamide monomerbyrespectively releasing and stabilising free radicals.
If using a whole-cell extract, or tissue preparation, many proteins will be present
on the SDS-PAGEgel. Individual proteins within the sample may beidentified
by antibodies coupled to a detectable dye or enzyme. This is usually done after
transfer of proteins from the gel to a nitrocellulose membrane using a strong
electrical field. The membrane can be incubated with primary and then secondary
antibodies to confirm the presence of a specific protein using enhanced
chemiluminescence (ECL). In a western blot, the secondary antibody is usually
linked to a horseradish peroxidise (HRP) enzyme whichcatalyses the oxidation
of luminol, a cyclic diacylhydrazide. After oxidation, the luminol emits light in a
bid to return to its ground state. The location of the secondary antibody can
therefore be revealed by exposing the membraneto a light-sensitive film. The
weight of the protein of interest can be determined by comparing its band with
molecular weight protein markers also run on the SDS-PAGEgel.
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4.2 Methods
For immunocytochemistry, cells were seeded onto glass coverslips at
approximately 1 x 10°cells/ml. The following day, cells were fixed using 2%
paraformaldehyde before being quenched and permeabilised. After washing,
non-specific binding sites were blocked and primary antibodies were added. The
cells were incubated with the antibody solution overnight at 4°C. The following
morning, the primary antibody solution was removed, cells were washed and the
secondary antibody was added and incubated at RT for one hour. During this
time, the coverslips were covered in foil to prevent bleaching of the fluorophore.
Cells were washed again and the coverslips immersed in MilliQ water to remove
the final traces of unbound secondary antibody. Coverslips were mounted onto a
labelled slide using VECTASHEILD® Hard-set mounting medium with 4',6-
diamidino-2-phenylindole (DAPI) (Vector Labs).
For western blotting experiments, one lot of protein was extracted from each of
the three cell lines and two western blots were performed using this sample.
Confluent petri dishes of cells were lysed and the sample was centrifuged.
Protein extract was obtained from the supernatant fraction and equal volume of
Laemmli 2x sample buffer added (~500p1). Protein extracts were run on SDS-
PAGE gels, before being transferred to a nitrocellulose membrane. The
membrane wasthen incubated in 1% or 5% skimmed milk (Marvel) TBST for a
minimum of 1-2 hours prior to the addition of rabbit primary antibodies
(Alomone Labs). Primary antibodies were incubated with the membrane at 4°C
overnight. The goat anti-rabbit horseradish peroxidase-linked secondary antibody
(Sigma) was incubated at RT with the membrane for 90 minutes. ECL was
freshly made up and applied to the membrane for one minute. The ECL was then
removed and the membrane wrapped in cling film. Small amounts of tape were
used secure the covered membrane in a Hypercassette™ (Amersham
Biosciences). Once in a dark room,a safe light was used to apply Hyperfilm™
ECL (Amersham Biosciences) to the front of the blot. The film was exposed in
the Hypercassette'|™ for 5 or 10 minutes. The film was developed and then rinsed
in water before being fixed and given a final rinse. Once dry the film could then
be overlaid onto the membrane whichwasstill secured in the Hypercassette™.
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The location of the molecular weight markers was then added to the film to aid
the sizing of the bands.
Table 4.1. Epitopes of the primary antibodies used for immunocytochemistry and
western blotting in this chapter (AlomoneLabs).
 
 
Antibody Epitope location Residues Epitope
Anti-TASK-1 C-terminus 252 - 269 (C)IEDEKRDAEHRALLTRNGQ
Anti-TASK-2 C-terminus 483 - 499 (C)YYEQLMNEYNKANSPKGT
Anti-TWIK-2 C-terminus 295 - 313 (CHESHQQLSASSHTDYASIPR
Anti-TRAAK C-terminus 343 - 359 (C)NLAFIDESSDTQSERGC
Anti-TREK-1 N-terminus 8 - 25 DPKSAAQNSKPRLSFSTK(C)    
4.3 Results: Immunocytochemistry
4.3.1 TASK-1
Staining for TASK-1 was weak in all cell lines studied. In MG-63 cells it is
diffuse and faint, prompting the possibility that TASK-1 protein is present in
these cells in small quantities. In MA16 and TE-85 cells staining is concentrated
close to the nucleus but is not seen elsewhere, which the image analysis confirms
(see section E of figures 4.2 — 4.4).
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Figure 4.2. MG-63 cells stained with primary antibodies against TASK-1. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image anaylsis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
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Figure 4.3. MA16 cells stained with primary antibodies against TASK-1. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
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Figure 4.4. TE-85 cells stained with primary antibodies against TASK-1. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
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4.3.2 TASK-2
TASK-2 staining is variable across cell lines. In MG-63 cells, it appears to be
membranousas well as perinuclear. In MA16 cells staining can only be observed
in the perinuclear region, although the confluence of these cells makesit difficult
to see if any other cellular locations are stained. TE-85 cells display a similar
pattern to MG-63cells but the staining not associated with the nucleusis slightly
weaker.
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Figure 4.5. MG-63 cells stained with primary antibodies against TASK-2. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
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Figure 4.6. MA16 cells stained with primary antibodies against TASK-2. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
throughthe cell selected in D.
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Figure 4.7. TE-85 cells stained with primary antibodies against TASK-2. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
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4.3.3 TWIK-2
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Figure 4.8. MG-63 cells stained with primary antibodies against TWIK-2. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
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Figure 4.9. MA16 cells stained with primary antibodies against TWIK-2. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
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Figure 4.10. TE-85 cells stained with primary antibodies against TWIK-2. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
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Figure 4.11. TE-85 cells stained with primary antibodies against TWIK-2 (2x zoom). A)
Alexa Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI.
In MG-63 cells a clear definition of the cell shape can be seen due to TWIK-2
staining in the membrane. MA16 cells show diffuse perinuclear staining with no
apparent membranoussignal. TE-85 cells display in interesting punctate pattern
of staining close to the nucleus in addition to a more diffuse staining pattern in
the region of the cell membrane. In all cell lines stained with TWIK-2 the blue
DAPIsignal is more clearly seen without association with Alexa Fluor-488.
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4.3.4 TRAAK
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Figure 4.12. MG-63 cells stained with primary antibodies against TRAAK. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
77
 
 250 -
—~ 200-
-Ss2g 150
5a9eS8 100 +
ma2 4aE 350 4 0.00000 0.00001. -«=s«.00002«=S=S«i.00003 «(0.00004
Length (m)
Figure 4.13. MA16 cells stained with primary antibodies against TRAAK. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
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Figure 4.14. TE-85 cells stained with primary antibodies against TRAAK. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
throughthe cell selected in D.
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All cell lines show a strong punctate perinuclear and nuclear pattern of staining.
MG-63 and TE-85 cells also display what appears to be membranousstaining
whichis particularly strong in MG-63 cells. Signal intensity values were strong
in all cells stained with anti-TRAAKantibodies.
4.3.5 TREK-1
Anti-TREK-1 antibody gave the strongest indication so far of membranous
staining. All cell lines exhibited diffuse staining which clearly defined the shape
of the cell membrane andits processes. In the pictures taken with the 2x zoom
function, this was evident again on largerscale.
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Figure 4.15. MG-63 cells stained with primary antibodies against TREK-1. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
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Figure 4.16. MG-63 cells stained with primary antibodies against TREK-1 (2x zoom).
A) Alexa Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI.
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Figure 4.17. MA16 cells stained with primary antibodies against TREK-1. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
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Figure 4.18. MA16 cells stained with primary antibodies against TREK-1 (2x zoom). A)
Alexa Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI.
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Figure 4.19. TE-85 cells stained with primary antibodies against TREK-1. A) Alexa
Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken
for image analysis. E) Graph showing the intensity of staining along the sample line
through the cell selected in D.
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Figure 4.20. TE-85 cells stained with primary antibodies against TREK-1 (2x zoom). A)
Alexa Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI.
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4.3.6 Negative control
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Figure 4.21. MG-63 cells with primary antibody omitted. A) Alexa Fluor-488. B) DAPI.
C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken for image analysis. E)
Graph showingthe intensity of staining along the sample line throughthecell selected in
D.
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Figure 4.22. MA16 cells with primary antibody omitted. A) Alexa Fluor-488. B) DAPI.
C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken for image analysis. E)
Graph showingthe intensity of staining along the sample line through the cell selected in
D.
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Figure 4.23. TE-85 cells with primary antibody omitted. A) Alexa Fluor-488. B) DAPI.
C) Overlaid image of Alexa Fluor-488 & DAPI. D) Sample taken for image analysis. E)
Graph showingtheintensity of staining along the sample line through the cell selected in
D.
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No Alexa Fluor-488 staining was observed in any of the cell lines without
primary antibody. A small amount ofcross-talk between the fluorophores can be
seen in the analysis of the staining along the sample lines in each of the three cell
types. For brevity, only the images taken from MG-63 cells are shown in the
control peptide experiments below. No staining was seen in any of the negative
controls or experiments performed with the control peptides.
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4.3.7 TASK-1 control peptide
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Figure 4.24. MG-63 cells exposed to anti-TASK-1 preincubated with a control peptide.
A) Alexa Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D)
Sample taken for image anaylsis. E) Graph showingtheintensity of staining along the
sample line through the cell selected in D.
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4.3.8 TASK-2 control peptide
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Figure 4.25. MG-63 cells exposed to anti-TASK-2 preincubated with a control peptide.
A) Alexa Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D)
Sample taken for image anaylsis. E) Graph showing theintensity of staining along the
sampleline throughthecell selected in D.
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4.3.9 TWIK-2 control peptide
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Figure 4.26. MG-63 cells exposed to anti-TWIK-2 preincubated with a control peptide.
A) Alexa Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D)
 
Sample taken for image anaylsis. E) Graph showing the intensity of staining along the
sample line through the cell selected in D.
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4.3.10 TRAAK control peptide
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Figure 4.27. MG-63 cells exposed to anti-TRAAKpreincubated with a control peptide.
A) Alexa Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D)
Sample taken for image anaylsis. E) Graph showing the intensity of staining along the
sample line through the cell selected in D.
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4.3.11 TREK-1 control peptide
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Figure 4.28. MG-63 cells exposed to anti-TREK-1 preincubated with a control peptide.
A) Alexa Fluor-488. B) DAPI. C) Overlaid image of Alexa Fluor-488 & DAPI. D)
Sample taken for image anaylsis. E) Graph showing the intensity of staining along the
sample line through the cell selected in D
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Table 4.3. Mean Signal Intensity (SI) and width values for Kyp channelstaining outside
the nuclear region, with the mean distance from the nucleus (Data is expressed + SEM)
 
  
(n=5).
Cell Antibody Mean SI of Mean width of Mean distance
Type extranuclear extranuclear peaks from
peaks (um) the nucleus
(um)
TE-85 TASK-2 71.1412.8 14 +04 8.5 + 3.8
TE-85 TWIK-2 65.6 + 6.7 3.5+0.9 3.4+ 1.0
TE-85 TRAAK 79.6 + 6.6 2.5+0.4 3.1+ 0.6
TE-85 TREK-1 66.2 + 3.6 2.5+0.5 4.9+1.6
MA16 TREK-1 79.3 + 3.6 3.340.7 6.2 + 1.3
MG-63 TWIK-2 70.9 + 2.0 1.0+0.1 4.7+0.6
MG-63 TRAAK 108.4+5.6 1.5+0.1 5.2+1.0
MG-63 TREK-1 108.5 + 2.9 1140.1 8.0+1.5    
97
 
4.4 Results: Western Blotting
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Figure 4.29. Western blot of cell proteins targeted with an antibody against TASK-1.
Performed under reducing conditions with 1% skimmed milk powder. The blot was
exposed to the photographic film for 1 minute.
Figure 4.29 showsprotein extract from MG-63, TE-85 and MA16cells screened
with an antibody against TASK-1. Bands for TASK-1 appear strong in the lanes
containing protein extract from TE-85 and MA16 cells at around the level of
50kDa. There appear to be bands at approximately dimer weight in all lanes,
including a faint band in the MG-63 extract.
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Figure 4.30. Western blot of cell proteins targeted with an antibody against TASK-2.
Performed under reducing conditions with 1% skimmed milk powder. The blot was
exposed to the photographic film for 5 minutes.
Figure 4.30 shows a western blot performed against the TASK-2 channel protein.
The weight of the rather weak bands in MA16 & TE-85 lanes is approximately
57kDa. No bandscan be seen in the lane containing MG-63 protein extract, even
with a more prolonged exposure period (data not shown).
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Figure 4.31. Western blot ofcell proteins targeted with an antibody against TWIK-2.
Performed under non-reducing conditions with 1% skimmed milk powder. The blot was
exposed to the photographic film for 5 minutes.
Some very weak staining can be observed in Figure 4.31, which shows protein
extract from MG-63, TE-85 and MA16 cells screened with an antibody against
TWIK-2. The staining appears to be at the upper and lower extremities of the
blot, with two faint bands seen at above the level of 100kDa and a band in each
lane below the level of 50kDa.
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Figure 4.32. Western blot of cell proteins targeted with an antibody against TRAAK.
Performed under non-reducing conditions with 1% skimmed milk powder. The blot was
exposedto the photographic film for 5 minutes.
Anti-TRAAK targeted against osteoblast cell proteins revealed a band at ~52kDa
in MG-63 protein extract. Multiple bands at a variety of weights between
110kDa and 40kDa can be seen in the lanes containing MA16 and TE-85
proteins. However, a band giving very intense staining appears at around 110kDa
for TE-85 and MA16.
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Figure 4.33. Western blot of cell proteins targeted with an antibody against TREK-1.
Performed under non-reducing conditions with 1% skimmed milk powder. The blot was
exposed to the photographic film for 10 minutes.
Western blotting of osteoblastic cell lysate with anti-TREK-1 revealed two
narrow but intense bands at approximately 105kDa for TE-85 and MA16. No
other bands can be observed in the lanes containing these protein extracts, and
the MG-63 lane appears empty, despite the lengthy exposure of the blot to the
film.
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4.5 Discussion
The aim of this chapter was to look for protein expression of K2p channels in
osteoblastic cells using commercially available antibodies.
Immunocytochemistry gave a visual indication of the abundanceand localisation
of the protein whereas western blotting confirmed the presence of the protein
using a different technique. TWIK-2, TRAAK and TREK-1 appeared to reach
the plasma membrane and showedstrong staining in all three cell lines. TASK-2
stained to a lesser extent and was more variable between cell types. TASK-1
displayed very weak perinuclear staining in all cell lines studied. Negative
controls and control peptide staining were clean. However, they did show that
there was some cross-over from the nuclear DAPI signal into the Alexa Fluor-
488 signal. Western blotting proved helpful for TASK-1 & -2 as these results
showedstraightforward single bandsat the expected weight. Bands for TRAAK
& TREK-1 indicated the dimerisation of these proteins. The blot for TWIK-2
was confusing, but immunocytochemistry staining wasrelatively strong for this
channel.
4.5.1 Immunocytochemistry
TASK-1 gave a weak signal that appeared to be in close proximity to the nucleus
in all three cell lines observed. In MG-63cells there did appear to be some weak
staining in the cytoplasm. This may suggest that although mRNAand protein
may be present in osteoblastic cells, the channel is not trafficked to the plasma
membrane, orif it is, it is present in very small amounts. TASK-2 presents a
similar story to its relative TASK-1, however in MG-63 and TE-85 cells, there
appeared to be some weakstaining outside the nuclear region. TWIK-2 staining
in MA16 cells is similar to that of TASK-1 in the same cell type, but perhaps
slightly stronger and more diffuse. TWIK-2 signal from TE-85 cells shows an
intense area of staining in the perinuclear region, but also defines the outline of
the cell through what appears to be a signal coming from the membrane. Based
on theseresults, it does seem as though functional activity of TWIK-2 would be
likely in TE-85 cells. When stained for TRAAK,all cells displayed concentrated
perinuclear staining. In MG-63 and TE-85cells, the overall shape of the cells
was defined due to staining in the cell processes. This gives a good indication
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that TRAAK channels are trafficked to the plasma membrane. This was not the
case for MA16 cells, where the only staining remained close to the nucleus
again. With TREK-1staining, the cell processes becameclearly visible and there
did not appear to be any perinuclear staining. The TREK-1 antibody gave what
appears to bethe clearest indication yet of localising in the plasma membrane,
this time in all cell types; supporting the hypothesis that TREK-1 channels are
involved with the actin cytoskeleton (Lauritzen et al., 2005). Negative controls
and antibodies that were added with control peptides did not show any staining,
indicating the absenceoffalse-positives. Hughes ef al. (2006) only used TREK-1
antibodies in their immunohistochemical study. The pattern of staining they
observed was similar to that seen here in section 4.3.5. This is the only
comparison available from osteoblastic studies within the current literature.
Looking into the width of a staining pattern should give a reliable guide as to the
type of staining i.e. nuclear (broad), organellar (intermediate) or membranous
(narrow). Most antibodies screened produced positive signals in the perinuclear
region. The width of these signals showed a collection of very narrow peaks
towards the higher intensities, and a broad band underneath which roughly
corresponded with the DAPI signal. For TREK-1, and to some extent TASK-2,
TRAAK and TWIK-2, the staining appeared to be more independent of the
nuclear region. A Z-series scan could enable us to prove that the 488 signalis in
fact lying in a narrow plane around the nucleus, rather than throughout the
nucleus as it might appear on a 2D image. The process of fixing and
permeabilisation is bound to affect cellular morphology. For some of the more
diffuse staining appearing around the nucleus, it may be possible that the cell
membrane is brought into closer proximity to the nucleus through reduced
cytoplasmic volume, making it seem as though there is staining in the nucleus
itself when assessing a 2D image. As for why the signal might be congregating
close to the nuclear area, it is possible that the antibody is binding to a channel
still in the protein synthesis pathway. There is no reason whythese antibodies
could not have the ability to stain the protein present in the rough endoplasmic
reticulum (rER) or even in the Golgi apparatus. Both these organellesare situated
in close proximity to the nucleus. The issue of staining in the nuclear region is
exacerbated by somecross-talk between the two fluorescent stains used. This is
104
clearly evidenced by the images seen using the control peptides, and by the
resulting cross sections taken through stained cells. In the graphs shown
corresponding to the control peptide images, a small and even rise in Alexa
Fluor-488 signal is observed over the nucleus. Ion channels have been shown to
be present within the nuclear membrane, mainlyto aid in the transduction of Ca”*
signals into the nucleus (Bkaily et al., 2006, Gobeil ef al., 2002). Ion channels
are also present in organellar cell membranesother than the nucleus (Débska e¢
al., 2001). Other types of K” channel have been shown to be present in osteoblast
intracellular organelles through the use ofelectron microscopy (Butler ef ai.,
2010). It would be difficult to assign a possible role to Kp channels present
inracellularly, given that they mostly seem to be involved in transducing
extracellular stimuli into membrane potential changes and in the case of
mechanosensitive TREK-1 channels, are involved with the actin cytoskeleton
(Lauritzen etal., 2005).
4.5.2 Western Blotting
None of the blots shown in Section 4.4 revealed any strong staining from the
MG-63 cells. This could be addressed by either preparing a fresh sample of
protein extract then retesting the sample, or from running a positive control
antibody such as GAPDHoractin against the MG-63 sample used above. Bands
for TASK-1 appearstrongin the lanes containing protein extract from TE-85 and
MA16 cells at around the level of 50kDa. There appear to be bands at
approximately dimer weight forall three extracts. For the western blot performed
against TASK-2, the weight of bands in MA16 & TE-85 lanes is ~57kDa.
Beckett ef al., (2008) recorded bands for TASK-1 & -2 on western blots at
around the 50kDa level which agrees with the data shown in Figures 4.29 &
4.30. Staining with the TWIK-2 antibody was faint, and bands did not appearat
the expected weight. In their datasheet, Alomone Labs show a western blot of rat
brain membraneswith 2 distinct molecular weight bands. The smaller weight is
approximately 48kDaand the heavier weight band is around 88kDa. Theblot for
TWIK-2 seen in this chapter does not appear to correspond to the one shown in
the antibody datasheet. Anti-TRAAK targeted against osteoblast cell proteins
revealed a band at ~52kDa in MG-63 protein extract which corresponds with the
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example given in the antibody datasheet. Multiple bands can be seen in the lanes
containing MA16 and TE-85proteins, but the heaviest band appears to be around
dimer weight. Because multiple bands were seen for anti-TRAAK,a protein
BLAST search was run against the epitope of the antibody
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). No obvious result other than the target
was revealed. Western blotting of osteoblastic cell lysate with anti-TREK-1
revealed two narrow but intense bands at dimer weight for TE-85 and MA16.
Hugheset al. (2006) performed immunocytochemistry against TREK-1 channels
in osteoblasts using antibodies from Alomone Labs, yet the same paper used
antibodies produced by Santa Cruz for western blotting. The authors do not
explain their reasons for this, but presumably the respective antibodies gave the
best results for the method they were selected for. Since the experiments for this
thesis were performed, more antibodies for Kyp channels have becomeavailable.
Alomone Labs now provide a more complete range of antibodies against some of
the less well studied proteins such as THIK-1 & TRESK as well as TWIK-1 &
TREK-2. Although to date only Hughesef al. (2006) have published Kp western
blotting data from osteoblasts, others have shown the presence of different
members of K* channel family in this cell type (Moreauet al., 1997, Hernandez
et al., 2007).
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4.6 Conclusions
In this Chapter, osteoblastic cells were screened for protein expression of
selected Kp channels using immunocytochemistry and western blotting. Protein
was observed for all the Kyp channels studied in varying quantities. The most
striking and promising result is that for TREK-1, which wasstrongly positive in
all cell lines using immunocytochemistry and showed clear evidence of
localising to the plasma membrane. Theresults obtained using the anti-TRAAK
antibody were also positive, but western blotting revealed the possibility of non-
specific binding: a suspicion that was refuted upon a protein BLAST search
using the epitope sequence. TWIK-2 and TASK-2 appeared to be expressed in
moderate amounts, particularly in TE-85 and MG-63 cells although the bandsfor
the corresponding western blots were weak in comparison. Anti-TASK-1 gave a
small amount of immunochemical staining which did not appear to reach the
plasma membrane. There were some discrepancies between the techniques, for
example a strong cellular signal for TWIK-2 did not complement the weak
staining obtained using western blotting. Conversely, anti-TASK-1 gave strong
bands at the correct weight in the western blot but weak staining in the
immunocytochemistry. Overall the results supported the data from Chapter 3,
which confirmed mRNAexpression of members of the TASK, TALK, TWIK
and TREK families. This data in the current Chapter shows that the mRNA
expression observed previously is successfully translated into protein which is
able to reach the plasma membrane.
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5.0 Effects of K° and Ca’ Channel Agents on
Osteoblastic Markers
5.1 Introduction
C-fos is a proto-oncogene found in manycell types. It is an immediate early gene
which encodesthe transcription factor Fos. Fos heterodimerizes with members of
the Jun family of transcription factors to form a complex known as AP-1. C-fos
expression can be induced by rises in intracellular Ca’* or cAMP. Upon Ca’*
entry into a cell through L-type Ca”* channels, cAMP response element binding
protein (CREB) becomes phosphorylated at serine 133. Transactivation of the
promoter cAMP response element (CRE) by phosphorylated CREB,results in
the initiation and elongation of c-fos transcription (Thompsonef al., 1995). The
increase in fos subsequently increases AP-1 transactivation which has
downstream effects on osteoblast differentiation and function. Fos expression is
also important for osteoclast function. Fos -/- mice exhibit osteopetrosis due to
impaired osteoclast differentiation (Grigoriadis et al., 1995). In contrast, mice
over-expressing the c-fos gene develop osteosarcomas. C-fos measurementis
often used in osteoblasts to study the cellular response to PTH. See Chapter 1 for
an overview onthe effects of PTH on c-fos expression.
Manyofthe agents used in this Chapter are K” channel openers (KCOs) and K*
channel blockers (KCBs). Opening of K* channels results in potassium efflux
and subsequent hyperpolarisation. Closure of these channels prevents potassium
efflux and may contribute to a depolarization. Calcium channel agents used in
these experiments target L-type voltage-gated Ca”* channels. Blockade of these
channels prevents Ca’* influx during a depolarization resulting in downstream
effects on secretion and genetranscription.
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5.2 Methods
The reporter cells described in this chapter were transfected with the full c-fos
promoterlinked to the luciferase gene. If c-fos expression was induced then there
was more luciferase present in the cell with which to catalyse the transformation
of luciferin substrate into oxyluciferin. A useful by-product of this reaction is the
emission of light. This allows c-fos induction to be determined by the amount of
light produced by the cell lysate upon addition of the substrate. The following
equation summarizesthe reaction (Promega technical bulletin, TB281):
Firefly luciferase
Luciferin + O2 + ATP — Oxyluciferin + AMP + PP; + CO, + Light
Mg”*
For the assay, cells were seeded in 96-well luminometric plates andleft to settle
for 24 hours. The following day, the medium was changed to serum-free and the
cells were left overnight. On the day of the assay, solutions were freshly prepared
and the cells were exposed to the treatments in serum-free medium for 4 hours.
Following the treatment time, the medium was removedand the cell layer was
washed with 1X PBS. 1X lysis reagent was then added to each well andleft at
RT for 15 minutes before the plate was stored at -80°C overnight, allowing for a
freeze-thaw cycle to aid cell lysis. Plates were fully defrosted at RT before being
read in the luminometer (LUCY 1, Labtech Int).
Cells for use in alkaline phosphatase assays were seeded into 24-well plates a
day prior to the experiment, and left to settle overnight. The following day,
treatments were added to the cells and plates were incubated for 24hrs. Medium
was then removedandthe cell layer was lysed and frozen. Both samples were
assayed using a kit from Pierce. For calcium imaging, cells were grown onglass
coverslips and loaded with Fura-2AM.Recordings of intracellular calcium were
madein responseto the addition of PTH and ATP.
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5.3 Results
5.3.1 Traditional and putative potassium channel modulators
The specific aim of the experiments in this Chapter was to see if K” channel
modulators could in any way affect the expression of the immediate early gene c-
fos or ALP levels in osteoblastic cells. In order to answer this query, a
preliminary experiment was designed to investigate the effects of several
compounds known for their ability to alter K” channel function. Observations
were made on both basal and elevated c-fos levels in stably transfected SaOS-2
reporter cells. Generic KCBs barium and TEA were used along with TREK-1
activators BL-1249 ((5,6,7,8-tetrahydro-naphthalen-1-yl)-[2-(1 H-tetrazol-5-yl)-
phenyl]-amine) and riluzole. Pinacidil opens Karp channels and relaxes vascular
smooth muscle at 10uM (Quayle et al., 1995). BL-1249 was used at 10uM
concentration as its ECs was calculated as 1-2uM by Tertyshnikova et al.,
(2005) and was shown to activate TREK-1 in unpublished observations from this
laboratory. 10 - 100uM riluzole also activates TREK-1 channels (Dupratet ai.,
2000). 0.1mM Barium and 1mM TEA have been used for decades to block
various K* channels (Hille, 2001).
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Vehicle Barium Riluzole Pinacidil BL-1249 TEA
Figure 5.1. Preliminary data which show the effects of various K’ channel modulators
on basal c-fos expression in SaOS-2 cells (n=6-9). Concentrations used were; 0.1mM
barium chloride, 104M riluzole, 104M pinacidil, 104M BL-1249 and I1mM TEA.Error
bars represent S.D.
The only significant differences compared with vehicle-treated control cells
came from the wells treated with 10uM pinacidil and 10uM BL-1249 (both
P<0.001). Exposure to pinacidil resulted in a 28% increase in c-fos expression
over basal levels whereas BL-1249 treatment gave a 31% reduction. To see if
BL-1249 could maintain this effect during a physiological elevation of c-fos
expression, its effects were then assessed in conjunction with 0.5nM PTH (1 —
34). Evanset al. (1996) report that PTH (1 — 34) in the nanomolar to millimolar
range activates c-fos gene transcription via PKA-dependentsignalling in SaOS-2
cells.
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Vehicle BL-1249 PIF PTH + BL-1249
Figure 5.2. The effect of 104M BL-1249 + 0.5nM PTHonc-fos expression in SaOS-2
cells (n=17). Each n numberrepresents an average value from between 6-24 wells. Error
bars represent S.D.
In this experiment 10uM BL-1249 treatment did not produce a statistically
significant reduction in basal c-fos levels, although a 20% reduction suggests that
the trend is reproducible given the high n value for this data set. Exposure to
0.5nM PTH gave a 5.1-fold increase over basal levels of c-fos expression
(P<0.001). 104M BL-1249 reduced the c-fos induction by PTH down to 1.9-fold
above basal expression levels. When compared with PTH treatment alone the
difference was significant (P<0.001). To test for the dose-dependency of this
effect a concentration-response experiment was performed.
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Figure 5.3. Concentration-response curve showing 0.5nM PTH-induced c-fos expression
with 0.1 - 100M BL-1249 (n=6-9). A sigmoidal curve wasfitted to the data. The ICs»
value calculated from this fit is 16.64M BL-1249. Error bars represent S.E.M.
The reduction in elevated c-fos levels by BL-1249 is shown in Figure 5.3 to be
dose-dependent. The ICs value against 0.5nM PTHis 16.64M BL-1249. Given
the measurable effects of the putative TREK-1 activator BL-1249 on c-fos
expression, the next candidate compound for screening was another TREK-1
activator; the anti-convulsant and neuroprotective drugriluzole.
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Vehicle Riluzole PTH PTH + Riluzole
Figure 5.4. The effect of 10M riluzole + 0.5nM PTH on c-fos expression in SaOS-2
cells (n=12-24). Error bars represent S.D.
10uM Riluzole was chosenas this was used effectively in a study done on human
skeletal muscle (Wang ef al., 2008). Treatment with 10uM riluzole induced a
modest 17% increase in c-fos expression over basal levels, which was not
significant. As seen previously, the induction of c-fos by 0.5nM PTH proved to
be significant versus vehicle-treated control cells (P<0.001). When combined
with PTH treatmentriluzole produced a synergistic increase in c-fos expression,
doubling the amount of c-fos present compared with PTH treatment alone
(P<0.001). As investigations into Kp channel openers had shown effects on
basal and PTH-induced c-fos expression, the next stage was to look at generic K*
channel inhibitors. Barium was used in the preliminary experiment to no effect
and so tetraethylammonium (TEA) wasused asit is another commonly used K*
channelinhibitor.
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Vehicle TEA PTH PTH + TEA
Figure 5.5. The effect of 10mM TEA + 0.5nM PTH onc-fos expression in SaOS-2 cells
(n=5-8). Error bars represent S.D.
The use of ImM TEAin the preliminary experiment yielded no change in the
basal c-fos response and so it was decided to increase the concentration used.
Treatment with 10mM TEA gave an increase of 16% in c-fos compared with
vehicle-treated control cells. This was notstatistically significant. 0.5nM PTH
gave a 9-fold increase over basal expression (P<0.001). When combined with
PTH, TEA gave an almostidentical value to that of PTH alone.
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Vehicle Pinacidil PTH PTH + Pinacidil
Figure 5.6. The effect of 104M pinacidil + 0.5nM PTH on c-fos expression in SaOS-2
cells (n=9-18). Error bars represent S.D.
Asin the preliminary experiment (see Figure 5.1), 10M of the Karp opener
pinacidil increased basal c-fos expression although this time only by a non-
significant 9%. 0.5nM PTH gavea 2.4-fold increase over vehicle-treated control
cells (P<0.001). PTH and pinacidil together did not produce a significant change
compared with PTH alone.
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Vehicle Glibenclamide PTH PTH + Glibenclamide
Figure 5.7. The effect of 10uM glibenclamide + 0.5nM PTH on c-fos expression in
SaOS-2 cells (n=9-18). Error bars represent S.D.
Glibenclamide blocks Karp channels at concentrations less than 101M (Quayle ef
al., 1995). Glibenclamide is a sulphonylurea prescribed to diabetics as its
depolarizing action assists insulin secretion from pancreatic B-cells (Rendell,
2004). It reduced basal c-fos levels by 26% but this was not significant. A 2.4-
fold induction by PTH wassignificant compared with the vehicle-treated control
(P<0.001). Glibenclamide and PTH in combination did not producea significant
change when compared to PTH alone.
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Table 5.1. Data from repeated experiments using traditional and putative K’ channel
modulators. Data represents normalized c-fos expression following treatment. Data
displayed in the figures above are shownin bold.
 
  
Vehicle Treatment PTH PTH +] n
Treatment
Riluzole 1 1.17 8.6 17.9 (#**) 17
1 1.06 4.0 10.3 (***) 9-18
1 1.32 6.1 12.7 (***) 9-24
TEA 1 1.16 9.0 9.2 5-8
1 1.13 6.6 5.1 (**) 9-12
1 1.37 5.1 6.4 (**) 9-12
Pinacidil 1 1.09 2.4 2.6 9-18
1 1.14 7.9 7.7 9-18
Glibenclamide| 1 0.74 2.4 2.4 9-18
1 0.89 7.9 6.2 (*) 9-18     
5.3.2 Depolarization and Calcium Entry
Activators of TREK-1 showed variable but significant changes in c-fos
induction. TREK-1 activation would likely cause Vm hyperpolarisation (see also
Chapter 6). One of the possible mechanisms of AV,, on c-fos expression is via
changes in intracellular calcium concentration mediated by L-type VDCCs. In
order to test this hypothesis, high external potassium was used to activate
VDCCsvia depolarization. The dihydropyridines BAY K 8644 and nimodipine
were usedto directly open and inhibit voltage-gated Ca”* channels respectively
(De Vry et al., 1999).
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Figure 5.8. The effect of elevated extracellular potassium + 0.5nM PTH on c-fos
expression in SaOS-2 cells (n=12). Error bars represent S.D.
Elevation of extracellular potassium is often used as a simple method of
producing depolarization (Hille, 2001). The driving force on potassium ions to
leave the cell is lowered by increasing external K*, therefore K* efflux and
subsequent hyperpolarisation produced by K” channel opening is less likely. As
is evident from Figure 5.8, this had little effect on c-fos expression. 40mM K*
did not producea statistically significant effect when compared with the 5mM K*
control. PTH elevated the response basal response (P<0.001), yet there was no
discernible difference between 5mM and 40mM K”.
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Figure 5.9. The effect of 0.5uM BAY K 8644 + 0.5nM PTH on c-fos expression in
SaOS-2 cells (n=12). Error bars represent S.D.
0.5uM BAY K 8644 had no effect on basal c-fos expression. Treatment with
PTHresulted in an 8.8-fold increase over vehicle-treated control cells (P<0.001).
BAY K 8644 reduced the PTH response to 7-fold over vehicle-treated control
cells which amounts to a 17% reduction of the PTH response (P<0.001).
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Vehicle Nimodipine PTH PTH + Nimodipine
Figure 5.10. The effect of 1M nimodipine + 0.5nM PTH on c-fos expression in SaOS-2
cells (n=6-12). Error bars represent S.D.
1uM of the calcium channel blocker (CCB) nimodipine gave a non-significant
effect on basal c-fos response. This time PTH treatment gave a 2-fold increase
over vehicle-treated control cells (P<0.01). In contrast to its action on basal
levels, nimodipine elevated the PTH-induced rise by a further 15% yet this did
not prove significant.
122
Table 5.2. Data from repeated experiments observing the effects of depolarization and
calcium entry. Data represents normalized c-fos expression following treatment. Data
displayed in the figures above are shownin bold.
 
  
Vehicle Treatment PTH PTH +}n
Treatment
High kK" 1 1.17 3.6 3.7 12
1 0.90 1.4 1.6 6-9
1 1.01 2.0 4.2 (***) 4-7
BAYK 8644 1 1.00 8.8 710 (#**) 9-12
1 0.85 4.0 2.8 (***) 12-15
1 0.88 Dae 2.8 12-19
Nimodipine 1 0.90 2.0 2.3 6-12
1 1.07 5.1 6,5 (**) 12
1 0.90 4.0 3.2 9-12     
5.3.3 PTH signal transduction
The signal transduction pathway for PTH neededfurther investigation in order to
better understand the effects of K” channel modulators on c-fos expression. This
series of experiments began with observations on the effects of ATP on PTH-
induced c-fos expression. Experiments done previously in the laboratory showed
that ATP synergises with PTH to produce a large increase in c-fos (Buckley ef
al., 2001). It has since been demonstrated that this effect is mediated through the
proximal CRE bindingsite on the c-fos promoter (Murrills et al., 2009). Looking
at the effects of ATP should give a positive control and provide a foundation for
further studies. After this experiment, the effects of PKA inhibition (H-89 &
KT5720) and stimulation (forskolin) were the primary target of investigation.
Following this, 8-pCPT-2'-O-Me-cAMP (8-pCPT) was used to test for an
exchange protein activated by cAMP (Epac)-mediated component of the PTH
responseafter recent literature suggested a role for this signalling molecule in the
osteoblastic response to PTH (Fujita et al., 2002).
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Vehicle ATP PTH PTH + ATP
Figure 5.11. The effect of 104M ATP + 0.5nM PTH on c-fos expression in SaOS-2cells
(n=9-12). Error bars represent S.D.
The concentration of ATP used here has previously demonstrated an effective
calcium response in this cell line (Bowler et al., 1999). 10uM ATP produced an
84% rise in c-fos levels compared to vehicle-treated control cells. Despite this
large increase the results were not significantly different. PTH produced a 4.3-
fold increase over basal levels (P<0.001). As predicted, the PTH response was
enhanced by ATP which almost doubled the PTH response alone (P<0.001).
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Vehicle Forskolin PTH Forskolin + PTH
Figure 5.12. The effect of 104M forskolin + 0.5nM PTH onc-fos expression in SaOS-2
cells (n=9-18). Error bars represent S.D.
Forskolin acts indirectly on PKA by activating AC and increasing intracellular
cAMPlevels. 101M forskolin gave an 8.6-fold increase over vehicle-treated
control cells (P<0.001). On this occasion, 0.5nM PTHtreatment led to a 4-fold
increase in c-fos expression over basal levels (P<0.05). Forskolin acted
synergistically with PTH to give a response which was twice that of forskolin
alone, and 8-times that of PTH alone (P<0.001). In orderto test the effects of the
compound BL-1249 further, a concentration-response experiment was performed
against 10uM forskolin.
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Figure 5.13. Concentration-response curve showing 10M forskolin-induced c-fos
expression with 0.1 - 100M BL-1249 (n=6-9). A sigmoidal curve wasfitted to the data.
The ICso value calculated from this fit is 6.914M BL-1249.Error bars represent S.E.M.
The reduction in forskolin-elevated c-fos levels by BL-1249 is shown in Figure
5.13 to be dose-dependent. The ICs value for BL-1249 against 10uM forskolin
is 6.94M, which is approximately half the amount of BL-1249 needed to produce
the same effect against 0.5nM PTH (see Figure 5.3).
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Vehicle H-89 PTH PTH + H-89
Figure 5.14. The effect of 104M H-89 + 0.5nM PTHonc-fos expression in SaOS-2cells
(n=9-12). Error bars represent S.D.
H-89 is a commonly used non-selective PKA inhibitor (Lochner & Moolman,
2006). The concentration of H-89 was decided upon because 10M had been
used previously in this cell line to block the effects of PTH on the CRE (Murrills
et al., 2009). H-89 did not significantly affect c-fos expression when compared to
the control. On this occasion 0.5nM PTHtreatment produced a 5.2-fold increase
in expression which proved significant (P<0.001). H-89 administered alongside
PTH brought c-fos expression back down to just 9% above basal level. This was
significant when compared with PTH treatmentalone (P<0.001).
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Vehicle KT5720 PTH PTH + KT5720
Figure 5.15. The effect of 5uM KT5720 + 0.5nM PTH on c-fos expression in SaOS-2
cells (n=6-9). Error bars represent S.D.
KT5720 is another PKA inhibitor but is thought to be more selective than H-89
(Lochner & Moolman, 2006). Exposure to KT5720 gave a value close to basal
levels of c-fos expression. PTH produced a 3.7-fold increase over vehicle-treated
control cells (P<0.001). Despite having no effect on basal expression, KT5720
wasable to inhibit the PTH-induced elevation by 21% (P<0.01). Although H-89
and KT5720 had reduced the PTH response, it seemed prudent to test their
effects on a c-fos elevation induced by forskolin.
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Figure 5.16. The effect of 104M H-89 and 5uM KT 5720 on forskolin-induced c-fos
expression in SaOS-2 cells (n=9). Error bars represent S.D.
10uM forskolin treatment was again significantly different from the vehicle-
treated control cells producing a 2.8-fold increase (P<0.001). 104M H-89 again
reduced elevated c-fos levels, this time to below that of basal levels (P<0.001).
KT 5720 wasnot able to reduce forskolin-induced c-fos.
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Vehicle 8-pCPT PTH PTH + 8-pCPT
Figure 5.17. The effect of 5uM 8-pCPT + 0.5nM PTHon c-fos expression in SaOS-2
cells (n=6-9). Error bars represent S.D.
5uM wasselected as an appropriate concentration of 8-pCPT as this was used by
Purves et al. (2009) and Enserink ef al. (2002) to activate Epac without also
activating PKA. Cells treated with 5uM 8-pCPT did not differ from vehicle-
treated control cells. 0.5nM PTH gave a 7.6-fold increase over basal c-fos
expression (P<0.001). 8-pCPT administered with PTH did not prove to
significantly affect c-fos levels versus PTH alone.
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Table 5.3. Data from repeated experiments observing PTH signal transduction. Data
represents normalized c-fos expression following treatment. Data displayed in the
figures above are shownin bold.
 
  
Vehicle Treatment PTH PTH +}n
Treatment
ATP 1 1.84 4.3 7.9 (***) 9-18
1 1.60 4 19?"*) 9-18
1 2.1 6.1 10.4 (***) 9-24
Forskolin 1 8.6 (***) 4.0 16.6 (***) 9-18
1 8.0 (***) 6.1 11.3 (***) 9-24
1 3.4 (***) 1.9 5.1 **) 6-9
H-89 1 0.80 5.2 1.1 (***) 9-12
1 0.62 2.4 1.0 (***) 9-18
KT 5720 1 1.04 3.7 2.9 (**) 6-9
1 1.34 7.9 6.6 9-18
1 1.14 5.2 3.1 (***) 9-12
8-pCPT 1 0.96 7.6 6.4 6-9
1 1.01 8.8 8.1 9-12
1 0.94 4.6 4.0 6-9     
5.3.4 Intracellular calcium signalling
The following experiments were performed on wild-type SaOS-2 cells, in a live
cell calcium imaging system. Cells were bathed in HEPES buffer solution and
incubated at 37°C during recording. Intracellular calcium concentrations were
visualised by use of the ratiometric dye fura2-AM.
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Figure 5.18. The intracellular calcium response to the addition of 104M ATP to fura2-
AM loaded SaOS-2 cells. Recordings were taken simultaneously from 4 cells which
were incubated in medium containing calcium.
Figure 5.18 showsthat the addition ofATP to the extracellular environmentofan
osteoblastic cell produces a rapid rise in intracellular calcium levels. Here, the
responseis biphasic, with a sharp initial peak followed by a smaller, flatter peak.
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Figure 5.19. Concentration-response experiment measuring intracellular calcium in
fura2-AM loaded SaOS-2 cells in response to 0.01 — 100ng PTH. Recordings were taken
simultaneously from 5 cells which were incubated in medium containing calcium.
PTH was addedin increasing concentrations to the medium covering the cells.
No intracellular calcium release or calcium influx was seen. After the
concentration-response series was finished, 10uM ATP was added into the
medium in the bath to provethat the cells were responsive.
5.3.5 Potassium and calcium channel modulators on alkaline
phosphatase expression andsecretion
ALP is a marker protein for osteoblast differentiation. C-fos expression can
demonstrate early stage responses to various stimuli and is a useful tool, but the
measurement of ALPis late stage effect and can demonstrate a direct effect on
protein levels. A dose-response experiment using TEA wasperformedalong with
elevated external K* and the CCB verapamil to test for a direct effect on an
osteoblast marker of differentiation.
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Figure 5.20. Measurement of alkaline phosphate in A) cell lysate and B) conditioned
medium from TEAtreated wild-type SaOS-2 cells (n=8). Error bars represent S.D.
TEAsignificantly reduced cell-bound ALP at 30mM (p<0.05) but not at lower
concentrations. TEA did not appear to affect the amount of ALP found in the
medium ofcultured SaOS-2cells.
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Figure 5.21. Measurement of alkaline phosphate in A) cell lysate and B) conditioned
medium from wild-type SaOS-2 cells treated with high external K* and 10M verapamil
(n=6). Error bars represent S.D.
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Neither elevated external K* nor 10M verapamil gavea statistically significant
result in the cell layer or the conditioned medium.In addition to this, no obvious
trend was observed from the pattern of results. The standard deviation appeared
large in this cohort of SaOS-2cells.
5.4 Discussion
The experiments in this chapter have generated a large amount of data which
requires detailed consideration. The key points are summarised as follows;
1. The putative TREK-1 openers BL-124 andriluzole increase and decrease
osteoblastic c-fos expression respectively. This difference must be due to
some ofthe other known and unknown effects of both compounds.
2. Other KCOs and KCBshadlittle consistent effect on c-fos or ALP.
3. Opening or closure of calcium channels via depolarization or BAY K
8644 treatment and CCBsappeared to have very little effect on basal or
PTH-elevated c-fos and ALP.
4. PTH second messengersignalling is not increased by an Epac agonist or
decreased by CCBs.Signalling in this system is predominantly through
PKA and can be blockedby the non-selective antagonist H-89.
5.4.1 Traditional and putative potassium channel modulators
Riluzole and BL-1249 are two compounds which purport to open TREK-1
channels and yet this study has shown they have contrasting effects on c-fos
expression. There is very limited information on BL-1249, which makes a
detailed anaylsis rather difficult. In these experiments it reproducibly lowers
basal and PTH-elevated c-fos in a dose-dependent manner (P<0.001 in PTH
treated cells). Riluzole produced a small increase basal c-fos levels and
significantly increased the response of PTH alone (P<0.001 in PTHtreatedcells).
This discussion aims to relate the current literature on these compounds to
explain the results shown above.
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The compound BL-1249 is marketed as an activator of TREK-1 channels by
Sigma. It was found to produce membrane hyperpolarisation in human bladder
myocytes and evoked relaxation of pre-contracted bladder strips but not aortic
strips, provoking the possibility that it may be a potential therapy for overactive
bladder (Tertyshnikova et al., 2005). Because TREK-1 was shown to be
expressed at 12 times the level in bladder compared with aorta, the affects of BL-
1249 wereattributed to activation of TREK-1 (Tertyshnikovaet al., 2005). We
know through electrophysiology experiments done in this laboratory on
transfected Xenopus laevis oocytes that BL-1249 directly activates TREK-1
channels (personal communication, Quayle & Goonetilleke).
Riluzole is a neuroprotective, anticonvulsant and sedative agent used in the
treatment of amyotropic lateral sclerosis (ALS) (Van Dammeet al., 2005). Its
many in vivo actions hint at its complex pharmacology. Riluzole inhibits
glutamatergic signalling via inhibition of glutamate release and indirect blockade
of excitatory amino-acid receptors (Doble, 1996). Riluzole activates TRAAK and
TREK-1 channels dose-dependently, although TREK-1 is only activated
transiently (Dupratet al., 2000). Exposure to riluzole increases cell cAMP levels
and the subsequent PKA activation results in the phosphorylation and closure of
TREK-1 which can be reversed during metabolic stress (Dupratef al., 2000). The
reactivation of TREK-1 is likely to occur through its sensitivity to intracellular
acidosis and the decreased production of cAMP underthese conditions (Maingret
et al., 1999). Riluzole is thought to interact directly with the channels, given the
time course of effects demonstrated by electrophysiology data. The rise in cAMP
is an indirect effect that is due to an inhibition of phosphodiesterases (PDEs)
(Duprat ef al., 2000). Riluzole activates BK currents and inhibits voltage-gated
Na” currents in skeletal musclecells contributing to muscle relaxation (Wang et
al., 2008).
Riluzole is increasing c-fos expression through one or both of the following
mechanismsin this model.
1. PDEinhibition leading to PKA activation and CREB phosphorylation.
2. Inhibition of TREK-1 following its phosphorylation by PKA,resulting in
depolarization or a less negative Vm.
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Barium and TEA showed nosignificant differences compared with controlcells,
indicating that blockade of K” channelssensitive to these inhibitors do not affect
c-fos expression. Studies of these KCBs are extremely limited in osteoblastic
cells, perhaps because others have observed negative results such as those seen in
Figures 5.1 & 5.5 which have not been published.
Pinacidil is a KCO that acts specifically to open Karp channels whereas
glibenclamide inhibits the currents produced by these channels (Quayle ef ai.,
1995). Karp channels have been observedin osteoblasts and have been shownto
have a role in the response to calcitonin gene-related peptide (CGRP) and
1,25(OH)2D3 (Kawaseet al., 1996, Burnset al., 2004, Moreauef al., 1997). Karp
modulators appeared to show more promise than barium and TEA but did not
prove significantly different apart from in the initial experiment where pinacidil
elevated basal c-fos (P<0.001) and in one out of two experiments, glibenclamide
reduced the PTH response (p<0.05). In subsequent experiments, pinacidil
continued to elevate c-fos but not to significant levels. In support of this
observation, glibenclamide treatment non-significantly reduced basal c-fos.
Closure of Karp channels by glibenclamide would predictably cause a
depolarization and indeed this is related to its clinical applications (Rendell,
2004).
In summary, the effects of TREK-1 openers in this system cannot be entirely
explained by their action on Kyp channels. The pharmacology of riluzole has
been fairly well documented but it will take considerable time and requires a
multitude of experiments to map any additional effects of BL-1249. Generic
KCBs barium and TEA showednosignificant effects on c-fos expression and
very limited effects on ALP expression. Karp modulators pinacidil and
glibenclamide showedlittle consistent effect.
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5.4.2 Depolarization and Calcium Entry
Depolarization using high external [K"] gave nosignificant responses and neither
did treatment with the CCB nimodipine. It was therefore surprising to see that
BAY K_ 8644 significantly reduced the response to PTH on more than one
occasion (P<0.001 twice, ns once). Others have previously studied the blockade
of calcium influx through L-type channels in osteoblasts and the overriding
conclusion seems to be that they do not affect proliferation or differentiation
(Labelle et al. 2007, Zahanich et al., 2005). Labelle et al. (2007) found no
significant effects of verapamil or nifedipine on osteoblast proliferation. They
propose that TRPC channels are involved in CCE and L-type VDCCs are more
likely to be involved in secretory functions (Moreau ef al., 1997, Bergh et al
2003). L- & T-type calcium channels are expressed in human MSCs. L-type
currents were recorded from differentiating and non-differentiating MSCs.
Nifedipine had no effect on ALP activity in hMSCs undergoing osteogenic
differentiation (Zahanich ef al., 2005). The authors propose that another type of
Ca’* channel mediatesthe entry of calcium into the cell. In contrast to the studies
mentioned previously, Nishiya & Sugimoto (2002) suggest that the
dihydropyridine Ca”* channel blocker benidipine promotes ALP activity and
mineralization. The same study reported no effects of nifedipine. The evidence
from the literature suggests that further studies involving calcium channels in
osteoblasts should include TRP modulators alongside more traditional Ca’
channel modulators. This data showsan inhibitory effect of BAY K 8644 on c-
fos expression which webelieve has not been reported to date.
5.4.3 PTH signal transduction
As predicted, ATP increased both basal and PTH-induced c-fos expression
repeatedly although only elevation of the PTH response proved significant
(P<0.001). This gave a positive control for an attempt to dissect some of the
second messengers implicated in the PTH response.It is generally accepted that
PTHacts to increase osteoblastic c-fos through the PKA pathway (Evansef al.,
1996, Bowleret al., 1999). The AC activator forskolin showsthat activation of
the PKA pathway via accumulation of cAMP doesinduce c-fos expression in our
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model. The known PKA inhibitors H-89 and KT5720 both significantly reduced
the PTH-induced elevation (P<0.001 & P<0.01), again pointing to PKA as a
major signalling pathway.
H-89 effectively reduced both PTH- & forskolin-induced c-fos expression.
Although this compoundfeatures often in studies to negate the effects of PKA,it
has other known effects which may have influenced these results. A review by
Lochner & Moolman (2006) states that H-89 inhibits K, currents through direct
blockade of the channelpore. It also inhibits Karp and Kj, currents at micromolar
concentrationsin arterial smooth muscle (Sun Park ef al., 2006). H-89s collection
of alternative effects are not limited to K” channels, with PKG inhibition being
among the others (Satake et al., 1996). H-89 binds to PKA on its ATP binding
site which is highly conserved among kinases, thus helping to explain its non-
specific effects among the kinase family (Breitenlechneref al., 2005). Possession
of this knowledge led to the inclusion of another commonly used and more
selective PKA inhibitor KT5720 (Lochner & Moolman, 2006). This alternative
to H-89 did not prove as effective at preventing c-fos induction although it did
reduce PTH-induced c-fos expression in 3 out of 3 experiments (ns, P<0.05,
P<0.001). Whentested against forskolin there was no discernible effect, although
H-89 inhibited the response back down to beyondbasal levels (P<0.001). If the
experiments were to be performed again (Rp)-8-Br-cAMPS would perhaps be a
better choice as a comparison against H-89. (Rp)-8-Br-cAMPS prevents the
dissociation of the catalytic subunit of PKA from the regulatory subunit and
therefore acts a step earlier than H-89 (Gjertsen ef al., 1995).
8-pCPT is a cAMP analoguethat selectively activates Epac (Enserink ef ai.,
2002). Used alone it did not elevate c-fos and when combined with PTH
treatment a small and non-significant decrease was observed in all three
experiments. Fujita et al., (2002) demonstrate the presence of Epac 1 & 2 in
several osteoblastic cells. They propose that activation of PTHR1 increases
cAMP which induces Epac signalling and activation of the ERK pathway. The
activation of ERKsincreases proliferation which may help to explain the dual
effects of PTH onosteoblast proliferation. Our model is perhaps not best suited
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to confirming these effects in SaOS-2 cells, as c-fos expression is most often
associated with differentiation (Ionescu et al., 2001).
5.4.4 Intracellular calcium signalling
Theelevation in [Ca”"]; produced by 10M ATPin osteoblastic cells has been
observed by our group and by others (Bowleret al., 1999, Nishii et al., 2009).
Bowleret al., (1999) showed that ATP increases [Ca”*]; and stimulates c-fos
expression in SaOS-2cells via its activation of P2Y receptors. The second part of
the biphasic response to ATP seenin figure 5.18 is likely to be the replenishment
of intracellular stores via CCE as described by Berridge, (1995). P2 receptors
undergo desensitization making a secondaryactivation by a nucleotide agonist
unlikely (Sistare ef al., 1994). Figure 5.19 shows PTHfailing to elicit a rise in
[Ca’*];. This is also an observation which has been made previously in our
laboratory (Buckley ef al., 2001). Others have noted calcium increases to PTH
(Reid et al., 1987, Yamaguchief al., 1987). Resolution concerning the
mechanism behindthis difference maylie in the regulation of Ga; and Gag
coupling to the PTHR1. Distinction between opening of Ca** channels andstore-
operated Ca”* release can be madeby repeating an experiment performed with
Ca** in the extracellular solution to one using no Ca’* and Ethylene glycol
tetraacetic acid (EGTA).
5.4.5 Potassium and calcium channel modulators on alkaline
phosphatase expression andsecretion
The ALP measurements showed a greater standard deviation compared to the
data from the c-fos experiments and the data were not normally distributed. A
Kruskal-Wallis Test (non-parametric ANOVA) had to be performed to test for
significance. A dose-response experiment using 1-30mM TEA showed a
decrease in ALP protein present in the cell lysate (P<0.05 at 30mM TEA). No
effect was observed on ALPlevels outside the cell even at 30mM TEA.At high
doses, TEA appears to inhibit the production but not the secretion of ALP. The
spread of the data and large standard deviation in the depolarisation and calcium
entry experiment could indicate a large experimental error or more interestingly,
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a heterogeneous response. This could occur if there was a difference in Ca**
channel expression among the population. Despite differences in the spread of
the c-fos and ALP data, the ALP results do agree with the c-fos results obtained
with TEA, depolarization and CCBs.It appears that generic KCBs and Ca’* entry
are not able to modulate osteoblast differentiation (Labelle et al., 2007, Zahanich
et al., 2005). In order to determine morefully the effects of K” and Ca** channel
agents on osteoblasts, further experiments could be performed to measure the
levels of other osteoblastic markers such as collagen I, osteocalcin, OPG and
ntelopeptide of type 1 collagen (P1NP).
5.5 Conclusions
Both TREK-1 modulators used in combination with PTH showed marked
differences when compared to PTH treatment alone. The more traditional
voltage-gated and Karp modulators failed to show such dramatic effects. As the
myriad actions of riluzole presented difficulties in this model and undoubtedly
influenced these results, it would appear that activation of TREK-1 by BL-1249
may give a better idea of the effects of TREK-1 activation on c-fos expression.If
BL-1249 simply activates TREK-1 channels, then an increase in TREK-1
currents inhibits stimulatory events following PTH administration in SaOS-2
cells. Further experiments would be needed in order to conclude that BL-1249
exerts its effects solely via activation of TREK-1 channels. These may include
cAMP measurements and electrophysiological studies. The data given in this
chapter appear to add support to the hypotheses that PTH-induced gene
expression is mediated by PKA and L-type Ca”* channels are not involved in
osteoblast differentiation.
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6.0 Electrophysiological Observations Made Using
Arachidonic Acid & BL-1249
6.1 Introduction
The aim of these experiments was to characterise the electrophysiological
response of osteoblastic cells to the putative TREK-1 activator BL-1249.
Responses to AA were also recorded to provide a comparison with a known
activator of TREK channels. In addition to current-voltage (IV) recordings, the
response of the membranepotential was also observed following the addition of
BL-1249. The electrophysiological effects of BL-1249 have been documented by
Tertyshnikova et al. (2005). Becauseit is a putative TREK-1 activator it is one of
the few pharmacological tools available to study the currents produced by these
channels. Also, the results in Chapter 5 warrant further investigation into the
actions of BL-1249 in osteoblast-like cells.
BL-1249 caused hyperpolarization of human bladder myocytes and induced a
non-inactivating and instantaneous outward current which reversed around Ex
(Tertyshnikova et al., 2005). The current and the relaxation were inhibited by
10mM Ba’* but not by other commonly used KCBs. Added to the evidence
pointing towards activation of a Kyp channel were theresults of real-time PCR on
bladder myocytes and aorta showing TREK-1 expression was over 12 times
higher in bladder myocytes than in aorta (Tertyshnikovaet al., 2005). TASK-1 &
-2 channels have been observed by another group in bladder smooth muscle,
Suggesting that Kyp channels have a functional role in bladder tissue (Beckett et
al., 2008).
One of the features of Kp channels are the effects of various intracellular and
extracellular stimuli on channel kinetics. Members of the K>p channel family
show various degrees of voltage-dependence. A number ofrecent studies have
pointed to the ability of Kyp channels to modulate their voltage-dependence upon
interaction with signalling molecules (Bockenhauer etal., 2001, Lopes et al.,
2005, Cheminet al., 2003). This phenomenonis not exclusive: Kj, channels have
previously demonstrated variation in their response to voltage when exposed to
PIP». PIP: hydrolysis via activation of PKC has been shown to inhibit TASK &
TREK channel activity and cause a shift in voltage-dependence towards more
depolarized potentials (Lopesef al., 2005, Chemin et al., 2003). Phosphorylation
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of TREK-1 at serine 348 by PKA similarly transforms the channel from leak to
a voltage-dependent phenotype (Bockenhauer ef al., 2001). A component of
TREK-1 current activates instantaneously, is outwardly-rectifying and non-
inactivating. Another componentof a typical TREK-1 current showsan increase
during the first few milliseconds of membrane depolarization (Fink et al., 1996).
Membrane potential recordings in osteoblasts are infrequent among
electrophysiological studies in this cell type. Ferrier ef al. (1987) recorded an
average membrane potential of -24mV in ROS 17/2.8 cells measured within
80ms of microelectode entry. This figure was based on observations from 29
different cells. Hughes e¢ al. (2006) recorded a resting membrane potential of-
21.5mV in MG-63 cells based on recordings from 8 cells. The same paper
reported the resting membrane potential of primary human osteoblasts as -
38.1mV (n=11), considerably more negative than the recording from MG-63
cells.
145
6.2 Methods
A cell suspension was obtained through a routine passage. Recordings were
made from single cells in suspension. Extracellular solution contained (mM): 6
KCl, 134 NaCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 10 glucose (pH adjusted to 7.4
with NaOH). The standard pipette (intracellular) solution contained (mM): 107
KCl, 33 KOH, 10 HEPES, 10 EGTA, 3 MgCl2, 3 Na2ATP, pH 7.2. Membrane
current and voltage were amplified using an EPC-8 amplifier (List Instruments),
digitised via a Digidata 1200 analogue to digital interface (Axon Instruments),
and recorded on computer using pCLAMP8software (Axon Instruments). Data
were analysed using pCLAMP$8and SigmaPlot. Experiments were conducted at
room temperature (18-22°C). Stock solutions were added to the extracellular
solution via a perfusion system to give the desired final concentration. A fresh
glass microelectrode was used for each cell patch. After the cells were patched, a
voltage-step protocol was performed which recorded current at voltages between
-120mV and +100mV in 10mV increments. Two control recording were taken
from a single cell whilst cells were perfused in the extracellular solution
described above. Then either 201M AA or 101M BL-1249 wasperfused through
the recording chamberandafter three minutes, two further recordings were taken
from the cell. Immediately after the second recording with the treatment, the
recording chamber was washed out. After a further three minutes two washout
recordings were taken to determineif the response wasreversible. For recordings
of membrane potential, current was clamped and voltage was recorded
continuously over a period of approximately 10 minutes. Initially, the cell was
perfused with the extracellular solution, and after a suitable baseline was
recorded 104M BL-1249 wascirculated through the recording chamber. After
several minutes, BL-1249 was washed out and the recovery of the membrane
potential was observed.
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6.3 Results
6.3.1 Current-voltage recordings in osteoblastic cells exposed to AA
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Figure 6.1. Typical whole cell current-voltage recording from a single SaOS-2 cell made
using a voltage clamp protocol which made 10mV step changes from -120mV to
+100mV, shown in A). Control current recording is shown in B). C) Cell was exposed to
20nM AA. D) Wash-out.
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Figure 6.2. Mean IV curve obtained from SaOS-2 cells exposed to 20uM AA (n=5).
Error bars represent S.E.M.
Figures 6.1 & 6.2 show a clear increase in whole-cell current upon application of
20M AA.The effect is reversible as seen in part D of Figure 6.1. The increase
in current starts to be becomediscernable at around -20mV,priorto this there is
no difference between the AA-treated and control cells. At +100mV, cells
exposed to 20M AA display currents almost twice those of controlcells.
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Figure 6.3. Mean current for SaOS-2 cells + 201M AAat -120 and +80mV (n=5).
Current values were very small at -120mV in both treated and non-treated cells.
At +80mV,control current measured approximately 150pA but in cells exposed
to AA the value was around 260pA. Dueto the variability between the samples
the standard error was high andthe increase, although large, did not prove to be
significant (P>0.05).
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Figure 6.4. Typical whole cell current-voltage recording from a single TE-85 cell made
using a voltage clamp protocol which made 10mV step changes from -120mV to
+100mV, shownin A). Control current recording is shown in B). C) Cell was exposed to
20uM AA.D) Wash-out.
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Figure 6.5. Average IV curve obtained from TE-85cells exposed to 204M AA (n=9).
Error bars represent S.E.M.
Whole-cell currents decrease in TE-85 cells exposed to 201M AA at more
depolarized potentials. There appears to be a small reduction in inward current
towards hyperpolarized potentials. The inhibitory effects of AA can be seen at
membranepotentials above -20mV. This is the same point at which AA-induced
currents in SaOS-2 cells start to show an increase over the control current (see
Figure 6.2). Variability between TE-85 cells appeared to be more constant across
the range of voltages than SaOS-?2cells.
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Figure 6.6. Mean current for TE-85 cells + 20M AA at -120 and +80mV (n=9),
Control cells showed similar whole-cell current to TE-85 cells treated with 20M
AA at the more negative membrane potentials. As the membrane potential
became more positive, whole-cell currents were greater in control cells compared
with treated cells. This difference proved to be significant at a membrane
potential of +80mV (p<0.5).
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6.3.2 Current-voltage recordings in osteoblastic cells exposed to BL-
1249
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Figure 6.7. Typical whole cell current-voltage recording from a single SaOS-2 cell made
using a voltage clamp protocol which made 10mV step changes from -120mV to
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+100mV, shownin A). Control current recording is shown in B). C) Cell was exposed to
10M BL-1249. D) Wash-out.
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Figure 6.8. Mean IV curve obtained from SaOS-2 cells exposed to 101M BL-1249
(n=6). Error bars represent S.E.M.
Administration of 10M BL-1249 to SaOS-2 cells results in a large increase in
whole-cell current at depolarized values, seen in Figures 6.6 & 6.7. Treated cells
begin to show an increase in current compared to controls at around +40mV.
Currents are roughly 3 times larger at +100mV in BL-1249 treated cells when
compared with non-treated cells. Cell currents decrease after wash-out, showing
that the effects of BL-1249 are reversible.
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Figure 6.9. Mean current for SaOS-2 cells + 101M BL-1249at -120 and +80mV (n=6).
Prior to BL-1249 administration, current values were around -20pA at -120mV.
This value did not noticeably change upon exposure ofthe cells to 104M BL-
1249. The difference between the treatment and the control did prove significant
at the more depolarized potentials, with the current being twice as large in BL-
1249treated cells at +80mV than in the control experiment (P<0.05).
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Figure 6.10. Whole cell current-voltage recording from a single TE-85 cell made using a
voltage clamp protocol which made 10mV step changes from -120mV to +100mV,
shown in A). Control current recording is shown in B). C) Cell was exposed to 10M
BL-1249. D) Wash-out.
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The group of eight TE-85 cells exposed to BL-1249 produced five different
outcomes. Three cells showed no change in current following BL-1249
administration. One cells showed a small increase in whole-cell current. Onecell
showedthe activation of a small current in the first 100ms of the recording and
none thereafter. Two cells displayed a more pronounced activation of this brief
current at the start of the trace. Onecell followedinitial activation of this current
followed by a small increase in overall whole-cell current. Because the results for
BL-1249 were so variable and displayed no consistent pattern in TE-85cells,it
wasdecided not to construct a mean IV curve.
6.3.3 Membranepotential recordings
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Figure 6.11. Membranepotential recording obtained from a single SaOS-2 cell exposed
to 10M BL-1249.
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Recordings of membrane potential were made from six different SaOS-2 cells
exposed to 104M BL-1249. Results from one of these cells are shown above in
Figure 6.11. This trace was typical of the six recordings made. A repeated
measures analysis of variance test was performed on the three stages of the
recording; resting membrane potential, BL-1249 treatment and wash out. The
mean resting membranepotential was -22.9mV but following treatment with BL-
1249, it became significantly more negative and the average value was -31.6mV
(n=6, P<0.001). The effect of BL-1249 on membranepotential was reversible,
and observations made after the wash out showed recovery of the membrane
potential back to resting levels (-22.9mV, n=6). All six of the cells studied
showed the same pattern of hyperpolarization upon exposure to BL-1249,
followed by recovery.
6.4 Discussion
The experiments performed in this chapter have shown that BL-1249 directly
activates ion channel currents in SaOS-2 cells. Although there is no definitive
evidence that this current is caused by the outward flow of K*, the membrane
potential recordings reveal a distinctive hyperpolarization usually attributed to
K* channel opening. Exposure to AA resulted in an increase in whole-cell current
for SaOS-2 cells but a decrease in TE-85 cells. The difference in response to
TREKactivators continued upon the administration of BL-1249 to SaOS-2 and
TE-85 cells. TE-85 cells displayed a large variability within the group studied
whereas the response from SaOS-2 cells was consistent and proved significant
when comparedto the control (P<0.05 for +80mV recordings in the absence and
presence of BL-1249).
The effects of BL-1249 reported in this Chapter wholly support the data
presented by Tertyshnikova etal., (2005), who reported anincrease in whole cell
current and membrane hyperpolarization in response to BL-1249 administration.
Although the experiments by Tertyshnikova and colleagues were done on human
bladder smooth muscle cells, they agree with the results shown here for SaOS-2
cells. The published study by Tertyshnikova ef al., (2005) represents the only
item ofliterature documentingthe effects of BL-1249. Soonafter the publication
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of the paper, Sigma beganselling the compoundas a putative TREK-1 activator.
The scarce data on the pharmacology of BL-1249placeslimitations on the depth
of analysis applied to these results. Until further studies are performed on the
compound and are subsequently published, it will remain a putative TREK-1
activator. The currents activated by BL-1249 in the study by Tertyshnikova ef
al., (2005) appear to show voltage-independence, but the results shown in this
chapter seem to implicate a voltage-dependent channel. As mentioned in the
introduction to this Chapter, TREK-1 channels have the ability to display
different voltage phenotypes depending onthe levels of intracellular PIPorits
phosphorylationstate. It is possible that BL-1249 mayhavetheability to activate
other members of the TREK sub-family. TRAAKis a voltage-dependent channel
that showsincreased currents at depolarized potentials (Lesage ef al., 2000). In
order to test for specificity against TREK channels an experiment could be
designed using oocytes transfected with a particular channel and exposed to BL-
1249. This would clearly demonstrate any activation of current or a
hyperpolarizing effect.
The results obtained for AA in SaOS-2 cells are clear despite being non-
significant. AA causes a considerable increase in current towards the more
depolarised potentials. In TE-85 cells the data shows an opposing trend. Whole-
cell currents appear to decrease upon administration of AA. The precise reason
behind this difference cannot be determined from the results shown here. The
difference may comefrom the expression of other ion channels beyond the scope
of this study. It is probable that the inhibitory effect of AA on K, channels is
causing a reduction in whole-cell currents in this cell type (Meves, 2008).
Another possibility is that the regulation of certain ion channels is somehow
underalternative control in one ofthe cell lines studied.
The data for AA in SaOS-2 cells showssimilarity to the results for BL-1249.
Perhaps the most interesting difference is the voltage at which currents start to
increase for the two compounds. In SaOS-2cells treated with 101M BL-1249,
currents start to increase over control values at around +40mV.The samepointin
cells treated with AA is much lower at approximately -20mV. Although the
differences do not becomesignificant at these points in the IV curve,it is the
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start of a divergence between the control and treated groups. Relatively few K*
channels are activated by AA, and in fact most are inhibited by the
polyunsaturated fatty acid (Meves, 2008). TASK-1 & -3 currents are inhibited by
AA whereas TRAAK, TREK-1 & -2 currents increase rapidly following its
application (Patel & Honoré, 2001). TWIK-2 channels are weakly activated by
AA (Patel et al., 2000). This supports the idea that functional K>p currents in
osteoblasts can be observed by adding AA, given that in previous chapters the
expression of TRAAK, TREK-1 and TWIK-2 have all been noted.
The value of the resting membranepotential in SaOS-2 cells was foundto be-
22.9mV in this study (n=6). This was comparableto the values given by Ferrier
et al. (1987) and Hughes et al. (2006) of -24 and -21.5mV made from rat
osteoblastic cells and MG-63 cells respectively. Hyperpolarization induced by
10uM BL-1249 brought the membrane potential down to 31.6mV, which proved
to be a significant change (P<0.001, n=6). Membrane potential recovered back to
resting levels upon the removal of BL-1249 from the bathing solution. If the
reversal potentials for Cl’, Na’ and non-selective cation channels are calculated
using the Nernst equation, then it becomesclear that activation of any of these
channels would lead to depolarization. Whole-cell IV recordings in SaOS-2 cells
showtheactivation of a current in response to BL-1249 treatment.It is therefore
likely that the hyperpolarization seen in Figures 6.10 & 6.11 is caused by the
activation of a K* channel andnotthe inhibition of a depolarizing current.
In hindsight, it may have been wise to run a third compoundalongside BL-1249
and AA in these studies. LPC is a known TREKactivator and it has a much more
stable half-life in solution than AA. Pharmacological agents that block these
channelsarestill scarce and usually require very high doses, meaning that other
K* channels arealso inhibited. Also, to confirm the identity of the ion movement
responsible for the increased current in SaOS-2cells, different concentrations of
extracellular K* could be used. Comparison of these mean IV curves would
enable an accurate conclusion to be formed aboutthe ion involved in creating the
outward current seen here.
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6.5 Conclusions
In SaOS-2 cells the administration of 10UM BL-1249 results in an increase in
whole cell current at depolarized membrane potentials (P<0.05 at +80mV). It
also producesa significant hyperpolarization during current clamp protocols in
the same cell type (P<0.001). These data strongly agree with the single study
detailing the effects of BL-1249in the literature (Tertyshnikovaet al., (2005).
The results for TE-85 cells were not so clear, but because the experiments done
in Chapter 6 had incorporated BL-1249 treatment on SaOS-2 reporter cells, it
was decided to focus onresults from this cell type. Further electrophysiological
characterization of the currents enhanced by BL-1249 is required so that any
future use of the compound by others can be carefully considered. Due to the
lack of commercially available Kp activators, BL-1249 could represent an
importanttool in the further study ofTREK channels.
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7.0 General Discussion
7.1 Discussion ofresults in the context ofthe currentliterature
The experiments detailed within this thesis have demonstrated mRNA and
protein expression of various Kp channels in primary osteoblasts and
osteoblastic cells. Various methods pointed to the presence of members of the
TASK, TWIK, TALK & TREK families in osteoblastic cells. Functional
expression did not prove as straightforward to characterise, due to the limited
range of pharmacological agents that are able to target this group of channels and
variations in the responses from different cell lines. The use of the putative
TREK-1 activator BL-1249 posed a number of questions in addition to the
answers it provided, due to the relatively unknown pharmacology of the
compound. BL-1249 significantly reduced the expression of c-fos induced by
PTH in SaOS-2 reporter cells in a dose-dependent manner (P<0.001, ICs9 value
was calculated as 16.6uM). It also increased whole-cell current and
hyperpolarized the membranepotential in the samecell type.
In the most part, the expression profile of Kyp channel mRNA shown in Chapter
3 agreed with the limited data published in the literature. Perhaps the most
anomalous finding was the lack of TREK-1 mRNA in MG-63cells (see Figure
3.18) despite Hughes ef al., (2006) claiming it was strongly expressed in their
study. There were no obvious reasons for this discrepancy, as successful
sequencing showedthat the primers werecorrectly targeting TREK-1 mRNAand
the same batch of cDNA yielded positive results for other members of the Kp
channel family. Also, immunocytochemical staining of this cell type revealed
TREK-1 protein to be present at the plasma membrane. Other than forthis result,
the expression profile of the TREK channels was not dissimilar, with TRAAK
channels being strongly expressed throughout samples and a lack of TREK-2
mRNA.Rat osteoblastic cells observed by Chen et al., (2005) were shown to
express TREK-2 and that the channel was necessary for the majority of the
upregulation of PTHrP expression following mechanical stimulation. This
prompts speculation that there may be species-variation of TREK channel
expression in osteoblasts. Species-specific differences have already been
reported for TWIK and TRESK channels (Patel et al. 2000, Keshavaprasadetal.,
2005). The profile of mRNA expression in osteoblasts showsgreat similarity to
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that reported for human periodontal ligament (PDL) fibroblasts (Saeki ef al.,
2007). The PDL acts as a cushion between boneandtooth.It is exposed to large
forces during mastication and therefore may require protection through Kop
channels. High performance liquid chromotography (HPLC) analysis showed
almost a two-fold increase in cyclically stretched PDL fibroblast AA levels over
control conditions (Saeki et al., 2007). Autocrine release of AA would provide
another mechanism of activating TREK channels to bring the membrane
potential back down to resting levels after a mechanical excitation, thus
preventing cell damage.
Data from the immunocytochemistry and western blotting experiments provided
evidence that the mRNA expression described in Chapter 3 translated into
protein expression. Immunocytochemistry also gave an indication thatfor at least
some of the channels, protein wastrafficked to the plasma membrane. This was
particularly the case with the results obtained using the anti-TREK-1 antibody,
although expression of TRAAK, TWIK-2 and TASK-2 appeared strong in some
of the cell lines studied. TASK-1 expression seemed weak and mainly
perinuclear, although western blotting for this channel gave intense bands.
Western blotting appeared to reveal dimerization of TRAAK & TREK-1
channels.
Experiments using SaOS-2 cells stably transfected with a c-fos reporter gene,
proved useful in characterizing osteoblastic responses to various ion channel
agents. Riluzole demonstrated a significant increase in c-fos in cells treated with
PTH, but showed no effect on its own (P<0.001 for PTH-treated cells). The
fellow TREK-1 activator, BL-1249, produced contrasting effects by significantly
reducing the PTH-induced elevation of c-fos (P<0.001). The explanation of these
results must lie in the alternative pharmacology of both drugs. Riluzole is known
to have effects on manyothercellular proteins whereaslittle is known about the
actions of BL-1249. Otherinteresting points from this set of experiments include
the apparent lack of c-fos modulation by voltage-gated K* & Ca** channels. The
experiments designed to reveal PTHR1 second messengers in the reportercells
supported the study by Evans ef al., (1996) who found that PKA was solely
responsible for the effects of PTH in SaOS-2 cells. Data shown in this thesis
164
suggests that H-89 totally inhibited the c-fos response to PTH, although the
supposedly more selective PKA inhibitor KT5720 displayed limited effects on
PTH-induced c-fos expression. Live cell Ca’* imaging also indirectly supported
the involvement of PKA,as no elevation of [Ca”*]j was observed upon addition
of PTH to SaOS-2cells.
Whole-cell patch clamp recording from SaOS-2 cells revealed an increase in
current in response to both AA and BL-1249 (P<0.05 for +80mV recordings in
the absence and presence of BL-1249). These compounds activate TREK
channels although the experimental protocols used did not allow the specific
identification of the channel or channels responsible for this effect. Results from
TE-85 cells differed greatly from those obtained with SaOS-2 cells. TE-85 cells
displayed a decrease in overall current upon the addition of AA whereas the
response to BL-1249 was highly variable, making comparison difficult.
Membranepotential recordings from SaOS-2 cells gave an averageresting value
of -22.9mV (n=6). When treated with 101M BL-1249 there wasa significant
hyperpolarization which brought the membrane potential down to -31.6mV (n=6,
P<0.001). Hyperpolarization and an increase in whole cell current have
previously been reported following the administration of BL-1249 in bladder
smooth muscle (Tertyshnikovaet al., 2005).
Two immediate questions are raised by this body of work. Firstly, what is the
functional significance of Kp channels in osteoblasts, and secondly whatis the
specific pharmacology of BL-1249? The second question is one that further
experimental work should answer over time. Electrophysiological
characterization is neededin thefirst instance, but effects on proteins other than
ion channels also need to be investigated. In order to addressthe first questionit
is necessary to look again at the basic properties of Kyp channels, which include
setting the resting membrane potential and transducing intracellular and
extracellular stimuli. Both of these functions would serve to help an osteoblast
perform its role as a secretory cell whichis tightly regulated by several factors in
its immediate environment. Maintenance of resting membrane potential is crucial
to manycells but this is particularly the case for excitable or secretory cells. This
simple observation explains why the potassium channel superfamily is so large
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and widely expressed in mammals and even lower organisms. The emerging
properties assigned to K»p channels mean that this versatile group ofproteins are
likely to have a large profile of expression and it should come asnosurprise that
they are present in bone. The external environmentofan osteoblast varies greatly
according to the stage of the remodelling process. During resorption the
surrounding pH can become low, whereas cells which are actively involved in
bone formation can be exposed to high pH during to the deposition of
hydroxyapatite. Extracellular Ca?* can be high in both scenarios. Acidosis is
known to inhibit the mineralization of the collagenous matrix (Arnett, 2008).It is
conceivable that the presence of one or more TASK channels would be a useful
addition to an osteoblasts repertoire of proteins during remodelling. Therole of
TWIK channels in osteoblasts has yet to be uncovered. The consistent expression
of this sub-family across the cell lines studied here points towards a functional
role for these channels in skeletal tissue. Characterization of the properties of
these channels in other cell lines may help us in understanding the presence of
these proteins in osteoblasts. The relevance of TREK channels in bone has
obviously been spotted by others, and this sub-family would seem the most
obviouscandidate to screen for. It is interesting that no studies have yet focussed
on the expression of TREK-1 in osteocytes. As a terminally differentiated
osteoblast whose primary function is mechanosensing, it would seem that the
expression of TREK-1 is likely in these cells. Figure 7.1 demonstrates some of
the potential functions K>p channels could usefully serve in an osteoblast.
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Figure 7.1. A schematic representation of the potential roles K2p channels may
perform in osteoblasts.
This thesis has provided a thorough examination of Kyp channel expression in
osteoblastic cells and provides unequivocal evidence that exposes the presence of
TASK, TWIK, TALK & TREK channels. The knowledge that TREK channels
are not the only Kp sub-family to be expressed in osteoblasts will hopefully
influence the scope of future studies. This interesting family of proteins certainly
deserves someattention from scientists working in the field of skeletal biology.
The data obtained using BL-1249 also warrants further investigation, by
electrophysiologists in particular. It may prove to be a potentially useful
compoundfor the study of TREK-1 channels.
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7.2 Further experiments
If time had allowed, experiments would have continued using more detailed
electrophysiological studies. Experiments to confirm the identity of the channel
or channels involved in the response to BL-1249 would provide much-needed
information on the definitive pharmacology of BL-1249. Characterization of the
currents seen during voltage clamp protocols using pharmacological compounds
would have been useful in profiling the functional expression of other K*
channels expressed in osteoblasts and in eliminating them as potential targets of
BL-1249. Membranepotential recordings from MA16 cells could be taken to
compare with the values found from SaOS-2 cells, given that Hughes ef ai.,
(2006) found primary osteoblasts to have a more negative resting membrane
potential. Membrane potential recordings for TE-85 cells exposed to BL-1249
would perhaps give more clues as to the actions of this compound given the
variation seen between this cell type and SaOS-2 cells during the voltage clamp
experiments. Although there is no direct evidence to suggest effects of BL-1249
on cAMPlevels, it would be wise to rule this out before any further c-fos
reporter experiments. cAMP measurements following the addition of BL-1249
could be compared with non-treated cells. Riluzole could also be added to
providea positive control. It would have been interesting to compare the results
obtained in Chapter 4 using antibodies from Alamone Labs, to experiments
performed with ones produced by Santa Cruz. This is particularly the case for
western blotting, given that the results gained would be more comparable with
those obtained by Hughesef al., (2006). The use of Santa Cruz antibodies may
also give a clearer indication of protein expression for TRAAK when taking into
account the potential for non-specific binding exposed in during the western blot
for this particular antibody. Had time allowed, sequencing reactions would have
been carried out on PCR product from TASK-3 & -5 and TREK-2 primersets
run with MA16 or SK-N-AS cDNA.A tissue sample from human spinal cord
would perhaps validate the primer set for TRESK,although this would not be
easy to obtain.
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For more complex experiments involving a longer time frame, Kyp knockout
animals could be observed for bone phenotypes. To the authors’ knowledge, no
effects on bone have been reported in Kyp knockout mice at the present time.
However, given the possible role of the TREK subfamily in
mechanotransduction, it might seem possible that effects of Kop channels could
be observed upon mechanical loading of bones in wild-type, heterogeneous and
homogeneous animals. Another series of experiments on similar lines could
involve the use of siRNA (small interfering RNA) to observe the effects of
temporary abolition of K2p gene products on bonestructure and function, as seen
in the paper by Chenet al., (2005).
169
Bibliography
Abed, E., D. Labelle, et al. (2009). "Expressionoftransient receptor potential(TRP) channels in human and murineosteoblast-like cells." Mol MembrBiol26(3): 146-58.
Abou-Samra, A. B., H. Juppner,et al. (1992). "Expression cloning of acommonreceptor for parathyroid hormoneand parathyroid hormone-relatedpeptide from rat osteoblast-like cells: a single receptor stimulates intracellularaccumulation of both cAMPandinositol trisphosphates and increasesintracellular free calcium." Proc Natl Acad Sci US A 89(7): 2732-6.
Alesci, S., M. U. De Martino,etal. (2005). "Glucocorticoid-inducedosteoporosis: from basic mechanismsto clinical aspects."Neuroimmunomodulation 12(1): 1-19.
Allen, M.R., J. M. Hock,et al. (2004). "Periosteum: biology, regulation, andresponse to osteoporosis therapies." Bone 35(5): 1003-12.
Amoroso, S., H. Schmid-Antomarchi,etal. (1990). "Glucose, sulfonylureas,and neurotransmitter release: role of ATP-sensitive K+ channels." Science
247(4944): 852-4.
Arnett, T. R. (2008). "Extracellular pH regulates bonecell function." J Nutr138(2): 415S-418S.
Bakker, A. D., M. Joldersma,etal. (2003). "Interactive effects of PTH andmechanicalstress on nitric oxide and PGE2 production by primary mouseosteoblastic cells." Am J Physiol Endocrinol Metab 285(3): E608-13.
Baldi, C., G. Vazquez,et al. (2003). "TRPC3-like protein is involved in thecapacitative cation entry induced by lalpha,25-dihydroxy-vitamin D3 in ROS17/2.8 osteoblastic cells." J Cell Biochem 90(1): 197-205.
Balemans, W. and W. Van Hul(2007). "The genetics of low-densitylipoprotein receptor-related protein 5 in bone:a story of extremes."Endocrinology 148(6): 2622-9.
Bayliss, D. A., E. M.Talley,et al. (2001). "TASK-1 is a highly modulatedpH-sensitive 'leak' K(+) channel expressed in brainstem respiratory neurons."Respir Physiol 129(1-2): 159-74.
Beckett, E. A., I. Han,et al. (2008). "Functional and molecularidentificationof pH-sensitive K+ channels in murine urinary bladder smooth muscle." BJUInt 102(1): 113-24.
Beresford, J. N., J. A. Gallagher,et al. (1986). "1,25-Dihydroxyvitamin D3and human bone-derived cells in vitro: effects on alkaline phosphatase, type Icollagen and proliferation." Endocrinology 1 19(4): 1776-85.
170
Bergh,J. J., Y. Shao, et al. (2003). "Rodentosteoblastic cells expressvoltage-sensitive calcium channels lacking a gammasubunit." Calcif TissueInt 73(5): 502-10.
Bergh,J. J., Y. Shao,et al. (2006). "Osteoblast Ca(2+) permeability andvoltage-sensitive Ca(2+) channel expressionis temporally regulated by 1,25-dihydroxyvitamin D(3)." Am J Physiol Cell Physiol 290(3): C822-31.
Berridge, M.J. (1995). "Capacitative calcium entry." Biochem J 312 ( Pt 1):1-11.
Bizzarri, C. and R. Civitelli (1994). "Activation of the Ca2+ message systemby parathyroid hormoneis dependent onthe cell cycle." Endocrinology134(1): 133-40.
Bkaily, G., M. Nader,et al. (2006). "G-protein-coupled receptors, channels,and Nat+-H+ exchanger in nuclear membranesofheart, hepatic, vascularendothelial, and smooth muscle cells." Can J Physiol Pharmacol 84(3-4):431-41.
Bockenhauer, D., N. Zilberberg,etal. (2001). "KCNK2:reversibleconversion of a hippocampalpotassium leak into a voltage-dependentchannel." Nat Neurosci 4(5): 486-91.
Boland,C. J., R. M. Fried,et al. (1986). "Measurementof cytosolic freeCa2+ concentrations in humanand rat osteosarcomacells: actions of boneresorption-stimulating hormones." Endocrinology 118(3): 980-9.
Bowler, W.B., C. J. Dixon,etal. (1999). "Signaling in humanosteoblasts byextracellular nucleotides. Their weak induction ofthe c-fos proto-oncogenevia Ca2+ mobilizationis strongly potentiated by a parathyroidhormone/cAMP-dependentprotein kinase pathway independently ofmitogen-activated protein kinase." J Biol Chem 274(20): 14315-24.
Boyce, B. F. and L. Xing (2008). "Functions of RANKL/RANK/OPGinbone modeling and remodeling." Arch Biochem Biophys 473(2): 139-46.
Brazier, S. P., H. S. Mason,et al. (2005). "Cloning of the human TASK-2(KCNKS5) promoter and its regulation by chronic hypoxia." BiochemBiophys Res Commun 336(4): 1251-8.
Breitenlechner, C. B., D. Bossemeyer,et al. (2005). "Crystallography forprotein kinase drug design: PKA and SRCcasestudies." Biochim BiophysActa 1754(1-2): 38-49.
Buckler, K. J. (2007). "TASK-like potassium channels and oxygen sensing inthe carotid body." Respir Physiol Neurobiol 157(1): 55-64.
17]
Buckler, K.J., B. A. Williams,et al. (2000). "An oxygen-, acid- andanaesthetic-sensitive TASK-like background potassium channelinratarterialchemoreceptorcells." J Physiol 525 Pt 1: 135-42.
Buckley, K. A., S. C. Wagstaff,et al. (2001). "Parathyroid hormonepotentiates nucleotide-induced [Ca2+]i release in rat osteoblastsindependently of Gq activation or cyclic monophosphate accumulation. Amechanism for localizing systemic responsesin bone." J Biol Chem 276(12):9565-71.
Burns,D. M., L. Stehno-Bittel, et al. (2004). "Calcitonin gene-related peptideelevates calcium and polarizes membranepotential in MG-63 cells by bothcAMP-independent and -dependent mechanisms." Am J Physiol Cell Physiol287(2): C457-67.
Butler, J., A. Warley, et al. (2010). “Immunolocalization of mitoKATP
subunits in human osteoblast-like cells.” Front Biosci 2: 739-51.
Caffrey, J. M. and M. C. Farach-Carson (1989). "Vitamin D3 metabolitesmodulate dihydropyridine-sensitive calcium currents in clonalratosteosarcomacells." J Biol Chem 264(34): 20265-74.
Chavez, R. A., A. T. Gray,et al. (1999). "TWIK-2, a new weak inwardrectifying memberofthe tandem pore domain potassium channel family." J
Biol Chem 274(12): 7887-92.
Chemin,J., C. Girard, et al. (2003). "Mechanisms underlying excitatoryeffects of group I metabotropic glutamate receptorsvia inhibition of 2Pdomain K+ channels." EMBO J 22(20): 5403-11.
Chen, X., C. M. Macica,et al. (2005). "Stretch-induced PTH-related proteingene expression in osteoblasts." J Bone Miner Res 20(8): 1454-61.
Chesnoy-Marchais,D.and J. Fritsch (1994). "Concentration-dependentmodulations of potassium andcalcium currents ofrat osteoblastic cells byarachidonic acid." J MembrBiol 138(2): 159-70.
Chow,J. W., S. Fox,et al. (1998). "Role for parathyroid hormoneinmechanical responsivenessof rat bone." Am J Physiol 274(1 Pt 1): E146-54.
Civitelli, R., Y. S. Kim,et al. (1990). "Nongenomicactivation of the calciummessage system by vitamin D metabolites in osteoblast-like cells."
Endocrinology 127(5): 2253-62.
Cole, J. A. (1999). "Parathyroid hormoneactivates mitogen-activated proteinkinase in opossum kidneycells." Endocrinology 140(12): 5771-9.
Damsky, C. H. (1999). "Extracellular matrix-integrin interactionsinosteoblast function and tissue remodeling." Bone 25(1): 95-6.
172
De Vry,J., R. Schreiber, et al. (1999). "Discriminative and affective stimuluseffects of dihydropyridine calcium channel modulators: relationship toantialcohol effects." Pharmacol Biochem Behav 64(2): 203-11.
Debska, G., A. Kicinska,et al. (2001). "Intracellular potassium and chloridechannels: an update." Acta Biochim Pol 48(1): 137-44.
Doble, A. (1996). "The pharmacology and mechanism ofactionofriluzole."Neurology 47(6 Suppl 4): S233-41.
Dobnig, H. and R. T. Turner (1995). "Evidence that intermittent treatmentwith parathyroid hormoneincreases bone formationin adultrats by activationof bonelining cells." Endocrinology 136(8): 3632-8.
Doyle, D. A., J. Morais Cabral,et al. (1998). "The structure of the potassiumchannel: molecular basis of K+ conduction and selectivity." Science280(5360): 69-77.
Ducy,P. (2000). "Cbfal: a molecular switch in osteoblast biology." Dev Dyn219(4): 461-71.
Ducy, P., M. Amling,et al. (2000). "Leptin inhibits bone formation through ahypothalamic relay: a central control of bone mass." Cell 100(2): 197-207.
Ducy,P., T. Schinke, et al. (2000). "The osteoblast: a sophisticated fibroblastundercentral surveillance." Science 289(5484): 1501-4.
Duprat, F., C. Girard, et al. (2005). "Pancreatic two P domain K+ channelsTALK-1 and TALK-2 areactivated bynitric oxide andreactive oxygenspecies." J Physiol 562(Pt 1): 235-44.
Duprat, F., I. Lauritzen, et al. (2007). "The TASK background K2P channels:chemo- and nutrient sensors." Trends Neurosci 30(11): 573-80.
Duprat, F., F. Lesage,et al. (2000). "The neuroprotective agent riluzoleactivates the two P domain K(+) channels TREK-1 and TRAAK." MolPharmacol 57(5): 906-12.
Dworetzky,S. I., E. G. Fey,et al. (1990). "Progressive changesin the proteincomposition of the nuclear matrix during rat osteoblast differentiation." ProcNatl Acad Sci U S A 87(12): 4605-9.
Enserink, J. M., A. E. Christensen,et al. (2002). "A novel Epac-specificcAMPanalogue demonstrates independentregulation of Rap1 and ERK."Nat Cell Biol 4(11): 901-6.
Evans, D. B., R. A. Hipskind,et al. (1996). "Analysis of signaling pathwaysused by parathyroid hormoneto activate the c-fos gene in human SaOS2osteoblast-like cells." J Bone Miner Res 11(8): 1066-74.
173
Ferrier, J., A. Ward-Kesthely, et al. (1987). "Further analysis of spontaneousmembranepotential activity and the hyperpolarizing response to parathyroidhormonein osteoblastlike cells." J Cell Physiol 130(3): 344-51.
Fink, M., F. Duprat, et al. (1996). "Cloning, functional expression and brainlocalization of a novel unconventional outward rectifier K+ channel." EMBO
J 15(24): 6854-62.
Franceschi, R. T. (1999). "The developmental control of osteoblast-specificgene expression:role ofspecific transcription factors andthe extracellularmatrix environment." Crit Rev Oral Biol Med 10(1): 40-57.
Fujita, T., T. Meguro,et al. (2002). "New signaling pathway for parathyroidhormoneand cyclic AMPaction on extracellular-regulated kinase and cellproliferation in bone cells. Checkpoint of modulation by cyclic AMP."J BiolChem 277(25): 22191-200.
Fukayama, S., A. H. Tashjian,Jr., et al. (1992). "Mechanisms ofdesensitization to parathyroid hormonein humanosteoblast-like SaOS-2cells." Endocrinology 131(4): 1757-69.
Gallagher, J. A. (2004). "ATP P2receptors and regulation of bone effectorcells." J Musculoskelet NeuronalInteract 4(2): 125-7.
Gesty-Palmer, D., M. Chen,etal. (2006). "Distinct beta-arrestin- and Gprotein-dependent pathwaysfor parathyroid hormone receptor-stimulatedERK1/2 activation." J Biol Chem 281(16): 10856-64.
Gjertsen, B. T., G. Mellgren,et al. ( 1995). "Novel (Rp)-cAMPSanalogs astools for inhibition of cAMP-kinasein cell culture. Basal cAMP-kinaseactivity modulates interleukin-1 beta action." J Biol Chem 270(35): 20599-607.
Gobeil, F., Jr., I. Dumont,et al. (2002). "Regulation of eNOS expressioninbrain endothelial cells by perinuclear EP(3) receptors." Circ Res 90(6): 682-9.
Goldstein, S. A., D. A. Bayliss,et al. (2005). "International Union ofPharmacology. LV. Nomenclature and molecular relationships of two-Ppotassium channels." Pharmacol Rev 57(4): 527-40.
Goltzman, D.(1999). "Interactions of PTH and PTHrP with the PTH/PTHrPreceptor and with downstream signaling pathways: exceptions that providethe rules." J Bone Miner Res 14(2): 173-7.
Gray, A. T., B. B. Zhao,et al. (2000). "Volatile anesthetics activate thehuman tandem pore domain baseline K+ channel KCNKS." Anesthesiology92(6): 1722-30.
174
Gu, Y., P. G. Genever,et al. (2002). "The NMDA type glutamate receptorsexpressed by primary rat osteoblasts have the same electrophysiologicalcharacteristics as neuronalreceptors." Calcif Tissue Int 70(3): 194-203.
Gu, Y., M. R.Preston,et al. (2001). “Three types of K(+) currents in murineosteocyte-like cells (MLO-Y4).” Bone 28(1): 29-37.
Harada,S. and G. A. Rodan (2003). "Control of osteoblast function andregulation of bone mass." Nature 423(6937): 349-55.
Heberden,C., I. Denis,et al. (1998). "TGF-beta and calcitriol." Gen
Pharmacol 30(2): 145-51.
Heitzmann,D., R. Derand,et al. (2008). “Invalidation of TASK1 potassiumchannels disrupts adrenal gland zonation and mineralocorticoid homeostasis.”EMBOJ 27: 179-87.
Henney, N.C., B.Li, et al. (2009). “A large-conductance (BK) potassiumchannel subtype affects both growth and mineralization of human
osteoblasts.” Am J Physiol Cell Physiol 297(6): 1397-408.
Hernandez, L., K. H. Parket al. (2007). “The antiproliferative role of ERG
K+ channels in rat osteoblastic cells.” Cell Biochem Biophys.;47(2): 199-208.
Heurteaux, C., N. Guy, et al (2006). “TREK-1, a K* channel involved inneuroprotection and general anaesthesia.” EMBO J 23: 2684-95.
Hille, B. (2001). “Ion Channels of Excitable Membranes.” Sinauer
Associates, 3" edition.
Hodgkin, A. L. and A. F. Huxley (1952). "A quantitative description ofmembranecurrent andits application to conduction and excitation in nerve."J Physiol 117(4): 500-44.
Honore, E., F. Maingret, et al. (2002). "An intracellular proton sensorcommandslipid- and mechano-gating of the K(+) channel TREK-1." EMBOJ 21(12): 2968-76.
Honore, E., A. J. Patel, et al. (2006). "Desensitization of mechano-gated K2Pchannels." Proc Natl Acad Sci U S A 103(18): 6859-64.
Huang, J. C., T. Sakata, et al. (2004). "PTH differentially regulatesexpression ofRANKL and OPG." J Bone Miner Res 19(2): 235-44.
Hughes,S., J. Magnay,et al. (2006). "Expression of the mechanosensitive2PK+ channel TREK-1 in human osteoblasts." J Cell Physiol 206(3): 738-48.
175
Tonescu, A. M., E. M. Schwarz,etal. (2001). "PTHrP modulates chondrocytedifferentiation through AP-1 and CREB signaling." J Biol Chem 276(15):11639-47.
Kang, D., C. Choe,et al. (2004). "Functional expression of TREK-2 ininsulin-secreting MIN6cells." Biochem Biophys Res Commun 323(1): 323-31.
Kang, D. and D. Kim (2004). "Single-channel properties and pHsensitivityof two-pore domain K+ channels of the TALK family." Biochem BiophysRes Commun 315(4): 836-44.
Kano,J., T. Sugimoto,et al. (1994). "Direct involvement of cAMP-dependentprotein kinase in the regulation ofalkaline phosphataseactivity byparathyroid hormone (PTH) and PTH-related peptide in osteoblastic UMR-106 cells." Biochem Biophys Res Commun 199(1): 271-6.
Kano,J., T. Sugimoto,et al. (1994). "Second messengersignaling of c-fosgene induction by parathyroid hormone (PTH) and PTH-related peptide inosteoblastic osteosarcomacells:its role in osteoblast proliferation andosteoclast-like cell formation." J Cell Physiol 161(2): 358-66.
Karsenty, G. (2001). "Minireview:transcriptional control of osteoblastdifferentiation." Endocrinology 142(7): 2731-3.
Karsenty, G. (2003). "The complexities of skeletal biology." Nature423(6937): 316-8.
Kawase, T., G. A. Howard,et al. (1996). "Calcitonin gene-related peptiderapidly inhibits calcium uptake in osteoblastic cell lines via activation ofadenosine triphosphate-sensitive potassium channels." Endocrinology 137(3):984-90.
Keshavaprasad,B., C. Liu,et al. (2005). "Species-specific differencesinresponse to anesthetics and other modulators by the K2P channel TRESK."Anesth Analg 101(4): 1042-9, table of contents.
Kindler, C. H. and C. S. Yost (2005). "Two-pore domain potassium channels:new sites of local anesthetic action andtoxicity." Reg Anesth Pain Med30(3): 260-74.
Krishnan, V., H. U. Bryant,et al. (2006). "Regulation of bone mass by Wntsignaling." J Clin Invest 116(5): 1202-9.
Komarova, S.V., S. J. Dixon and S. M.Sims. (2001). “Osteoclast ionchannels: potential targets for antiresorptive drugs.” Curr Pharm Des 7(8):637-54.
176
Kubo,Y., J. P. Adelman,et al. (2005). "International Union of
Pharmacology. LIV. Nomenclature and molecular relationships of inwardlyrectifying potassium channels." Pharmacol Rev 57(4): 509-26.
Labelle, D., C. Jumarie, et al. (2007). "Capacitative calcium entry andproliferation of human osteoblast-like MG-63cells." Cell Prolif 40(6): 866-84.
Lauritzen,I., J. Chemin,et al. (2005). "Cross-talk between the mechano-
gated K2P channel TREK-1 and the actin cytoskeleton." EMBO Rep6(7):642-8.
Lefebvre, V., R. R. Behringer, et al. (2001). "L-Sox5, Sox6 and Sox9 control
essential steps of the chondrocyte differentiation pathway." Osteoarthritis
Cartilage 9 Suppl A: S69-75.
Lesage, F. (2003). "Pharmacology of neuronal background potassium
channels." Neuropharmacology 44(1): 1-7.
Lesage, F., E. Guillemare,et al. (1996). "TWIK-1, a ubiquitous human
weakly inwardrectifying K+ channel with a novelstructure." EMBO J 15(5):1004-11.
Lesage, F., F. Maingret, et al. (2000). "Cloning and expression of human
TRAAK,a polyunsaturated fatty acids-activated and mechano-sensitive K(+)channel." FEBS Lett 471(2-3): 137-40.
Lesage, F., R. Reyes,et al. (1996). "Dimerization of TWIK-1 K+ channel
subunits via a disulfide bridge." EMBO J 15(23): 6400-7.
Lewiecki, E. M. (2008). "Denosumab:an investigational drug for the
management of postmenopausal osteoporosis." Biologics 2(4): 645-53.
Lieberherr, M. (1987). "Effects of vitamin D3 metabolites on cytosolic freecalcium in confluent mouse osteoblasts." J Biol Chem 262(27): 13168-73.
Lips, P. (2006). "Vitamin D physiology." Prog Biophys Mol Biol 92(1): 4-8.
Liu,C., J. F. Cotten, et al. (2005). "Protective effects of TASK-3 (KCNK9)
and related 2P K channelsduringcellular stress." Brain Res 1031(2): 164-73.
Liu, P., B. O. Oyajobi,et al. (1999). "Regulation of osteogenic differentiationof human bone marrowstromalcells: interaction between transforming
growth factor-beta and 1,25(OH)(2) vitamin D(3)In vitro." Calcif Tissue Int
65(2): 173-80.
Lochner, A. and J. A. Moolman (2006). "The many faces of H89:a review."
Cardiovasc Drug Rev 24(3-4): 261-74.
177
Lopes, C. M., T. Rohacs,et al. (2005). "PIP2 hydrolysis underlies agonist-inducedinhibition and regulates voltage gating of two-pore domain K+channels." J Physiol 564(Pt 1): 117-29.
Lotinun,S., J. D. Sibonga,et al. (2002). "Differential effects of intermittentand continuous administration of parathyroid hormone on bonehistomorphometry and gene expression." Endocrine 17(1): 29-36.
Lu, Z., J. Gao, et al. (2007). "Two-pore K+ channels, NO and metabolicinhibition." Biochem Biophys Res Commun 363(1): 194-6.
MacDonald,B.R., J. A. Gallagher,et al. (1986). "Parathyroid hormonestimulates the proliferation of cells derived from human bone."Endocrinology 118(6): 2445-9.
Magra, M., S. Hughes,et al. (2007). "VOCCs and TREK-1 ion channelexpression in human tenocytes." Am J Physiol Cell Physiol 292(3): C1053-60.
Maingret, F., M. Fosset, et al. (1999). "TRAAK is a mammalian neuronalmechano-gated K+ channel." J Biol Chem 274(3): 1381-7.
Mancini, L., N. Moradi-Bidhendi,et al. (1998). "Nitric oxide superoxide andperoxynitrite modulate osteoclast activity." Biochem Biophys Res Commun243(3): 785-90.
Manolagas, S. C., D. C. Anderson,etal.(1979). "Glucocorticoids regulatethe concentration of 1,25-dihydroxycholecalciferol receptors in bone." Nature277(5694): 314-5.
Mathie, A. (2007). "Neuronal two-pore-domainpotassium channels and theirregulation by G protein-coupled receptors." J Physiol 578(Pt 2): 377-85.
Medhurst, A. D., G. Rennie,et al. (2001). "Distribution analysis of humantwo pore domain potassium channelsin tissues of the central nervous systemand periphery." Brain Res Mol Brain Res 86(1-2): 101-14.
Meszaros,J. G., N. J. Karin,et al. (1996). "Down-regulation of L-type Ca2+channeltranscript levels by 1,25-dihyroxyvitamin D3. Osteoblastic cellsexpress L-type alphalC Ca2+ channel isoforms." J Biol Chem 271(51):32981-5.
Meves,H. (2008). "Arachidonic acid and ion channels: an update." Br JPharmacol 155(1): 4-16.
Miller, P. D. (2008). "Anti-resorptives in the managementof osteoporosis."Best Pract Res Clin Endocrinol Metab 22(5): 849-68.
178
Moreau, R., R. Aubin,etal. (1997). "Pharmacological and biochemicalevidencefor the regulation of osteocalcin secretion by potassium channels inhuman osteoblast-like MG-63 cells." J Bone Miner Res 12(12): 1984-92.
Mulkey, D. K., E. M.Talley, et al. (2007). “TASK channels determine pHsensitivity in select respiratory neurons but do not contribute to centralrespiratory chemosensitivity.” J Neurosci 27: 14049-58.
Mulkins, M.A., S. C. Manolagas,etal. (1983). "1,25-Dihydroxyvitamin D3increases bone alkaline phosphatase isoenzyme levels in human osteogenicsarcomacells." J Biol Chem 258(10): 6219-25.
Murrills, R. J., J. L. Andrews,et al. (2009). "Parathyroid hormonesynergizeswith non-cyclic AMP pathwaysto activate the cyclic AMP responseelement." J Cell Biochem 106(5): 887-95.
Nakashima, K., X. Zhou,et al. (2002). "The novel zinc finger-containingtranscription factor osterix is required for osteoblast differentiation and boneformation." Cell 108(1): 17-29.
Nishii, N., N. Nejime,et al. (2009). "Effects of ATP onthe intracellularcalcium level in the osteoblastic TBR31-2 cell line." Biol Pharm Bull 32(1):18-23.
Nishiya, Y., N. Kosaka,et al. (2002). "A potent 1,4-dihydropyridine L-typecalcium channelblocker, benidipine, promotes osteoblast differentiation."Calcif Tissue Int 70(1): 30-9.
Nomura,S. and T. Takano-Yamamoto (2000). "Molecular events caused bymechanicalstress in bone." Matrix Biol 19(2): 91-6.
Novak, A. and S. Dedhar (1999). "Signaling through beta-catenin andLef/Tcf." Cell Mol Life Sci 56(5-6): 523-37.
O'Connell, A. D., M. J. Morton,etal. (2002). "Two-pore domain K+channels-molecular sensors." Biochim Biophys Acta 1566(1-2): 152-61.Ohnaka, K., M. Tanabe,et al. (2005). "Glucocorticoid suppresses thecanonical Wntsignalin cultured human osteoblasts." Biochem Biophys ResCommun 329(1): 177-81.
Otto, F., A. P. Thornell,et al. ( 1997). "Cbfal, a candidate gene forcleidocranial dysplasia syndrome,is essential for osteoblast differentiationand bone development." Cell 89(5): 765-71.
Owen,T. A., M. S. Aronow,et al. (1991). "Pleiotropic effects of vitamin Don osteoblast gene expressionare related to the proliferative anddifferentiated state of the bone cell phenotype: dependency uponbasallevelsof gene expression, duration of exposure, and bone matrix competencyinnormalrat osteoblast cultures." Endocrinology 128(3): 1496-504.
179
Pardo, L. A. (2004). "Voltage-gated potassium channelsin cell proliferation."
Physiology (Bethesda) 19: 285-92.
Partridge, N. C., A. L. Opie, et al. (1985). "Inhibitory effects of parathyroid
hormone on growth of osteogenic sarcomacells." Calcif Tissue Int 37(5):
519-25.
Patel, A. and E. Honore (2002). "The TREK two P domain K+ channels." J
Physiol 539(Pt 3): 647.
Patel, A. J. and E. Honore (2001). "Anesthetic-sensitive 2P domain K+
channels." Anesthesiology 95(4): 1013-21.
Patel, A. J. and E. Honore (2001). "Properties and modulation of mammalian
2P domain K+ channels." Trends Neurosci 24(6): 339-46.
Patel, A. J., F. Maingret, et al. (2000). "TWIK-2, an inactivating 2P domain
K+ channel." J Biol Chem 275(37): 28722-30.
Plant, L. D., S. Rajan, et al. (2005). "K2P channels andtheir protein
partners." Curr Opin Neurobiol 15(3): 326-33.
Purves, G. I., T. Kamishima,etal. (2009). "Exchange protein activated by
cAMP (Epac) mediates cAMP-dependentbut protein kinase A-insensitive
modulation of vascular ATP-sensitive potassium channels." J Physiol 587(Pt
14): 3639-50.
Qin, L., X. Li, et al. (2005). "Parathyroid hormone uses multiple mechanisms
to arrest the cell cycle progression of osteoblastic cells from G1 to S phase." J
Biol Chem 280(4): 3104-11.
Quayle, J. M., A. D. Boney, etal. (1995). "Pharmacology of ATP-sensitive
K+ currents in smooth muscle cells from rabbit mesenteric artery." Am J
Physiol 269(5 Pt 1): C1112-8.
Quinn, C. O., R. A. Rajakumar,et al. (2000). "Parathyroid hormoneinduces
rat interstitial collagenase mRNAthrough Ets-1 facilitated by cyclic AMP
response element-binding protein and Ca(2+)/calmodulin-dependentprotein
kinase II in osteoblastic cells." J Mol Endocrinol 25(1): 73-84.
Rajan, S., E. Wischmeyer,et al. (2001). "THIK-1 and THIK-2, a novel
subfamily of tandem pore domain K+ channels." J Biol Chem 276(10): 7302-
11.
Ravesloot, J. H., R. J. van Houten,et al. (1990). “Identification of Ca(2+)-
activated K+ channels in cells of embryonic chick osteoblast cultures.” J
Bone MinerRes 5(12): 1201-10.
180
Rawlinson,S. C., A. A.Pitsillides,etal. (1996). "Involvementofdifferention channels in osteoblasts' and osteocytes' early responses to mechanicalstrain." Bone 19(6): 609-14.
Reid,I. R., R. Civitelli, et al. (1987). "Parathyroid hormoneacutely elevatesintracellular calcium in osteoblastlike cells." Am J Physiol 253(1 Pt 1): E45-Bi.
Reimann, F. and F. M. Ashcroft ( 1999). "Inwardlyrectifying potassiumchannels." Curr Opin Cell Biol 11(4): 503-8.
Rendell, M. (2004). "The role of sulphonylureasin the managementoftype 2diabetes mellitus." Drugs 64(12): 1339-58.
Rodan, G. A. (1997). "Bone mass homeostasis and bisphosphonate action."Bone 20(1): 1-4.
Rodan,S. B., Y. Imai,et al. (1987). "Characterization of a humanosteosarcomacell line (Saos-2) with osteoblastic properties." Cancer Res47(18): 4961-6.
Sabbadini, M. and C. S Yost (2009). “Molecular biology of background Kchannels: Insights from K>p knockout mice.” J Mol Biol 385: 1331-44.
Saeki, Y., A. Ohara,et al. (2007). "The presence of arachidonic acid-activated K+ channel, TREK-1, in human periodontal ligamentfibroblasts."Drug Metab Rev 39(2-3): 457-65.
Sano, Y., K. Inamura,etal. (2003). "A novel two-pore domain K+ channel,TRESK,is localized in the spinal cord." J Biol Chem 278(30): 27406-12.
Satake, N., S. Fujimoto,et al. (1996). "The potentiation of nitroglycerin-inducedrelaxation by PKGinhibitionin rat aortic rings." Gen Pharmacol27(4): 701-5.
Shieh, C. C., M. Coghlan,etal. (2000). "Potassium channels: moleculardefects, diseases, and therapeutic opportunities." Pharmacol Rev 52(4): 557-94.
Sistare, F. D., B. A. Rosenzweig,etal. (1994). "Separate P2T and P2Upurinergic receptors with similar second messengersignaling pathwaysinUMR-106 osteoblasts." J Pharmacol Exp Ther 269(3): 1049-61.
Sommer, B., M. Bickel,etal. ( 1996). "Expression of matrix proteins duringthe developmentofmineralized tissues." Bone 19(4): 371-80.
St-Arnaud, R. (2008). "The direct role of vitamin D on bone homeostasis."Arch Biochem Biophys 473(2): 225-30.
181
Sun Park, W., Y. Kyoung Son,etal. (2006). "The protein kinase A inhibitor,H-89,directly inhibits KATP and Kir channels in rabbit coronaryarterialsmooth muscle cells." Biochem Biophys Res Commun 340(4): 1104-10.
Tertyshnikova,S., R. J. Knox,et al. (2005). "BL-1249 [(5,6,7,8-tetrahydro-naphthalen-1 -yl)-[2-(1 H-tetrazol-5-yl)-phenyl]-amine] : a putative potassiumchannel opener with bladder-relaxant properties." J Pharmacol Exp Ther313(1): 250-9.
Van Damme,P., M. Dewil, et al. (2005). "Excitotoxicity and amyotrophiclateral sclerosis." Neurodegener Dis 2(3-4): 147-59.
Vezeridis, P. S., C. M. Semeins,et al. (2006). "Osteocytes subjected topulsating fluid flow regulate osteoblast proliferation and differentiation."Biochem Biophys Res Commun 348(3): 1082-8.
Wagner,E. F. and G. Karsenty (2001). "Genetic controlof skeletaldevelopment." Curr Opin Genet Dev 11(5): 527-32.
Walsh, C. A., W. B. Bowler,et al. (1997). "Effects of PTH on PTHrP geneexpression in humanosteoblasts: up-regulation with the kinetics of animmediate early gene." Biochem Biophys Res Commun 239(1): 155-9.
Wang, L.L. (2005). "Biology of osteogenic sarcoma." Cancer J 1 1(4): 294-305.
Wang, Y. J., M. W.Lin,et al. (2008). "Riluzole-induced block of voltage-gated Nat current and activation ofBKCa channels in cultured differentiatedhumanskeletal musclecells." Life Sci 82(1-2): 11-20.
Weidema,A.F., J. Barbera,etal. (1 997). “Extracellular nucleotides activatenon-selective cation and Ca(2+)-dependent K+ channels in rat Osteoclasts.” JPhysiol 503(2): 303-15.
Wilson,J.R., N. A. Duncan,et al. (2004) “A voltage-dependent K*currentcontributes to membranepotential of acutely isolated canine articularchondrocytes.” J Physiol 557.1: 93-104.
Wonderlin, W.F. and J. S. Strobl (1996). "Potassium channels, proliferationand G1 progression." J MembrBiol 154(2): 91-107.
Xiao, G., D. Wang,et al. (1998). "Role of the alpha2-integrin in osteoblast-specific gene expression and activation of the Osf2 transcription factor." JBiol Chem 273(49): 32988-94.
Yamaguchi, D. T., T. J. Hahn,et al. (1987). "Parathyroid hormone-activatedcalcium channels in an osteoblast-like clonal osteosarcomacell line. cAMP-dependent and cAMP-independentcalcium channels." J Biol Chem 262(16):7711-8.
182
Yellowley, C. E., J. C. Hancox,et al. (1998). "Whole-cell membranecurrents
from human osteoblast-like cells." Calcif Tissue Int 62(2): 122-32.
Ypey, D. L., A.F. Weidema,et al. (1992). “Voltage, calcium, and stretch
activated ionic channels andintracellular calcium in bonecells.” J Bone Min
Res 7(2): $377-87.
Zahanich,I., E. M. Graf, et al. (2005). "Molecular and functional expression
of voltage-operated calcium channels during osteogenic differentiation of
human mesenchymalstem cells." J Bone Miner Res 20(9): 1637-46.
Zallone, A. (2006). "Direct and indirect estrogen actions on osteoblasts and
osteoclasts." Ann N Y Acad Sci 1068: 173-9.
Zanello, L. P. and A. W. Norman (2003). "Multiple molecular mechanismsof
1 alpha,25(OH)2-vitamin D3 rapid modulation of three ion channelactivities
in osteoblasts." Bone 33(1): 71-9.
Zhong, N., R. P. Gersch, et al. (2006). "Wnt signaling activation during bone
regeneration andthe role of Dishevelled in chondrocyte proliferation and
differentiation." Bone 39(1): 5-16.
183
